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Abstract 
Background 
Acute exacerbations of COPD (AECOPD) requiring admission have high mortality, 
readmission rates and healthcare costs. The DECAF score (Dyspnoea, Eosinopenia, 
chest radiograph Consolidation, Acidaemia and atrial Fibrillation) risk stratifies for 
acute mortality in these patients, but no validation or implementation study has been 
performed. Low risk patients may be suitable for Hospital at Home treatment. 
No risk stratification score to predict 90 day readmission/ death without readmission 
has been developed and validated in this patient group. 
Methods 
Consecutive patients with AECOPD were admitted to one of six hospitals. Predictors 
of mortality and readmission were collected. Data were combined with the DECAF 
derivation study to create a score to predict 90 day readmission/ death without 
readmission. Discrimination was assessed with the area under the receiver operator 
curve characteristic (AUROC). 
A non-inferiority, randomised controlled trial was performed to compare usual care to 
Hospital at Home (HAH) with patient selection by low risk DECAF score (0 or 1). The 
primary outcome was cost, with a cost-utility analysis as a secondary outcome. 
Results 
In 1,725 patients, the DECAF AUROC curve for inhospital mortality was 0.82 (95% CI 
0.79 to 0.85), with a mortality risk of 1.0% in the DECAF 0 or 1 group and an overall 
mortality risk of 7.7%. 
In those that survived to discharge (n=2417), the strongest predictors of readmission/ 
death without readmission in the final model were: Previous admissions, eMRCD 
score, Age, Right-sided heart failure and Left sided heart failure (PEARL). The 
PEARL AUROC was 0.70 (95% CI 0.66 to 0.72). 
In 118 patients in the RCT, mean 90-day costs were £1,016 lower in HAH than usual 
care, but the one sided 95% cost interval crossed the non-inferiority limit (CI -2343 to 
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312). A sensitivity analysis assuming an extra days’ stay in usual care met the 
inferiority limit: cost difference £-1262, (CI -2590 to 66). HAH had a 90% chance of 
cost-effectiveness at a threshold of £30,000 per quality adjusted life year. 
Discussion 
The DECAF and PEARL score are simple tools that can be used at the bed side to 
risk stratify patients with AECOPD for inpatient mortality and readmission/ death 
without readmission respectively. Patient selection for Hospital at Home services 
using DECAF is cost effective. 
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Glossary of abbreviations 
AECOPD Acute exacerbation of COPD 
APACHE II Acute Physiology and Chronic Health Evaluation 
AUROC Area Under the Receiver Operator Characteristic (Curve) 
BAP-65 Blood urea nitrogen, Acute mental status change, Pulse rate and 
age 65 
BTS British Thoracic Society 
CAP Community Acquired Pneumonia 
CAPS COPD and Asthma Physiology Score 
CAT COPD Assessment Tool 
CEAC Cost effectiveness acceptability curves 
CI Confidence Interval 
COPD Chronic Obstructive Pulmonary Disease 
CT-PA Computed Tomography Pulmonary Angiogram 
CURB-65 Confusion, Urea, Respiratory rate, Blood pressure and age 65 
CXR Chest x-ray 
DECAF score Dyspnoea, Eosinopenia, Consolidation, Acidaemia and atrial 
Fibrillation 
DVT Deep Vein Thrombosis 
ECG Electrocardiogram 
eMRCD score Extended Medical Research Council Dyspnoea score 
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ICD 10 International Classification of Diseases 10 
EQ-5D-5L European Quality of Life-5 Dimensions 
ESD Early supported discharge 
EXACT-PRO EXAcerbation of Chronic Pulmonary Disease Tool- Patient 
Reported Outcomes 
FEV1 Forced expiratory volume in one second 
FEV1% 
predicted 
Forced expiratory volume in one second, per cent predicted 
FVC Forced Expiratory Volume 
GCS Glasgow Coma Score 
GOLD Global Initiative for COPD 
HADS Hospital Anxiety and Depression Score 
HAH Hospital at Home 
HRQoL Health Related Quality of Life 
ICER Incremental cost effectiveness ratio 
IMV Intubation and mechanical ventilation 
MAR Missing at Random 
MCAR Missing Completely at Random 
MCID Minimum clinical important difference 
MNAR Missing Not at Random 
mMRCD score Modified Medical Research Council Dyspnoea score 
ix 
 
 
NICE The National Institute for Health and Care Excellence 
NIV Non-invasive ventilation 
pAECOPD Pneumonic AECOPD 
PEARL score Previous admissions, eMRCD, Age, Right sided heart failure and 
Left sided heart failure 
PE Pulmonary thromboembolism 
QALY Quality adjusted life year 
RCT Randomised controlled trial 
RRMH Risk Ratio Mantel-Haenszel 
RSN Respiratory Specialist Nurses 
SGRQ St George’s Respiratory Questionnaire 
UC Usual care 
VTE Veno-thromboembolism 
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Overview of programme of research 
In prognostic research, there are three key steps in creating a prognostic score: 
1) Derivation 
2) Validation 
3) Implementation 
Derivation refers to the development of a prognostic score. Validation refers to 
testing the developed score in: the same population (“internal validation”) or a 
different population at a different time (“external validation”). “Implementation” refers 
to the assessment of the tool in clinical practice to quantify its impact on patient care. 
This thesis is part of a larger programme of research which aims to derive, validate 
and implement prognostic scores for patients admitted with a COPD exacerbation 
(AECOPD) with respect to: 
a) Inpatient mortality 
b) Readmission or death without readmission within 90 days 
This thesis includes: 1) the internal and external validation of the Dyspnoea, 
Eosinopenia, Consolidation, Acidaemia and atrial Fibrillation (DECAF) score; 2) an 
RCT of the implementation of the DECAF score (“HoT DECAF”); and 3) the 
development, and internal and external validation of the Previous admissions, 
eMRCD, Age, Right sided heart failure and Left sided heart failure (PEARL) score. 
 OUTCOME, name of prognostic score 
 INPATIENT MORTALITY, 
 
The DECAF score 
READMISSION/ DEATH WITHOUT 
READMISSION, 
The PEARL score 
Derivation cohort Previous research1, 2 This thesis 
Validation cohorts This thesis This thesis 
Implementation study This thesis Future research 
Table 0.1 showing overview of programme of research and work included in this thesis 
The DECAF score was developed and published prior to this work in the DECAF 
derivation study.1, 2 An a priori aim of this work was to derive tools to predict 
readmission, or death without readmission, within 90 days of discharge and one year 
mortality. This study cohort was used in this thesis in the development of the PEARL 
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scores. The DECAF derivation study cohort will be referred to as the “derivation 
cohort” throughout this thesis. 
The validation study comprises an internal and external validation cohort. All tools 
were validated in these cohorts, and the terms “internal validation cohort” and 
“external validation cohort” will be used throughout. 
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Thesis overview 
The main topics of this thesis are the validation of prognostic tools to risk stratify 
acute exacerbations of COPD (AECOPD) requiring hospital admission for in-hospital 
mortality (DECAF) and post-discharge readmission risk (PEARL), and an 
implementation RCT assessing Hospital at Home (HAH) selected by low risk DECAF 
score.  
Five key aspects will be covered: 
 AECOPD requiring hospitalisation 
 Hospital at Home as a therapy for patients admitted with AECOPD 
 The validation of the DECAF score 
 The impact of the DECAF score when used to select patients for Hospital at 
Home therapy 
 The development and validation of the PEARL score to predict 90 day 
readmission or death 
Chapter 1 is a literature search which covers: COPD; AECOPD requiring 
hospitalisation; and tools that predict death or readmission following hospital 
admission with an AECOPD. We (Karen Brewin, Hazel Horobin, Andrew Bryant, 
Sally Corbett, John Steer, Stephen C. Bourke, and I)  have published a meta-
analysis of Hospital at Home for AECOPD which forms chapter 2.3 
Within the methods section (chapter 3 to 5) the development, validation and impact 
assessment of prognostic scores are discussed together in that order to avoid 
repetition as we have developed and validated both the DECAF score and the 
PEARL score. The order of the results section (chapter 6 to 10) differs so that the 
DECAF implementation study (HoT DECAF RCT) follows the DECAF validation 
study, with the PEARL score reported afterwards. The studies appear in the following 
order in the results section: 
1) The validation of the DECAF 
The performance of the DECAF score was assessed in two large cohorts (an internal 
and external validation cohorts) comprised of six hospitals throughout the UK (1,725 
patients). The DECAF score predicts in-hospital mortality. 
  
xxvi 
 
 
2) HoT DECAF (Home Treatment for low DECAF risk AECOPD) 
This is a randomised controlled trial (RCT) of 118 patients, in which patients admitted 
to hospital with a low risk DECAF score were allocated to receive Hospital at Home 
or usual care. Clinical and cost outcomes are described. 
3) The PEARL score 
The PEARL score was developed and validated to predict 90 day readmission or 
death without readmission in 2,417 consecutive admissions surviving to discharge. 
This includes 824 patients from the DECAF derivation cohort. 
At the end of each results section follows a discussion, which summaries the key 
results, discusses the strengths and limitation of the research, and places the 
findings in the context of the existing literature. 
The conclusion section synthesises the key results from the thesis. 
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Chapter 1 Introduction 
Chapter introduction 
All patients included in the studies in this thesis had an acute exacerbation of Chronic 
Obstructive Pulmonary Disease (AECOPD) that required hospital admission. This 
chapter will include a brief overview of COPD, and then a more detailed exploration 
of AECOPD with regards to the impact of AECOPD on the patient and society, and 
prevention and treatment. 
An overview is provided of prognostic scores which may be used for risk stratification 
and to guide management in patients admitted with an AECOPD. 
1.1 Chronic Obstructive Pulmonary Disease (COPD) 
This section begins with the definition and epidemiology of COPD and, then 
discusses the impact of COPD both globally and on the individual. The extended 
Medical Research Council Dyspnoea (eMRCD) score forms part of the DECAF 
score, and is therefore outlined along with the original MRCD score, the modified 
MRCD (mMRCD) score, the COPD Assessment Tool (CAT) and European Quality of 
Life-5 Dimensions (EQ-5D-5L). Lastly “1.1.7 Co-morbidity in COPD” discusses the 
importance of investigating and diagnosing co-morbidity which frequently complicate 
COPD. 
1.1.1 Definition and diagnosis 
The National Institute for Health and Care Excellence (NICE) and the Global Initiative 
for COPD (GOLD) 4, 5 describe chronic obstructive pulmonary disease as a multi-
system condition characterised by airflow obstruction that is usually progressive, but 
not fully reversible, and is commonly associated with respiratory symptoms such as 
breathlessness, cough and sputum production. Definitions include: 
 Respiratory symptoms (e.g. breathless, cough sputum production), functional 
impairment and impaired health status (partly through exacerbations) 
 Aetiological factors (smoking, occupational and environmental exposure) 
 Abnormal lung physiology and function (primarily airflow obstruction)  
 Chronic inflammation and structural lung changes (including emphysema) 
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Symptoms alone cannot define COPD, as they are non-specific and may occur in 
non-respiratory conditions. Breathlessness, cough and chronic sputum production 
(e.g. chronic bronchitis) may occur without airflow obstruction. Furthermore, 
symptomatic smokers/ former smokers (based on a CAT score of 10 or more) with 
normal spirometry suffer from acute exacerbations. This result was unchanged 
despite using various Forced Expiratory Volume in one second/ Forced Vital 
Capacity (FEV1/FVC) cut-offs (0.66, 0.7, 0.75 and the lower limit of normal).6 
Airflow obstruction and radiographic features of COPD may exist in the absence of 
symptoms. Emphysema and airflow obstruction usually co-exist, but patients with 
emphysema, especially younger patients, may lack airflow obstruction as defined by 
an FEV1/ FVC ratio of less than 0.7. Conversely, the normal FEV1/(F)VC ratio slowly 
falls with age and older individuals who are otherwise well may have spirometric 
values which meet this criterion for airflow obstruction. For this reason, use of the 
lower limit of normal has been advocated by some. 
Other respiratory diseases, such as asthma and bronchiectasis commonly co-exist 
with COPD and have several features which overlap. 
1.1.2 Epidemiology 
In a systematic review and meta-analysis, the global prevalence of COPD was 9 to 
10% in adults aged 40 year and over, though the reported prevalence varied 
considerably, partly due to methodological differences between studies.7 Data from 
the United States shows that COPD affects more than one in twenty people, and 
more than one in ten in patients aged 65 and over.8 In 2012, approximately 1.2 
million people in the UK had been diagnosed with COPD. The proportion of people 
with COPD is highest in the North-East of England, and it is estimated that there are 
millions of patients with undiagnosed COPD in the UK.9 
Historically, the reported prevalence of COPD has been higher in men, probably due 
to higher smoking rates. This remains true in some parts of Europe,10 but COPD 
prevalence and AECOPD frequency (requiring hospitalisation) are similar between 
men and women in the US and UK.8, 11 
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Whilst the prevalence of COPD in the UK population is rising, new diagnosis rates 
have declined from around 226 per 100,000 in 2004 to 187 per 100,000 in 2013, 
coinciding with reduced smoking rates. 
Estimates of prevalence and incidence are problematic, due to variation in diagnostic 
practice, and under- and over- reporting of the condition. A substantial proportion of 
patients with COPD remain undiagnosed 12, 13 and self-reported rates of COPD (or 
asthma) are twice the rate based on primary care records.14 Globally, 80% of patients 
with COPD may be undiagnosed.15 Under-reporting and undiagnosed COPD is 
associated with: older age (in the Netherlands);14 younger age, smoking status 
(never or current smokers are at higher risk), lower education, and milder disease 
(globally);15 and in low-income populations (US).16 Most of the epidemiological data 
on COPD comes from higher income countries. The most important risk factor for 
COPD is tobacco smoke. Whilst the prevalence of smoking has reduced over the last 
35 years, the world-wide absolute number of smokers has increased (there has been 
an increase in the global population).17 
Typically, 10 or fewer pack years is unlikely to result in COPD in most individuals, 
whilst a 40 pack year history is a strong predictor of airflow obstruction.18 Of interest, 
the higher the number of smoked cigarettes, the lower the median FEV1% predicted. 
This contradicts the commonly held view that susceptibility to smoke is binary. All 
individuals who smoke are at risk, though the extent varies between individuals.18 
In developing countries, combustion of biomass for use as an energy source is 
associated with an increase in the risk of COPD.19 The association between biomass 
smoke and COPD is higher in men than women, though smoking status may partly 
account for this difference; there is an especially high prevalence of smoking 
amongst middle-aged men in developing countries. In parts of the UK, industrial 
exposure, such as coal-dust, is an important risk factor for COPD.7 
1.1.3 Impact of COPD 
The key symptoms in COPD are breathlessness, chronic cough and sputum 
production; wheeze or chest tightness may also be reported. Most patients (92.5%) 
with severe COPD (FEV1% predicted less than 50%) will report having experienced 
these symptoms within the previous seven days, with breathlessness being the most 
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frequently reported symptom (72.5%).20 Despite this, many COPD patients 
underestimate the severity of their condition in relation to an objective breathlessness 
scale.21 Symptoms can vary over the course of a day or week, and morning 
breathlessness is a key complaint,20, 22 though some of this variation may be due to 
unreported exacerbation.23 In severe and very severe COPD fatigue, weight loss and 
anorexia are common.5 
Most patients will experience a general decline in lung function, which is 
accompanied by a deterioration in quality of life and worsening respiratory symptoms, 
and progressively more frequent exacerbations.24, 25 The decline in FEV1 is greater 
amongst patients who have more frequent exacerbations.26 
The burden of COPD is increasing and is predicted to be the fourth cause of death 
and seventh cause of disability-adjusted life years worldwide by 2030.27 Morbidity in 
those with COPD increases as patients age, which may be partly due to worsening 
COPD as well as the progression and/or development of co-morbidity.5 
The estimated annual healthcare cost of COPD is substantial;5 in the UK COPD is 
the second commonest respiratory reason to attend the GP,28 one of the commonest 
reasons for hospitalisation and total healthcare costs are close to one billion 
pounds.29 
1.1.4 MRCD and CAT score 
The severity of COPD is based upon the degree of airflow obstruction, symptoms (as 
measured by the mMRCD scale or CAT) and frequency of exacerbations. The GOLD 
guidelines provide the following categories:5 
 Group A have mild to moderate airflow obstructive, and/or 0 to 1 
exacerbations per year, and an mMRCD score of 0 to 1 or CAT score of less 
than 10. 
 Group B have mild to moderate airflow obstructive, and/or 0 to 1 
exacerbations per year, and an mMRCD score of 2 or more or CAT score of 
10 or more. 
 Group C have severe or very severe airflow obstructive, and/or 2 or more 
exacerbations per year, and an mMRCD score of 0 to 1 or CAT score of less 
than 10. 
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 Group D have severe or very severe airflow obstructive, and/or 2 or more 
exacerbations per year, and an mMRCD score of 2 or more or CAT score of 
10 or more. 
It has been suggested that this guideline needs to be refined as an mMRCD score of 
1 or more is approximately equivalent to a CAT of 10, and not an mMRCD score of 2 
or more.30 The Gold guide states that the CAT is the preferred method of assessment 
as it is more comprehensive, and this cut-off is associated with impaired health 
status.31 The CAT is used as a secondary outcome in the DECAF implementation 
study (5.7 Overview of outcomes). It is a self-reported questionnaire that measures 
health-related quality of life. There have been numerous publications looking at the 
CAT in AECOPD.32, 33 It has been shown to have good internal consistency and test-
retest reliability.32 Furthermore, scores worsen at the onset of AECOPD,34 and 
improve with recovery.35, 36 The minimum clinically important difference is 2.37 
1.1.5 MRCD and eMRCD score 
Breathlessness is the most frequently reported symptom in COPD and can be 
assessed with respect to daily activities using standardised tools such as the MRC 
breathlessness score.38 It shows good agreement between observers and with 
repeated use.39 The primary measure of COPD severity previously was the degree of 
airflow obstruction. Symptoms have been added to the severity assessment in the 
GOLD guidelines because FEV1% predicted and breathlessness as measured by the 
MRCD are not closely associated, and the MRCD is associated with health status 
and mortality risk.40, 41 
The extended MRC Dyspnoea score (Table 1.1) comprises one of the five indices in 
the DECAF score, which was developed to predict inpatient mortality; it is the 
strongest predictor of inpatient and 30 day mortality.1, 2 
There are important differences between the eMRCD and traditional instrument: the 
transition point between levels is clearly defined, and the most severe category of 
breathlessness has been refined and sub-categorised. One of the criticisms of the 
traditional instrument is that there are no precise limits, and scoring can be unclear. 
For example, individuals who can leave the house but walk less than 100 yards could 
be scored MRCD 4 or 5.42 Also, patients who can walk several hundred yards fall 
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between 3 and 4 for the traditional scale, whilst in the eMRCD it is clear they should 
be scored 3. 
The traditional score reads: “Too breathless to leave the house…”, sometimes 
referred to as housebound, “… or breathless when undressing”. The eMRCD reads: 
“Too breathless to leave the house unassisted…” which better captures patients’ 
functional limitations. Those only able to walk a few steps, but who routinely leave 
the house using a wheelchair or when driven by family, may not be considered/ 
consider themselves housebound, yet they clearly have very severe breathlessness 
and exercise limitation. 
Extended MRC Dyspnoea Score (eMRCD):  “In the past 3 months, when you were feeling at your 
best, which of the following statements best describes your level of breathlessness?” (please circle) 
Only breathless on strenuous exertion 1 
Breathless hurrying on the level or walking up a slight hill 2 
Walks slower than contemporaries, or stops after walking on the level for 15 minutes 3 
Stops for breath after walking 100 meters, or for a few minutes, on the level 4 
Too breathless to leave the house unassisted but independent in washing and/or dressing 5a 
Too breathless to leave the house unassisted and requires help with washing and dressing 5b 
Guidance notes: 
Remember that you are asking the patient about their level of breathlessness on a good day over the preceding 3 
months, not breathlessness during an exacerbation/on admission. 
A patient only achieves a higher grade if they are as breathless as defined in that higher grade. 
- for example, if worse than defined in eMRCD 3, but not as bad as eMRCD 4, they remain eMRCD 3. 
A key distinction is between eMRCD 4 and eMRCD 5a/5b: 
- only score 5a or 5b if the patient cannot leave the house without assistance.  
- if a patient can only walk 30 to 40 metres, but can leave the house unassisted, they are eMRCD 4. 
- if a patient can walk 5 or 10 metres, perhaps from their front door to a car, but need a wheelchair  
  otherwise, they require assistance: eMRCD 5a or 5b. Simple walking aids do not constitute assistance. 
If a patient requires assistance in personal washing and dressing they are eMRCD 5b. If they only require 
assistance in washing or dressing they are eMRCD 5a. Remember to ask about putting on socks and shoes. 
If patients are limited for a reason other than breathlessness, score based on their functional limitation. 
 
DECAF Score                                                                                                                        Circle 
D 
eMRCD 5a (Too breathless to leave the house unassisted but independent in washing and/or dressing) 
eMRCD 5b (Too breathless to leave the house unassisted and requires help with washing and dressing) 
1 
2 
E Eosinopenia (eosinophils < 0.05 x109/L)                             1 
C CXR Consolidation 1 
A Moderate or severe Acidaemia (pH < 7.3) 1 
F Atrial Fibrillation (including history of paroxysmal AF) 1 
Total:  
Table 1.1: eMRCD score, guidance notes for eMRCD, and DECAF score 
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In our experience, many patients who can leave their home unassisted are 
breathless dressing and, according to the traditional scale, would be classified grade 
5 (the most severe state); in the eMRCD score, patients must be unable to leave 
their home unassisted before scoring 5x. A range of activities of daily living were 
assessed during development of the eMRCD (including washing, dressing, feeding, 
cooking and cleaning), but crucially, if the patient experienced breathlessness but 
remained independent, they did not score: functional limitation is more clearly defined 
and probably offers more accurate prediction. The activities considered were then 
refined to optimise discrimination and ease of application. Level 5 is subcategorised 
into eMRCD 5a or 5b, with 5b referring to a person who requires assistance with both 
washing and dressing. This is essentially a composite assessment of breathlessness 
and frailty.  
Numerous variations of the traditional MRCD scale are in clinical and academic use 
and each variation may have different interpretations. For example, descriptors to 
define MRCD grade 3 include: “people of the same age”, “contemporaries”, “peers” 
or “most people”. In addition, grade 5 traditionally includes breathlessness too severe 
to leave the house, with some versions including breathlessness on dressing/ 
undressing and some including breathlessness on eating.38, 41, 43 Generally, such 
modified scores have not been compared to the traditional instrument, rendering their 
clinical relevance uncertain. 
The 2014 COPD UK national audit 11 has recommended that the DECAF score, 
which includes the eMRCD score, is captured in all patients admitted with an 
exacerbation of COPD. 
1.1.6 EQ-5D-5L 
The EQ-5D-5L score allows health related quality of life (HRQoL) to be valued on a 
scale where perfect health and death are 1 and 0 respectively. The EQ-5D-5L is a 
generic, multi attribute, preference-based measure preferred by NICE for broader 
cost-effectiveness comparative purposes.44 The EQ-5D-5L consists of two aspects. 
The first is a descriptive system, which defines HRQoL in terms of five dimensions: 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression. 
Responses to each of these dimensions are divided into five ordinal levels: first, no 
problems; second, slight problems; third, moderate problems; fourth, severe 
  
9 
 
problems; and fifth, unable to/extreme problems, generating a total of 3,125 possible 
health states. Index-based values (utilities) are a major feature of the EQ-5D 
instrument, facilitating the calculation of quality adjusted life years (QALYs) that are 
used to inform economic evaluations of health care interventions. The responses to 
the EQ-5D 5L questionnaire can be transformed using a standard algorithm to 
produce a health state utility score over various time points.45 
The EQ-5D-5L has been validated in patients with COPD.46 In a group of patients 
with stable COPD, and a group of COPD patients undergoing pulmonary 
rehabilitation, the validity of the EQ-5D-5L was compared to the St. George’s 
Respiratory Questionnaire, the Chronic Respiratory Questionnaire, the Clinical COPD 
Questionnaire and the COPD Assessment Tool. The EQ-5D-5L was shown to be a 
valid and responsive measure of health status. 
1.1.7 Co-morbidity in COPD 
The terms cardiovascular disease and metabolic syndrome (diabetes, high blood 
pressure, obesity and/or dyslipidaemia) cover the most common co-morbidities 
associated with COPD.5, 47 Cardiovascular disease and metabolic syndrome are seen 
more frequently in the COPD population than the general population,11, 47 including 
those with early stage COPD by GOLD classification.48, 49 This is of importance, as 
the investigation and treatment of these conditions can improve morbidity and 
mortality across all stages of COPD severity. Such treatments should include 
smoking cessation. Metabolic syndrome and cardiovascular disease are not discrete 
diagnoses, and share smoking as a common risk factor. Systemic inflammation, 
which is increased by smoking, is a feature of COPD, cardiovascular disease and 
metabolic syndrome.47, 50  
1.2 Acute Exacerbation of COPD 
Section “1.2.1 Definition, diagnosis and aetiology” is an in-depth review of the 
definition and diagnosis of AECOPD. Thousands of patients were screened 
throughout this research, and AECOPD (as a provisional diagnosis prior to specialist 
confirmation) was over- and under-diagnosed. Three key differentials were under-
recognised (heart failure and anxiety) or given undue attention (veno-
thromboembolism) and are discussed. This section also justifies both the inclusion of 
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patients with “pneumonic AECOPD” and the use of this term in preference to 
“community acquired pneumonia”. 
Measures of deprivation in AECOPD are shown in section “1.2.2 Epidemiology”, 
along with prevalence data. 
Section “1.2.4 Impact of AECOPD on patients” looks at the impact of AECOPD on 
patients. Evidence is sought to justify the current emphasis on exacerbation 
prevention, which is partly based on the view that this will slow disease progression. 
Accurate baseline measures of mortality aid risk assessment. The reliability of 
mortality data is considered, which builds on points raised in the first section 
regarding the definitions of npAECOPD and pAECOPD. In Chapter 5, Hospital at 
Home is compared to usual care, and the primary outcome is cost. Potential harm 
due to hospital admission is reviewed, which could be avoided hypothetically with 
home treatment. Finally, there is a description of the overall cost of COPD, and the 
proportion attributed to AECOPD and hospitalisation. 
Section “1.2.5 Management of AECOPD” examines the rationale for common in-
hospital treatments, including the benefits and harms of corticosteroids and 
antibiotics which are perhaps too frequently provided to individuals with COPD. This 
expands on literature from the previous section looking at exacerbation prevention 
and disease progression. Hospital at Home treatment for AECOPD does not appear 
in this section, and is included in the meta-analysis (Chapter 2). 
1.2.1 Definition, diagnosis and aetiology 
AECOPD are defined as a worsening of symptoms from baseline, which is beyond 
the typical daily variation. These symptoms include breathlessness, cough, or a 
change in sputum (increased volume or discolouration).4 The definition sometimes 
includes the requirement of medication, or admission.51 The GOLD 2017 guidelines 
classifies AECOPD as mild (treated with short acting bronchodilators only), moderate 
(treated with short acting bronchodilators plus antibiotics of oral corticosteroids), or 
severe (requires hospitalisation or visit to emergency room).52 The majority of 
exacerbation are caused by bacterial and/or viral infections, though air pollution may 
also be an important aetiological factor in AECOPD and is associated with 
hospitalisation admission.53 
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Bacterial infection may follow as a consequence of viral infection.54 Tests that confirm 
the presence of viruses tend only to be performed in the research setting.24 In the 
clinical setting, excluding infection as the cause of AECOPD is difficult, though 
discoloured sputum as reported by microbacteriologists strongly suggests the 
presence of bacteria.55, 56 
Bacteria are present in 4% of healthy adults, 29% of patients with stable COPD, and 
54% of those with an AECOPD, with higher microbial loads seen during AECOPD.57 
This increased load may represent new acquisition of bacteria rather than 
proliferation of existing strains.58 
49% (662 of 1,352) of patients with an AECOPD and purulent sputum have positive 
sputum cultures.59 Within this group, multivariate analysis showed that pre-treatment 
clinical factors, including sputum colour and viscosity, were not strong predictors of 
the presence of bacteria either as individual predictors or in combination (area under 
the receiver operator characteristic curve = 0.59).60  
In patients who meet the diagnostic criteria for chronic bronchitis and have an 
AECOPD and mucoid sputum, bacteria are commonly present. In one study, the rate 
of absence of bacterial growth was 22%,56 though in another study it was 62%.61 
Variation in disease severity may explain this difference, as more severe COPD 
correlates with the presence of bacteria.57, 60 High rates of bacterial growth in those 
with severe, stable COPD has been attributed to colonization. However, the 
presence of bacteria is associated with inflammation and an immune response, so 
chronic infection may be a more accurate description than colonization.62 
Pneumonia commonly occurs with AECOPD, especially in patients who require 
hospitalisation. The proportion of patients with AECOPD who have pneumonia is 
unclear, in part due to reporting. In the International Classification of Diseases (ICD) 
10 classification there are multiple possible codes for patients admitted with an 
AECOPD or a pneumonic AECOPD (pAECOPD). Furthermore, the term “pneumonia” 
may supersede pAECOPD, and “COPD” subsequently may not appear. Previous 
studies of COPD codes using ICD-9 or ICD-10 are limited in that they did not include 
pneumonia and/or patients did not require spirometric confirmation of COPD.63-66 
Many observational studies rely on administrative data to identify patients; accurate 
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identification of the population of interest is fundamentally important to the validity of 
their results. 
Some clinicians regard pneumonia as a separate diagnosis to an AECOPD, or even 
take the extreme view that a diagnosis of pneumonia (parenchymal disease) 
invalidates a diagnosis of AECOPD (airway disease). This observation is supported 
by the differences in the rates of pneumonia reported in the national COPD audit 
compared to the DECAF derivation study. The DECAF derivation study captured 920 
consecutive admissions with AECOPD, and included all those with co-existent 
pneumonia. Radiographic consolidation was seen in 32.5% in the DECAF cohort, 
compared to only 18% in the UK national audit.2, 11 
Throughout this thesis, an AECOPD complicated by pneumonia will be called a 
pneumonic exacerbation (pAECOPD). The primary justification for this terminology is 
that patients with pAECOPD and non-pneumonic AECOPD share more similar 
treatments than those with community acquired pneumonia (CAP) without COPD. 
Patients with pAECOPD have similar sociodemographic details, severity of 
underlying COPD and range of organisms to those with non-pneumonic AECOPD.67 
Patients with CAP have higher rates of pulmonary effusion, empyema, legionella 
pneumophilia infection, and lower rate of pseudomonas aeruginosa infection than 
patients with pAECOPD.68 
The recognition of pAECOPD is important because co-existent pneumonia is 
associated with worse outcome, and has important implications for treatment. In 
patients with acute hypercapnic respiratory failure and isolated CAP, most studies 
show non-invasive ventilation (NIV) does not improve outcome and current 
guidelines state NIV is not indicated.69 In pAECOPD NIV reduces intubation rates 
and improves survival. In high risk patients, broad spectrum antibiotic therapy with 
anti-pseudomonal cover should be considered. However, the presence of 
consolidation depends on the timing and type of radiographic modality; lack of 
consolidation on chest radiograph does not exclude pneumonia.70-72 
Blood eosinopenia (<0.05x10^9/l) is a marker of disease severity, and is a strong, 
independent predictor of inpatient mortality.2 Airway eosinophilia is associated with 
response to corticosteroids, and a serum eosinophil count of 2% or less may have a 
role directing oral corticosteroid therapy for AECOPD.73 Stable state eosinophil count 
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also appears to predict response to inhaled corticosteroids; consistent with earlier 
data, a threshold of 2% has been muted,74 however a post-hoc analysis of the 
Wisdom study showed that it is principally those with an absolute count of 0.3 or 
more, or a relative count of 4% or more who benefit.75 It is important to recognise that 
eosinophil counts may fall in the setting of sepsis and inflammation, and stability of 
eosinophil phenotype is uncertain. In the future, AECOPD may be classified based 
on eosinophil count, which may be used to direct corticosteroid therapy, and further 
research is awaited. 
GOLD guidelines prior to the initiation of our RCT did not recommend (diagnostic) 
spirometry during an AECOPD because “it can be difficult to perform and 
measurements are not accurate enough.”5 One study specifically questioned the 
validity of this recommendation.76 Whilst less than half of patients admitted with an 
AECOPD could perform spirometry, the mean FEV1% predicted was 38.7% (SD 
14.4) at discharge and 40.6% (14.3) at one month (p = 0.18). Crucially, of 41 patients 
who met GOLD criteria for COPD at discharge, only 2 failed to meet the criteria at 
one month. In previously undiagnosed patients hospitalised with a clinical history 
consistent with AECOPD, this data supports using pre-discharge spirometry to 
confirm COPD. Patients are at particularly high risk of adverse events immediately 
after an exacerbation requiring hospitalisation; confirmation of airflow obstruction 
supports initiation of therapy to improve symptom control and reduce risk. Of interest, 
the recommendation not to perform diagnostic spirometry during an AECOPD does 
not appear in the 2017 GOLD guidelines.52 
Clinical features which point towards underlying COPD in a patient presenting to 
hospital with a suspected AECOPD include: a heavy smoking history; progressive 
breathlessness, chronic cough, sputum production and onset after age 35 years. 
Physical examination may show hyper-inflation, hyper-resonance or decreased 
cardiac dullness on percussion; decreased breath sounds; wheeze; and a prolonged 
expiratory time.77 Features suggestive of primary or co-existent asthma should be 
sought, and other differential diagnoses considered. Such factors are important, as 
there are a number of medical conditions which can mimic AECOPD and co-
morbidity is common in patients with COPD.5 An autopsy study of 43 inpatient COPD 
deaths who died within 24 hours of admission showed the primary cause of death to 
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be heart failure (n = 16), pneumonia (n = 12) and pulmonary thrombo-embolism (n = 
9).78 
In patients with known COPD who present with symptoms suggestive of AECOPD, 
pulmonary thromboembolism and heart failure are common final diagnoses.79 It is not 
appropriate to label such episodes as AECOPD, not least because the required 
treatments are different. 
Differential diagnosis for AECOPD 
AECOPD are the focus of this research and their correct identification is crucial. 
Common conditions that can mimic AECOPD will be considered in detail in the 
following section. The GOLD guidelines state that the diagnosis of an exacerbation 
relies exclusively on the presence of symptoms. However, the symptoms that define 
an AECOPD are non-specific, and not all patients with these symptoms should 
receive a diagnosis of AECOPD. A diagnosis of AECOPD also involves assessing 
patients for features that favour an alternative diagnosis. 
Heart failure 
Decompensated heart failure can cause or mask the symptoms and signs of an 
AECOPD.80 Pulmonary congestion is associated with airflow obstruction, acute 
breathlessness, wheeze and cough.81, 82 Bronchial hyper-responsiveness to 
acetylcholine provocation testing has been observed in patients with chronic 
pulmonary overload.83 The prevalence of COPD is approximately 30% in stable heart 
failure, though estimates vary between 9 and 45%.84 The proportion of never 
smokers is higher than might be expected.85, 86  The lower COPD prevalence 
reported in some studies may be due to more aggressive treatment of heart failure in 
the acute and chronic setting. Variation in COPD prevalence may also reflect 
differences in study populations (such as smoking prevalence and age) and accuracy 
of diagnosis; most studies did not include spirometric testing.84  
Few studies have performed serial spirometry to establish the prevalence of fixed 
airflow obstruction following admission due to heart failure. In an early study,81 airflow 
obstruction was common at the time of decompensation, but improved rapidly in 
most patients over two weeks. After several months, only 8 of 15 patients had 
persistent airflow obstruction. 
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In another study of patients hospitalised with congestive heart failure,86 144 of 619 
(23%) patients had a previous diagnosis of COPD at admission, of whom 79 of 144 
(55%) were on COPD therapy. However, in those with a previous diagnosis of 
COPD, 112 of 144 (78%) had COPD excluded by pulmonary function testing at six 
months’ follow-up. COPD was both over-diagnosed and under-recognised; an 
additional 26 new cases were identified. A previous history of asthma was an 
exclusion criterion, so is unlikely to account for the variability in lung function results.  
Within this same study, 272 patients had lung function testing prior to discharge and 
at six months’ follow-up. This showed significant increases in FEV1% predicted, FVC, 
residual volume and total lung capacity, showing that patients had a mixed 
obstructive and restrictive picture. The FEV1/FVC ratio improved, but did not reach 
statistical significance (p = 0.12). Of note, the authors used an FEV1/FVC cut off of 
0.7 to define COPD, which tends to result in a higher prevalence of COPD compared 
to using the lower limit of normal in this group.87 
It is important to differentiate between AECOPD and decompensated heart failure to 
ensure patients receive the correct treatment. Concerns have been raised regarding 
the use of beta-agonists in those with heart failure. In a cohort of 1,529 patients, a 
dose-response increase in risk was reported between beta-agonist use in heart 
failure and all-cause mortality, which persisted after adjusting for cofounders.88 This 
cannot prove causation, as beta-agonist use may be a marker of disease severity. In 
a related example, an association between mortality and chronic beta-agonist has 
been reported in asthma,89 90 but was not seen in the 4 to 12 months prior to death, 
making a causal relationship more doubtful.90 
Pulmonary thromboembolism 
Presenting symptoms and signs are similar between AECOPD and pulmonary 
thromboembolism (PE). A literature review from 2009 aimed to determine the 
prevalence of pulmonary thromboembolism during AECOPD.91 Eligibility criteria 
included a diagnosis of COPD supported by symptoms and spirometry, and 
investigation of pulmonary thromboembolism based on CT angiography or pulmonary 
angiography within 48 hours of presentation. The review incorrectly concluded that 
one in four patients hospitalised with AECOPD may have PE. This is misleading as 
the selected studies largely looked at subpopulations of patients with AECOPD 
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without a clear cause, rather than consecutive unselected patients. Hartman et al. 
looked at consecutive patients with suspected pulmonary thromboembolism, not 
consecutive AECOPD, and the prevalence of PE was similar in patients with and 
without COPD.92 
Lesser et al.93 and Mispelaere et al.94 looked at a select group of AECOPD, namely 
those in whom a diagnosis of pulmonary thromboembolism was suspected 93 and 
those with a COPD exacerbation without evidence of infection.94 Tillie-Leblond et al. 
found 25% of patients with COPD exacerbation of unknown cause had pulmonary 
thromboembolism.95 
Rutschmann et al.96 may provide the most representative picture of the prevalence of 
pulmonary thromboembolism in patients thought to have an AECOPD. Consecutive 
patients with a diagnosis of AECOPD who had moderate to very severe COPD were 
recruited. AECOPD was defined as a worsening of breathlessness sufficiently severe 
to warrant admission to the emergency room, but, importantly, patients with an 
obvious alternative cause for their breathlessness were excluded. Clinicians reported 
whether pulmonary thromboembolism was clinically suspected or not, with no 
suspicion defined as a patient who would not have otherwise been investigated for a 
pulmonary thromboembolism. In those patients with an AECOPD in whom pulmonary 
thromboembolism was not clinically suspected, only 1 of 75 patients had a confirmed 
pulmonary thromboembolism. Also, the proportion of people with veno-
thromboembolism (VTE) risk factors was appreciably lower compared to other 
studies. 
Newer imaging techniques may have a higher pick up rate for pulmonary 
thromboembolism in AECOPD: recent studies of pulmonary thromboembolism in 
AECOPD report figures of 18% 97 and 30%.98 Both of these studies have included 
patients in whom pulmonary thromboembolism was the favoured diagnosis.  
Shapira-Rootman et al.97 defined AECOPD broadly as any worsening of dyspnoea 
sufficiently severe to warrant admission to hospital, and alternative obvious causes of 
breathless were not part of the exclusion criteria. Similarly, Akpinar et al.98 failed to 
exclude those whose likely diagnosis was not an AECOPD: 22% of patients 
diagnosed with pulmonary thromboembolism had leg asymmetry in whom the 
primary diagnosis perhaps should not have been an AECOPD.  
  
17 
 
Post-mortem studies show high proportions of pulmonary thromboembolism, but 
cannot provide an estimate of the prevalence of PE in AECOPD. In COPD patients 
admitted to a respiratory intensive care unit who died, 30% had VTE 99 and in 
patients admitted with an AECOPD who died within 24 hours of admission, 21% had 
VTE.78 Both of these studies involve patients at especially high risk of VTE. 
Whilst the prevalence of PE in AECOPD is probably overestimated, the risk of PE in 
COPD may be higher than in the general population. The risk of venous 
thromboembolism and adverse outcome (including risk of death, bleeding and VTE 
recurrence) is higher in patients with COPD than those without COPD. The ratio of 
pulmonary thromboembolism to deep vein thrombosis (DVT) is higher in COPD 
patients than the general public and COPD patients are also more likely to re-present 
with pulmonary thromboembolism rather than DVT.100 This could be explained by a 
higher rate of in-situ thrombosis,91 which has been implicated as a cause of 
pulmonary thrombosis in idiopathic pulmonary arterial hypertension and chronic 
thromboembolic pulmonary hypertension.101 COPD is associated with systemic 
inflammation, and hypothetically such patients may be more likely to produce DVTs 
that embolise. Lastly, patients with COPD are more likely to have a CT-PA and 
receive a diagnosis of PE, which includes incidental sub-segmental PE and false 
positive CT-PA results. The significance of incidental and/or isolated subsegmental 
PE is uncertain. Recent guidance recommends that they should be managed the 
same way as symptomatic and non-subsegmental PE, though the evidence is not 
clear-cut.102 
Anxiety 
Anxiety is common in COPD and is associated with hospital admission.103, 104 During 
an AECOPD that requires hospitalisation, patients have high levels of anxiety as 
measured by the Hospital Anxiety and Depression score (HADs), which improve with 
recovery.105 AECOPD are characterised by breathlessness, which is a cause of 
anxiety.5 A cycle of breathlessness, arousal, and worsening breathlessness forms the 
cognitive model of panic attacks and panic disorder.106 The Diagnostic and Statistical 
Manual of Mental Disorders 4th Edition makes a distinction between panic attacks 
with and without an underlying general medical condition. Panic disorder involves 
recurrent, unexpected panic attacks with one month or more of persist concern about 
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further attacks, their consequences, and/or a change in behaviour. Anxiety disorder 
is the appropriate term for patients that experience symptoms akin to panic attacks at 
the time of an AECOPD. In practice, it may be difficult to distinguish between a 
COPD patient having a panic attack and patients with an AECOPD and high levels of 
coexistent anxiety. 
Anxiety and panic attacks are important to identify in COPD patients. Corticosteroids 
may induce a range of psychiatric disorders, and are associated with increased risk 
for panic disorder in elderly patients.107 Cognitive-based therapy is of benefit in those 
suffering panic attacks, and may stop the development of panic disorder.106 
Panic attacks may be of particular concern in patients with COPD who are “flow 
limited”. This describes patients whose expiratory time is insufficient to allow the end 
expiratory lung volume to reach its natural relaxation volume, which leads to 
hyperinflation.108 During AECOPD such patients are prone to worsening expiratory 
flow obstruction, dynamic hyperinflation and cardiorespiratory decompensation. In 
patients with severe hyperinflation, there are decreases in left and right ventricular 
end-diastolic volumes, and an impaired stroke volume and cardiac output compared 
to controls, due to changes in intrathoracic blood flow and mechanical 
compression.109 Acute anxiety can contribute to this deterioration through an 
increase in respiratory rate, which can worsen flow limitation and dynamic 
hyperinflation. 
1.2.2 Epidemiology 
The prevalence of AECOPD can vary substantially depending on whether the 
definition is symptom based, or includes the need for medication and/or admission.110 
Up to 50% of exacerbations are unreported to clinicians.23, 111 Symptoms and the 
time-course to recovery is similar between reported and unreported exacerbation,23, 
112 so a definition that includes these important events is appropriate from the 
patients’ perspective. Previously unreported events have been captured by the use of 
symptom diary cards,23 which pre-dated the EXAcerbation of Chronic Pulmonary 
Disease Tool- Patient Reported Outcomes (EXACT-PRO). The EXACT PRO has 
been used to identify the frequency, severity and duration of AECOPD and has been 
assessed in stable and exacerbating populations.113 
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Patients who do not report their exacerbations have worse health-related quality of 
life, and are more likely to be admitted to hospital; early treatment for AECOPD may 
shorten recovery.114 Those that do not report exacerbations may represent a more 
unwell population. 
Up to one in eight AECOPD may need emergency inpatient episodes.115 The 
TORCH study selected patients aged 40 to 80 with a baseline pre-bronchodilator 
FEV1 of less than 60%; in the Seretide treatment arm, the annual rate of 
exacerbations requiring treatment was 0.85 and hospitalisation 0.16. The WISDOM 
study, another large RCT, reported 0.95 exacerbation per patient-year for moderate 
to severe exacerbation.116 Such large RCTs may not be representative of the general 
population. In the US in 2010, there was an estimated 1.5 million emergency 
department visits (73.6 per 10,000 US population) and 699,000 hospital admissions 
(34.4 per 10,000 US population) for COPD.117 In the UK, between 2006 and 2009, 
COPD admissions were 26.5 per 10,000 UK population.118 
From a population perspective, data from Spain and Sweden show that the incidence 
of AECOPD is decreasing,119, 120 though these figures may not be generalisable to 
other parts of the world. 
COPD is associated with lower levels of education, lower income and employment 
rates, and higher health disability.8, 11 The  latest UK National COPD Audit 11 
assessed deprivation in patients admitted with AECOPD using the Index of Multiple 
Deprivation which is based on postcode and includes seven different domains. In 
four domains, there was more than a three-fold difference in the proportion of the 
total COPD population living in the most deprived national quintile compared to the 
least deprived quintile (Table 1.2). This trend was seen in Wales, as well as England. 
Patients with AECOPD have high levels of co-morbidity. In the most recent UK 
national audit,11 the most frequently reported co-morbidities were hypertension 
(31%), ischaemic heart disease (21%), diabetes (16%) and atrial fibrillation (12%). 
High levels of comorbidity were also seen in the DECAF derivation study:2 
hypertension (40%), ischaemic heart disease (29%), diabetes (15%) and atrial 
fibrillation (13%). Furthermore, 34% of patients were housebound, with 6.5% 
admitted from institutional care. The findings in the DECAF validation cohorts (6.1 
Patient characteristics) were consistent. 
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 % of national audit sample living in postcode areas within 
English national quintiles, from most deprived (Q1) to least 
deprived (Q5), % (total n = 12,245) 
 Q1 Q2 Q3 Q4 Q5 
Index of multiple Deprivation 33 24 19 15 10 
Income deprivation 32 25 19 15 10 
Employment deprivation 34 24 18 14 10 
Health deprivation and disability 33 23 18 15 11 
Education, skill and training deprivation 34 24 18 15 10 
Barriers to housing and services 16 19 21 22 23 
Crime 27 23 19 17 14 
Living environment deprivation 23 21 21 19 15 
Table 1.2: Index of multiple deprivation measures by national quintile, England 
Most studies which look at severe AECOPD only (those that require hospitalisation) 
include all patients who present between discrete time points, and at different stages 
in their disease. One inception cohort studied 73,106 patients from their first ever 
hospitalisation for COPD.25 The time between the first and second hospitalised 
exacerbation was around five years, and the gap between successive episodes 
shortened with time. Patients were followed up for a mean of 3.6 years, ranging from 
1 day to 17 years. The mean rate of severe exacerbation requiring hospitalisation 
was 37.8 per 100 per year. As patients were recruited following their first admission 
with an AECOPD, these rates will be higher than the general population with COPD. 
In Spain and Sweden, the incidence of hospital admissions seems to have 
decreased.119, 120 
1.2.3 Risk factors for AECOPD requiring hospitalisation 
Predictors of AECOPD requiring hospitalisation over six months include: age, FEV1 
% predicted, unscheduled clinic/Emergency Department visits in the prior year, 
hospitalisations in the prior year, cardiovascular disease, and oral corticosteroids.119-
121 In the ECLIPSE study,122 the best predictor of exacerbation was a previous history 
of exacerbations. One of the aims of COPD therapy is to reduce the risk of future 
AECOPD. Evidence from TORCH,123 and the Eclipse study 122 (as quoted in the 
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GOLD guidelines5) show that more severe airflow obstruction is associated with more 
hospitalisations per year (GOLD 2 = 0.11 to 0.2, GOLD 3 = 0.25 to 0.30, and GOLD 4 
= 0.40 to 0.54 hospitalisations per year). Consequently, therapy to reduce the 
frequency of AECOPD is directed by the number of exacerbations in the previous 
year, and the FEV1% predicted.5 One study of 107 patients with COPD reported the 
following potentially modifiable risk factors of AECOPD requiring admission: ACE 
inhibitor or angiotensin receptor blocker use, gastro-oesophageal reflux disease 
symptoms and poor adherence to inhaled therapy and outpatient visits;124 whether 
modifying these would reduce exacerbation frequency is unclear. 
Patients with undiagnosed COPD have a greater risk of hospital admission for 
AECOPD.118 Protective factors include being offered influenza immunisation, patient-
reported access to primary healthcare staff and the number of GPs and practice 
nurses per 1000 patients.118 
The number of AECOPD requiring hospital admission peaks in the winter and is at its 
lowest during the summer.125, 126 This may be due to low temperature, viruses, 
crowding of people indoors, a reduced immune system, or a combination of these 
factors.110 
1.2.4 Impact of AECOPD on patients 
AECOPD have a marked impact on patients with COPD and are associated with 
worsening symptoms, lung function, health-related quality of life, and mortality risk.26, 
112, 127-129 AECOPD become more frequent with time, tend to occur in clusters,130 and 
approximately one in three patients will be re-admitted within 90 days of discharge.131 
The severity of AECOPD tends to increase with subsequent exacerbations.25 
Symptoms and quality of life 
AECOPD are defined by worsening respiratory symptoms, notably breathlessness, 
and these symptoms have an important impact on health status. Improvements in 
health status following AECOPD may occur over a few weeks or many months, which 
may be due to several factors, including: a) individual variation in recovery; b) 
recurrent exacerbation (including both reported and unreported episodes); and c) a 
permanent decline in health status caused by exacerbation. 
  
22 
 
Individual variation in recovery of health status, as measured by the St George’s 
Respiratory Questionnaire (SGRQ), has been shown in a number of studies.127, 132 In 
one study, serial measures of health status following severe AECOPD showed an 
initial large mean improvement in the first four weeks.133 In 51 patients hospitalised 
due to an AECOPD there were significant improvements in health status (using the 
SGRQ) over the entire nine month follow up period.134 Measures of psychological 
distress (using the Hopkins Symptom Checklist) also improved, as did the physical 
domain of the World Health Organisation Quality of Life. 
In 183 patients admitted to hospital with an AECOPD, health status was assessed 
over one year post discharge in ventilated (n=80) and non-ventilated patients (n=96); 
7 patients failed to attend all assessments and were excluded. Most measures of 
quality of life peaked at 3 months, functional recovery peaked at six weeks, and most 
patients (70% and 76% in the ventilated and non-ventilated groups) did not 
experience a clinically important deterioration in St George’s Respiratory 
Questionnaire total score.105 
The changes in health status following AECOPD are different in those who do, and 
do not, have a further exacerbation. The non-exacerbator group tend to have a larger 
improvement in health status at 4 weeks and 12 weeks.133  
Assessing the impact of AECOPD is problematic as patients commonly have 
episodes of worsening symptoms which fulfil the diagnosis of an AECOPD for which 
they do not seek medical help. This was observed in a study of 70 patients in the 
community with stable COPD, using daily diary cards.112 Health status was strongly 
associated with exacerbation frequency, despite the fact that the mean time between 
administering the SGRQ and the previous exacerbation was 101 days. From this, the 
authors hypothesise that preventing AECOPD should be associated with a reduced 
decline in health status. 
Several RCTs have shown an improvement in health status associated with a 
reduction in AECOPD frequency. Typically, COPD studies measure health status 
with the SGRQ. The minimum clinical important difference (MCID) is -4 in unselected 
patients with COPD, though in those with more severe COPD a difference of -8.3 at 
one month and -7.1 at six months has been suggested.135 
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The ISOLDE study 136 showed a lower rate of deterioration in health status in patients 
receiving inhaled corticosteroids, with a reduction in exacerbation frequency, but no 
impact in the decline in FEV1 compared to placebo. In a subsequent analysis of this 
study, a regression model showed that the effect of inhaled corticosteroids on health 
status was largely explained by their effect on exacerbation frequency.137  
In the TORCH study 123 patients were randomised to treatment with salmeterol and 
fluticasone, fluticasone alone, salmeterol alone and placebo. There were significantly 
fewer moderate to severe exacerbation and better health status in the combined 
treatment group compared to the placebo group: the mean adjusted change in 
SGRQ over 3 years was -3.0 compared to +0.2, which falls short of the MCID. 
Similarly, the UPLIFT study showed that treatment with tiotropium in comparison to 
placebo caused fewer exacerbations with an improvement in the mean change in the 
SGRQ up to 4 years which was below the MCID.138 Whilst there was a reduction in 
exacerbation frequency requiring hospitalisation in TORCH, this was not the case in 
UPLIFT, though the annual rates of severe hospitalisation was low and similar in both 
arms and many patients in the UPLIFT study were already treated with LABA/ ICS. 
The SUMMIT study 139 compared vilanterol and fluticasone, fluticasone alone, 
vilanterol alone and placebo. Combination therapy reduced the annual rate of 
moderate and severe exacerbations, but health status was only collected on a subset 
of 4443 (27%) patients and is not reported in the primary paper.  
The FLAME study 140 compared two active dual therapies (LABA/ LAMA versus 
LABA/ICS) and showed a small improvement in exacerbation frequency and health 
status with LABA/ LAMA therapy. 
Lung function 
FEV1 deteriorates in adults as part of the normal ageing process, and a more rapid 
decline is seen in those who smoke.141 AECOPD are associated with deterioration in 
lung function (measured by FEV1 or peak expiratory flow rate) which, in a minority, 
may not fully recover. This lack of recovery in lung function could be predominantly 
due to the background deterioration in FEV1 and independent of AECOPD, or occur 
as a direct consequence of AECOPD. 
  
24 
 
On average, small changes in lung function are observed with AECOPD, though it 
varies between individuals. In 101 patients with stable COPD at recruitment, patients 
recorded daily symptoms and peak expiratory flow rates, and a subpopulation of 34 
performed daily spirometry over a two and a half year period.23 Patients reported a 
deterioration in their symptoms prior to any deterioration in lung function. Median 
recovery time of peak expiratory flow rate was six days, with complete recovery in 
only 75% of exacerbations at 35 days, and 93% of exacerbations at 91 days, though 
changes in lung function were small. Those patients who did not recover lung 
function had a larger fall at the time of exacerbation. This shows that AECOPD 
worsen lung function in the acute period and that in some patients, resolution is slow 
or incomplete.  
An association between AECOPD frequency and the annual rate of decline in FEV1 
has been shown.26, 142, 143 In a large cohort of 5887 smokers (The Lung Health 
Study), higher numbers of lower respiratory tract infection were associated with a 
higher annual rate of FEV1 decline in smokers.142 In 109 patients with moderate to 
severe COPD daily diary cards were used to identify reported and unreported 
AECOPD. Compared to infrequent exacerbators, patients experiencing frequent 
exacerbations showed greater declines in peak expiratory flow rate and FEV1 (in the 
subset of 32 individuals who performed daily spirometry). Frequent exacerbators 
tended to be more likely to be current smokers (39.3% v 22.2%; p = 0.056).26 
Exacerbation frequency, rather than smoking status, was the main determinant of 
FEV1 decline; the small numbers in the FEV1 subgroup may bias the results. In a 
similar study of 102 patients who performed six-monthly spirometry, exacerbation 
frequency was associated with decline in FEV1 per cent predicted. Whilst smoking 
was the major determinant of lung function decline, exacerbation frequency was also 
a factor.143 
Smoking has previously been shown to be the main determinant of FEV1 decline.141 
In contrast to more recent studies, Fletcher and colleagues found that decline in 
FEV1 occurred continuously and smoothly over a person’s life, and that bronchial 
infections were not a factor. This was a large study assessing the effect of smoking 
status in working men in London, and not limited to those with confirmed COPD, 
which could partially account for the differences observed. A more recent study in 
279 Japanese patients showed no relationship between AECOPD frequency and 
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decline in FEV1.144 This study reported a lower AECOPD rate than other studies, 
though the authors observe that a lower frequency was also observed amongst 
Japanese patients in the UPLIFT study.  
If AECOPD are responsible for a faster decline in FEV1, (rather than being 
associated with another cause, such as smoking) then preventing AECOPD should 
reduce this effect. 
The TORCH study showed a reduction in exacerbation frequency and, in a 
subsequent analysis, a slower decline in FEV1 with combination ICS/LABA treatment 
compared to placebo.123, 145 The rate of decline of FEV1 per year in mls was -39.0 
compared to -55.3 (green line and black line on Figure 1.1). The annual rate of 
decline in the treatment arm was lower than historical controls.145 This comparison 
accounted for other factors that may impact on lung function, such as differences in 
smoking. However, the difference in FEV1 decline between treatment and placebo 
was largest amongst those who reported no AECOPD, though treatment may have 
impacted on unreported events. As discussed, unreported events may account for 
50% of AECOPD, and acutely worsen lung function.23 It is now recommended that all 
AECOPD are captured in similar trials, including reported, self-managed and 
untreated events.146 
Lung function decline was not a primary outcome of the TORCH study, and the 
observed difference in the annual rate of decline of FEV1 in TORCH may be 
inaccurate: the proportion of drop-outs and missing FEV1 data was higher in the 
placebo arm than the treatment arm. The real difference in FEV1 decline may have 
been larger; patients who withdrew from the placebo arm had higher rates of decline 
(blue line Figure 1.1). Conversely, higher rates of missing data at baseline (18% had 
missing baseline data compared to 9% in the combination treatment arm) would 
overestimate the initial FEV1 and exaggerate the difference in decline in the placebo 
arm (red line Figure 1.1).147 
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Figure 1.1: Graph illustrating potential bias in FEV1 decline due to missing data 
 Green versus black line: The difference in rate of decline between combination 
therapy and placebo in the TORCH trial was 16mL per year.  
 Green versus blue line: There were more patients with missing FEV1 values in 
the placebo arm, whose inclusion may have widened the difference in FEV1 
decline. 
 Green versus red line: Missing FEV1 data was higher in the placebo arm at 
baseline, whose exclusion could have resulted in no difference in the rate of 
FEV1 decline. 
The UPLIFT trial showed that patients who were treated with tiotropium had 
significantly fewer exacerbations per patient year compared to the placebo group 
(0.85 versus 0.73).138 Whilst there was no difference in the rate of decline of FEV1 
(the primary outcome) between the two groups, the frequency of severe exacerbation 
was the same; milder exacerbations may have less impact on lung function decline. 
The SUMMIT study 139 showed that combination therapy reduced the annual rate of 
moderate and severe exacerbations and led to a modest (12mls) annual 
improvement in the rate of decline of FEV1. As with the TORCH study, this value 
may have been under or over-estimated due to missing data. They report that the 
reduction in FEV1 should be placed in the context of the 25-30ml annual decline in 
FEV1 which occurs in the general population. Other sources suggest that the decline 
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in FEV1 may be higher in certain populations (including the study population- those 
with COPD, smokers and ex-smokers), and this higher rate may still be an 
underestimate due to participant drop out.148 The absolute minimal clinical important 
difference for FEV1 in COPD is around 100mls, which is based on a volume that 
patients can perceive,148 though the proportional difference based on baseline lung 
function is also important.149 
RCTs of inhaler therapy in COPD generally report the mean annual difference in 
FEV1 between treatment groups. A more meaningful value to report would be the 
proportion of patients in each arm that reach the MCID: “the minimum worthwhile 
incremental advantage”.149 This would allow for the analysis of exacerbation 
frequency in responders to better understand the impact of exacerbation prevention 
on FEV1 decline. 
Mortality  
Inconsistency with terminology for COPD and AECOPD means mortality data may be 
inaccurate.5 For AECOPD that require admission, in-hospital mortality is reported to 
be between 4.3% and 10.4%.2, 11, 119, 125, 150-152 In a large inception cohort study, every 
new severe exacerbation increased the risk of death.25 Mortality peaked in the first 
week after admission and stabilised after three months. There is substantial variation 
in an individual’s risk of death, which can be calculated using the DECAF score and 
is discussed further in Chapter 6.2  
In the UK national COPD audits, inpatient mortality was 7.7% in 2003, 7.8% in 2008 
and 4.3% in 2014, though the reason for the drop in mortality in 2014 is unclear.11 
There have been no major developments in treatment that reduce mortality between 
2008 and 2014; differences may be due to reporting practices. The DECAF deviation 
study and the 2008 UK national audit had an inpatient mortality of 10.4% and 7.7% 
(this fall is consistent with local audit data), despite the fact both studies were in the 
UK and were performed at a similar time.2, 150 The higher mortality rate in the DECAF 
studies may reflect more complete case ascertainment; patients at risk of being 
missed are more likely to have died. A comparison of these studies provides insight 
into reported differences. Pneumonia is a strong, independent predictor of inpatient 
mortality in AECOPD,1 and the rate of pneumonia in the DECAF study was double 
that of the equivalent national audit data (32.5% versus 16%). This largely accounts 
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for the observed differences in mortality. In the DECAF derivation study, all those 
with COPD and coexistent pneumonia received a diagnosis of pneumonic AECOPD 
and were included. Of note, most patients with pAECOPD had severe airflow 
obstruction when stable. This practice is not the same throughout the UK; in the 
national UK audit some patients who received a diagnosis of pneumonia rather than 
pneumonic AECOPD may have not been included. Furthermore, the 2009 influenza 
pandemic and high rates of comorbidity could have contributed to the high rates of 
pneumonia in the DECAF study. 
Post discharge mortality was reported as 4.2%, 10.5%, and 17.4% at 30, 90 and 180 
days in a large study from Northern Denmark.125 As seen in previous studies,25 
mortality risk increased with each AECOPD hospitalisation. Ninety day mortality was 
5.9% in the European COPD audit.10 Again, this may be accounted for by differences 
in populations, as well as variations in healthcare systems.153 
Hospital admission 
Patients admitted for AECOPD have worse outcome than those that do not require 
admission. The need for hospital admission is used to define severe AECOPD.52, 123, 
138 Differences between the admitted and non-admitted population may explain the 
different outcome, for example COPD severity, comorbidity, and age.  
Hospital admission is associated with poor nutrition, infection and deconditioning. In 
both stable and acute settings, COPD patients with a low BMI have a worse 
mortality,2, 154 and poor exercise tolerance is a strong predictor of adverse outcome.1 
Whilst bed rest leads to physical deconditioning and muscle weakness, immobility is 
associated with many adverse outcomes, including increased risk of falls, delirium 
and venous thromboembolic disease.155, 156 Conversely, pulmonary rehabilitation 
improves exercise capacity, health-related quality of life and reduces hospitalisation 
in patients with AECOPD.,157 However, one large study of inpatients with AECOPD 
receiving an early, intensive rehabilitation programme compared to usual care failed 
to demonstrate a reduction in readmissions and showed increased mortality at one 
year. Falls and delirium are more likely in the unfamiliar hospital environment, the 
latter compounded by interruptions in the patient's usual routine and sleep patterns. 
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Advancing age and lung disease partly account for COPD patients' susceptibility to 
infection, the risk of which is increased by hospital admission. Viral and bacterial 
infections together account for 70-80% of exacerbations.62 
RCTs of home treatment compared to hospital treatment for AECOPD have shown 
that home treatment may reduce readmission rates.158 In one study, patients treated 
at home had fewer urinary tract infections.159 Home treatment for AECOPD is the 
intervention in the DECAF implementation RCT and is discussed in more detail in a 
meta-analysis in Chapter 2 
Cost to society 
The annual healthcare cost of COPD has been estimated as 38.6 billion Euros and 
49.4 billion dollars in the European Union and United States.5 The majority of these 
costs are due to hospitalisation and the management of AECOPD.152 In the UK, the 
cost of COPD care is between 817.5 million 160 and 982 million pounds,29 of which 30 
to 50 per cent is due to inpatient care. Costs of care dramatically increase with the 
severity of COPD, as hospitalisation and treatment with ambulatory or long-term 
oxygen is more common in severe disease.5 
In the United States, the average cost of hospitalisation has been estimated at 9,545 
dollars (plus or minus 12,700), with a total cost of 11.9 billion dollars.152 In this study, 
costs were higher in patients with more comorbidity. In the UK, a hospital admission 
is estimated to cost 1,960 pounds.161 A number of studies of Hospital at Home/ Early 
Supported Discharge (HAH/ESD) have calculated inpatient costs, though these were 
studies were performed in a subset of patients with milder disease. The cost of 
admission with regards to HAH/ESD are discussed in more depth in “2.3.6 Service 
costs”. 
Patients with COPD may be unable to work, and family members may miss work to 
care for their relative.5 In the late 1990s, the cost per year of lost productivity due to 
missed working days has been estimated at £2.7 billion.161 Disability adjusted life 
years is a measure of disease burden, which is a composite of years lost due to 
illness, disability or early death. It is estimated that from 2002 to 2030, COPD will 
have moved from the eleventh to the seventh most common cause of disability 
adjusted life years.27 
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1.2.5 Management of AECOPD 
Prevention 
Optimising the treatment of stable COPD is important to prevent AECOPD, and key 
treatments will be covered briefly. 
Smoking causes COPD, and smoking cessation is the most effective treatment to 
modify disease progression. Stopping smoking is associated with a reduced risk of 
AECOPD 162 and smoke-free public policies are associated with a fall in COPD 
hospitalisation.163 
In a randomised study of 60 patients, pulmonary rehabilitation was associated with a 
reduction in the number of AECOPD, but not admission to hospital.164 In a meta-
analysis of 432 patients, a reduction was seen in hospital readmission following 
AECOPD.157 Subsequently, a large randomised controlled trial showed that early 
rehabilitation did not affect readmission rates, and that mortality was actually higher 
in the intervention group at one year.165 In this study, patients were both recruited 
and rehabilitation initiated within 48 hours of admission to hospital for an AECOPD.  
Rehabilitation consisted of strength and anaerobic training, and neuromuscular 
electrical stimulation. 
Long-acting muscarinic antagonists reduce AECOPD, but do not reduce AECOPD 
requiring hospitalisation or the number of days in hospital.138 Treatment with long-
acting beta-agonists (LABA) and/or inhaled corticosteroids (ICS) reduces the 
frequency of moderate or severe AECOPD, though the impact on AECOPD that 
require hospitalisation is more modest (annual 0.19 to 0.16, rate ratio 0.83, p = 
0.03).123 In this study most patients were already on treatment to reduce 
exacerbation frequency with 60.1% taking a LABA and 61.6% taking an ICS. In a 
large RCT, combined LAMA/LABA reduced the annual rate of all AECOPD by 11% 
compared to LABA/ICS (3.59 vs 4.03, p = 0.003). For severe exacerbations, there 
was no difference (0.15 vs 0.17, p = 0.231).140 
Influenza and pneumonia vaccination should be offered to patients with COPD. A 
randomised controlled trial of 125 patients with COPD showed a 76% reduction in the 
incidence of influenza,166 though in practice the effectiveness varies depending on 
the closeness of fit between the strains in the vaccine and the circulating viruses. 
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Treatment for AECOPD 
Oxygen and bronchodilators 
Patients with AECOPD may require treatment with supplemental oxygen. Excess 
oxygen can cause hypercapnia, acidosis and death, and so oxygen should be given 
in a controlled manner and titrated based on the patients’ oxygen saturations.167 
Venturi masks can deliver a precise fraction of inspired oxygen, whilst the delivery of 
oxygen with simple face masks and nasal cannulae is variable. 
The dangers of excess oxygen in patients with AECOPD has been shown in a 
randomised controlled trial.168 This study included patients with a suspected 
diagnosis of AECOPD who were transported to hospital by paramedics. Paramedics 
were randomised to treat patients with either high flow oxygen, or oxygen via nasal 
prongs with target oxygen saturations of 88 to 92%. In the intention to treat and per 
protocol analysis, death rates were higher in patients that received high flow oxygen. 
Patients with AECOPD who are admitted to hospital receive nebulised short-acting 
beta-agonists (SABA) which can improve respiratory symptoms and improve airflow 
obstruction. There are no large randomised-controlled trials which demonstrate the 
clinical benefit of SABA in patients with AECOPD. In a randomised controlled trial of 
86 patients, there was no difference found between those receiving 2.5 mg or 5 mg 
four-hourly salbutamol nebulisers in terms of lung function parameters or length of 
stay.169 However, study numbers were small, and patients with more severe 
AECOPD were not included.  
Short-acting muscarinic antagonists (SAMA) improve symptoms and airflow 
obstruction in patients with stable COPD who have received beta-agonists. However, 
in patients with AECOPD who have already received high doses of nebulised SABA 
there is a lack of evidence of added benefit. In one study, 70 patients with AECOPD 
were randomised to receive 5mg salbutamol nebulisers, or 5mg salbutamol 
nebulisers and ipratropium bromide 500 micrograms. There was no difference in 
length of stay or airflow obstruction.170 A similar study recruited patients with asthma 
and COPD to receive 10 mg salbutamol or 10 mg salbutamol and 500 µg of 
ipratropium bromide.171 Within the COPD group, the improvement in peak flow rate 
was the same in both treatment arms. 
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Corticosteroid therapy 
In 56 patients hospitalised with a non-acidotic AECOPD, 14 days of oral prednisolone 
30 mg treatment was compared to placebo. Four in five patients were already 
receiving inhaled corticosteroids therapy. Corticosteroid therapy led to an early 
improvement in post-bronchodilation lung function (a daily increase of 90 ml versus 
30 ml in the first five days), though there was no difference at six week’s follow up.172 
Length of stay was seven days in the corticosteroid group compared to nine days in 
the placebo group. A greater improvement in symptoms was reported in the 
treatment arm. Five patients in the placebo arm withdrew, compared to one in the 
corticosteroid group which could have biased results. Compared to patients who 
completed the study, those who withdrew had greater improvements in their baseline 
post-bronchodilator percentage predicted FEV1 (withdrew = 14.1 to 31.4 compared 
to completed = 27.1 to 37.4).  
In a study of 199 patients, patients hospitalised with an AECOPD were randomized 
to receive: a) nebulized budesonide 2 mg six hourly for 3 days followed by inhaled 
budesonide and placebo oral prednisolone; b) oral 60 mg daily prednisolone for three 
days, then 40 mg daily for seven days and placebo inhaled budesonide (nebulisers 
then inhaler); or c) placebo treatment (tablets and nebulisers then inhaler). Both 
treatment groups showed larger improvements in FEV1 over the first 72 hours of 
treatment (the primary outcome) compared to placebo, though there was no 
difference at two weeks (budesonide compared to placebo = 100 mls, prednisolone 
compared to placebo = 160 mls). There were fewer complications, such as 
hyperglycaemia, in the inhaled therapy group compared to the oral therapy group. 
There was no difference in the change in Borg breathlessness scale or length of stay 
across the three groups. The authors acknowledged that oral corticosteroids have 
multiple side-effects, and patients with AECOPD who are prone to the side-effects 
may receive multiple courses. Of importance, they concluded that the long-term 
risk/benefit of oral corticosteroids is probably not favourable, and that inhaled 
budesonide may be an alternative treatment. 
In 261 patients hospitalised due to AECOPD,173 patients were randomised to: a) an 
eight week course of corticosteroids; b) two week course of corticosteroids and six 
weeks of placebo; or c) eight weeks of placebo. Patients in both treatment arms 
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received 125 mg of intravenous methylprednisolone every six hours for three days, 
before switching to a tapering dose of oral prednisolone starting at 60 mg. In the 
eight week corticosteroid arm, patients remained on 20 mg of prednisolone whilst the 
two week group finished this therapy. There was a significant reduction in the primary 
endpoint of death, intubation, readmission for COPD, and intensification of therapy at 
30 days and 90 days, but no difference at 182 days. The difference in the composite 
endpoint was due to intensification of therapy (mainly treatment with corticosteroids). 
The average length of stay in the glucocorticoid group was 8.5 versus 9.7 in the 
placebo arm. The absolute saving in bed days should not be generalised to current 
UK medical practice because length of stay has substantially reduced with time. 
Treatment with corticosteroids again led to an early improvement in FEV1 of 
approximately 100 mls, but there was no difference at or beyond two weeks. The 
high proportion of patients receiving corticosteroids in the placebo group could have 
diminished between-group differences. This may be unavoidable as: a) patients 
receiving placebo may be identifiable to clinicians (lower FEV1, potentially more 
symptoms and signs); and b) oral steroids treatment was part of usual care for 
AECOPD- receipt of systemic corticosteroids in the previous 30 days was the 
commonest reason for exclusion from the study (50% of those excluded). 
In an open-label randomised study, 217 patients with AECOPD requiring ventilatory 
support were randomised to usual care or daily steroids (1 mg per kg) for up to 10 
days.174 Patients with evidence of pneumonia were not included. There was no 
difference in ICU mortality (the primary end-point), NIV failure, median mechanical 
ventilation time, or ICU length of stay, though the study was underpowered. The trial 
was ended before completion due to slow recruitment. At the time the study was 
stopped, ICU mortality was higher in the corticosteroid group (15.3%, n = 17/111 
compared to 14.2%, n = 15/106). The authors state that the trial should not be 
regarded as negative, because the lower end of the CI meant that a 40% lowering in 
the risk of death with corticosteroids is possible. Similarly, the upper end of the CI 
means a 2-fold increase in death with corticosteroids is possible. At the end of the 
study, they had 70% power (as opposed to 80% power) to detect a 12% lowering the 
absolute risk of ICU mortality for an alpha of 0.05. As with previous trials, the main 
cause of non-inclusion was the receipt of corticosteroids within 30 days (n=160). 
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Hyperglycaemia requiring treatment occurred more frequently in the corticosteroid 
group (49.5% compared to 33%). 
A more recent study assessed the non-inferiority of a short course of oral 
corticosteroid therapy (five days 40 mg prednisolone daily) compared to 40 mg 
prednisolone for 14 days (though all patients initially received 40 mg intravenous 
methylprednisolone on the first day).175 The non-inferiority calculation was based on 
the judgement of 11 specialists who defined a 15% absolute difference in the 
percentage of patients suffering an AECOPD during six months of follow-up as the 
clinically tolerable upper-limit. Hospital readmission at six months is a more clinically 
relevant outcome to patients than changes in lung function within the first few days of 
treatment. A non-inferiority study, unlike a superiority study, is more likely to show a 
positive outcome if there is missing data so it may be appropriate to perform a per 
protocol analysis and intention to treat analysis. In both analyses, non-inferiority was 
demonstrated and the authors conclude that these findings support the use of five-
day corticosteroids treatment in AECOPD. However, they did not include a placebo 
arm. In the study by Niewoehner et al., the previous largest study of steroids in 
patients hospitalised with an AECOPD, there was no difference in readmission rates 
at six months between treatment and placebo arms.173 Both 14 days and 5 days of 
corticosteroids for AECOPD may have no impact on readmission rates at six months.  
On review of the evidence, there are only marginal benefits of using oral 
corticosteroid in patients admitted with an AECOPD. The main reported benefit is in 
lung function in the early stages (days) of an AECOPD, though this difference may 
be lost after a few weeks. There is no RCT evidence to show that oral steroids for 
AECOPD impact on the rate of decline of FEV1. In terms of hard clinical outcome, 
such as death, a meta-analysis of 1,319 patients in 11 RCTs showed that there was 
no difference between treatment and placebo (OR 1.00, 95% CI 0.60 to 1.66).176 This 
remained true when including studies with more unwell populations. Negative studies 
are less likely to be published, so the potential harm of steroids may be 
underestimated. The meta-analysis reported that there was no heterogeneity 
between studies, and that the funnel plot did not indicate a strong likelihood of 
publication bias. However, statistical tests for homogeneity lack power, and it is worth 
noting that the reported event rates in each arm varied substantially between studies, 
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although this may be due to the small number of events in smaller studies or 
differences in population. 
Treatment with oral corticosteroid therapy is common in COPD. This is evident from 
several RCTs which excluded large proportions of patients due to recent use of oral 
corticosteroid therapy. Corticosteroids are known to cause serious side-effects, which 
may include osteoporosis and bone fractures, hyperglycaemia, weight gain and 
metabolic syndrome, gastric irritation/ulceration, cardiac disease, infection, muscle 
wasting and mood disturbance.177 Inpatients with AECOPD have high rates of 
hypertension, IHD, and diabetes, and are elderly so are susceptible to the side-
effects of cumulative courses of oral corticosteroids. Randomised controlled trials that 
look at the benefits and harms of corticosteroids in AECOPD have only looked at 
outcome following a single episode. Further research is required to: a) better 
understand the cumulative benefits and/or harms of corticosteroid use in this 
population; and b) identify which patients are at particular risk or benefit from 
treatment with corticosteroids. Eosinophil count is a simple biomarker which shows 
promise in identifying patients that may respond to corticosteroids.73, 178 
Antibiotics 
In a retrospective cohort study of almost 70,000 patients admitted for AECOPD, 85% 
were treated with antibiotics.179 Given the large numbers of patients that are treated 
with antibiotics, concerns have been raised regarding the overprescribing of 
antibiotics and of antibiotic resistance.180 Whilst antibiotic therapy is used in the 
treatment of AECOPD, only some groups may benefit from this therapy. Guidelines 
on the assessment of patients with AECOPD are inconsistent in terms of the features 
that support antibiotic treatment.181 
Characteristics associated with antibiotic response include: a) more severe stable 
state COPD; b) a more severe AECOPD; and c) new/increased purulent sputum. 
This section will consider these three aspects when reviewing RCTs of antibiotics 
compared to placebo. Studies that compare different types of antibiotic therapy will 
also be considered briefly. The effect of antibiotics on mortality will be considered 
first, followed by treatment failure. 
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There is a shortage of placebo-controlled randomised trials comparing antibiotics to 
placebo for AECOPD that have assessed important clinical outcome such as 
mortality. Those that have reported numbers of deaths were generally underpowered 
to assess this outcome. Meta-analysis can provide useful pooled estimates of 
mortality outcome, but results must be interpreted with caution given the 
heterogeneity of the trials, especially in terms of treatment (which assumes that 
antibiotic type and mode of delivery are equally efficacious) and variation in the 
diagnosis of an AECOPD.  
A Cochrane meta-analysis from 2006 looked at three studies, and concluded that 
antibiotics improve survival 182 whilst a more recent Cochrane meta-analysis reported 
no such benefit based on five RCTs.183 To understand the difference in conclusions 
between these meta-analyses, the three trials which appear in both meta-analyses 
will be considered first, then the two that are in the most recent meta-analysis. 
Three trials are included in both mortality analyses; two by Pines et al. and one by 
Nouira et al..184-186 Pines et al. performed a small pilot study of 30 patients with 
chronic bronchitis and an acute purulent exacerbation, half of whom received 
intravenous penicillin three million units (for 14 days) and intravenous streptomycin 
0.5 g (for 7 days), and the other half received placebo.184 This pilot study was 
stopped early due to high rates of deterioration in the placebo group. One patient 
died in the treatment group compared to three in the placebo group. Based on these 
results, the larger study that followed compared three active treatments, and did not 
incorporate a placebo group due to ethical concerns.184 
Pines et al. compared chloramphenicol, tetracycline and placebo in an RCT, but 
excluded patients with a severe AECOPD in whom they thought there was sufficient 
evidence of benefit to warrant treatment.185 In “moderately ill” patients with purulent 
exacerbations of chronic bronchitis 0 of 89 patients died in the treatment group 
compared to 1 of 86 in the placebo group.  
Nouira 2001 186 showed that in a trial of 93 who required mechanical ventilation on 
the intensive care unit there was a reduction in the primary outcome of inpatient 
mortality with oral ofloxacin 400mg for ten days (4% versus 22%). This is the only 
RCT to show a significant reduction in mortality. Patients appeared well matched for 
baseline characteristics including severity of AECOPD and a third of the placebo 
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group (compared to 6% of the antibiotic group) received “additional” antibiotic 
therapy, which may have improved outcome in the placebo group and 
underestimated the benefit of ofloxacin. The patients in this study had both: a) severe 
COPD when stable; and b) were suffering from a severe AECOPD. The mean FEV1 
in the treatment and placebo groups was 0.79 L/s and 0.74 L/s with 1.7 and 1.6 
exacerbations in the previous year. Even though the presence of infiltrate on chest 
radiograph was part of the exclusion criteria, these AECOPD were severe based on: 
a) the need for hospital admission; b) the mean pH (7.22 and 7.21 for treatment and 
placebo groups) and high proportion who required invasive mechanical ventilation; 
and c) high SAPSII scores (31 and 35 for treatment and placebo groups). Most 
patients were treated with invasive mechanical ventilation (IMV): one third of patients 
in each arm initially received IMV, and 80% of the remaining two thirds progressed 
from NIV to IMV. Rates of pneumonia were substantially higher in the placebo arm 
and death occurred after approximately seven days. Antibiotic use is strongly 
associated with a reduction in the risk of pneumonia.187 Whilst antibiotics may 
prevent secondary infection in patients who have received IMV, these results cannot 
be generalised to the majority of patients with an AECOPD. 
In both studies by Pines et al., all patients had purulent sputum. It is unclear if 
patients without purulent sputum were included in the Nouira study, though 61% of all 
patients had a positive sputum culture. Although these three trials were included in 
both Cochrane meta-analyses, the reported number of events from the Nouira study 
differ. In the Ram meta-analysis 188 all-cause mortality was reported as 4 of 47 for the 
antibiotic group compared to 18 of 46 for the placebo group, whilst the Vollenweider 
meta-analysis 183 quotes 2 of 47 and 10 of 46. This discrepancy appears to have 
arisen depending on whether or not the ICU and hospital deaths were considered to 
be mutually exclusive. 
The Vollenweider meta-analysis includes two papers that do not appear in the earlier 
meta-analysis, one from 1967 by Petersen et al. (which included 19 patients and had 
only one death which occurred in the placebo arm)189 and a more recent, larger study 
published by Daniels et al. in 2010.190  
Daniels et al.190 compared doxycyline 200 mg daily to placebo in addition to systemic 
corticosteroids in 223 patients hospitalised with an AECOPD. An AECOPD was 
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defined by Anthonisen criteria as a type one or type two exacerbation.191 Type one 
exacerbations have all three cardinal symptoms of increased breathlessness, 
increased sputum volume and increased sputum purulence, whilst a type two 
exacerbations has two of these three cardinal symptoms. Patients with pneumonia 
and requiring mechanical ventilation were excluded (it is unclear if AECOPD newly 
treated with mechanical ventilation were included; no baseline pH levels are 
mentioned). There were seven deaths (7 of 107, 6.5%) in the treatment arm 
compared to three (3 of 116, 2.6%) in the placebo group. Compared to other studies 
reporting mortality outcome, this is perhaps most generalisable to the average 
inpatient with an AECOPD because: a) it uses a relatively modern definition of an 
AECOPD; b) treatment was more typical of current practices; and c) the study did not 
limit inclusion to patients with severe AECOPD. The study was underpowered to 
make any definite conclusions regarding mortality.  
Since this meta-analysis, a further placebo-controlled study has been performed. In 
100 outpatients with type one exacerbation of COPD, patients were randomised to 
antibiotics (a ten day course of a quinolone or amoxicillin). All patients received 
inhaled salbutamol, oral theophyllines and oral corticosteroids. Oral theophylline is 
not routinely recommended for the treatment of AECOPD. There are several 
significant limitations with this study. No primary outcome is provided, but rather a list 
of “main outcome measures”, no power calculation is provided, and neither the 
randomisation process or allocation concealment is adequately described. One 
patient died in the treatment arm (1 of 50) compared to three in the placebo arm (3 of 
50). 
There is a lack of evidence to determine the impact of antibiotics on mortality as 
studies are underpowered. A previous meta-analysis showing a mortality benefit was 
due to the inclusion of an ICU-based study 186 which is not generalisable to the 
majority of patients with AECOPD and may be due to the prevention of secondary 
pneumonia in invasively ventilated patients. 
In common with most RCTs, the most recent Cochrane analysis 183 measured 
treatment success/ failure as the primary outcome, though trials varied in their 
definitions. In seven RCTs of outpatients with AECOPD, there was low quality 
evidence that antibiotics reduce treatment failure, but this benefit did not reach 
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statistical significant when restricted to five trials that used modern antibiotic 
therapies. In four RCTs of inpatients with AECOPD (and in three RCTs that used 
modern antibiotic therapies) there was a significant reduction in treatment failure, and 
this evidence was regarded as high quality; this did not include the Nouira ICU study. 
As with studies of corticosteroids, patients in placebo arms receiving treatment (for 
treatment failure of placebo) may reduce differences between groups. 
There was no difference in length of hospital stay outside of the ICU setting in two 
trials that measured this outcome.183 No studies report hospital admission rates 
following treatment, or antibiotic resistance rates, though adverse events, including 
diarrhoea, were higher in those that received antibiotic therapy.192  
The largest single study in the meta-analysis is by Llor et al.193 They randomised 310 
patients with AECOPD to receive co-amoxiclav 625 mg three times a day or placebo 
for eight days. No data is provided on the number of patients that died, which is an 
important omission, especially given the conflicting data in previous, smaller studies. 
In common with other studies, the primary outcome was based on the short-term 
success or failure of treatment which was higher in the treatment group (“clinical cure 
at days nine to eleven”, 74.1% n = 117 of 158 compared to 59.9% n = 91 of 152). 
Patients were followed up for a year, which is an important strength as most RCTs 
have too short a follow-up period. Time to next exacerbation in those that had had a 
clinical success measured at days nine to eleven was longer in the treatment group 
(median time 233 compared to 160 days). The median time to next exacerbation in 
each allocation group is not provided which is another limitation of the study. Patients 
requiring hospital admission were not included, and patients needed an FEV1 of 
greater than 50% predicted for inclusion. Therefore, compared to studies of 
inpatients with AECOPD, the selected cohort was lower risk. Little data is provided 
on the severity of the exacerbation and the rates of corticosteroids treatment were 
lower than expected at 16.5% and 17.8% in the co-amoxiclav arm and placebo arm.  
In the study by Llor et al.193 treatment failure was lowest in patients who produced 
purulent sputum and were treated with antibiotics. Treatment failure was highest 
amongst those with purulent sputum treated by placebo. A similar finding was seen in 
one of the earliest trials of antibiotic use 191 which looked at 173 patients over three 
and half years. Patients who had an increase in sputum purulence were more likely 
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to benefit from antibiotic therapy (co-trimoxazole, amoxicillin or doxycycline) and 
purulent sputum was a predictor of treatment failure. Such sub-analyses should be 
interpreted with some caution. 
Given the uncertainty regarding the efficacy of antibiotic therapy and the problems of 
antibiotic resistance, further placebo control trials are appropriate in those patients 
with mild to moderate exacerbation of COPD. Rohde et al.194 are undertaking a 
placebo controlled study and aim to recruit 980 patients with moderate AECOPD. 
The “ultimate goal (of the study) is to reduce unnecessary antibiotic prescription”. In 
the planned study, a “moderate” AECOPD is defined as one without respiratory 
failure or need for intermediate or intensive care. Patients will be excluded if they 
have: a) a PaCO2 greater than 45 mmHg and/or pH less than 7.35; b) pneumonia; or 
c) fever. These are not optimal criteria for assessing the severity of an AECOPD.  
It is not clear which factors are most important in predicting response to antibiotics, 
though likely candidates include: severity of COPD, severity of AECOPD, and/or the 
presence of purulent sputum. In common with other studies, this study would benefit 
from a more discriminative measure of severity of AECOPD. 
The primary outcome is clinical failure defined by the need for additional antibiotic 
treatment at 30 days; it is worth noting that the previous largest trial by Daniels et al. 
showed no difference in this outcome at 30 days. In the planned study, patients are 
receiving a short course of five days antibiotics. A strength of the study is that 
subsequent exacerbation rates will be recorded up to one year. 
Observational data suggests antibiotic use in AECOPD may improve outcome. In a 
large, retrospective cohort study of 84,621, early antibiotic use was associated with 
improved outcome amongst inpatients with AECOPD.195 Whilst the results were 
adjusted for confounding factors, unmeasured population differences could account 
for the difference. 
A number of trials have been performed which compare different antibiotics in 
patients with AECOPD. These trials include far more patients and longer follow-up 
periods than the placebo controlled trials of antibiotics. Nine RCTs that report the 
long-term effect of treatment are summarised in a review by Wilson et al.196 
Measured outcome vary between studies. The primary outcome included clinical 
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response/success/cure/failure, time free of infection and time to re-exacerbation, and 
largely there is no difference between different agents. Recurrence/failure rates and 
bacterial eradication tend to be better with quinolones compared to clarithromycin or 
amoxicillin. One of the largest studies of 1,492 patients compared moxifloxacin 400 
mg four times a day for five days to co-amoxiclav 975/125 mg twice a day for seven 
days.59 The primary outcome of clinical failure was similar at eight weeks. Patients 
receiving moxifloxacin had higher bacterial eradication rates at the end of therapy, 
though this difference was not apparent at four and eight weeks post treatment.  
Antibiotic resistance is a global crisis and the current evidence base supporting their 
use in AECOPD is poor. Further research is required to identify who benefits from 
antibiotics, and the size of the effect, with a view to limiting the inappropriate 
provision of antibiotics to low-risk AECOPD who have no evidence of bacterial 
infection. 
1.3 Scores used to predict outcome following hospital admission with an AECOPD 
The validation of the DECAF score, and the Hot DECAF RCT form the major part of 
this thesis. In “1.3.1 DECAF and background”, the DECAF score is considered in 
detail, followed in “1.3.2 Other prognostic scores used to predict acute mortality”.  
No tool exists (prior to PEARL) that developed in patients with AECOPD to predict 
readmission/ death without readmission. “1.3.3 Scores that predict readmission and 
long term mortality in patients with an AECOPD following discharge” looks at the 
evidence base.  
1.3.1 DECAF and background 
In-hospital mortality is between 4.3% and 10.4%.2, 11, 119, 125, 150-152 Clinicians are 
unable accurately to estimate the risk of death in patients hospitalised with 
AECOPD.197 A reliable prediction tool, which stratifies patients according to mortality 
risk, may help inform management. This could include the selection of low risk 
patients for Hospital at Home (HAH) or Early Supported Discharge (ESD), and the 
identification of high risk patients for early escalation or appropriate palliation. 
The DECAF score was derived in a large cohort of consecutive unique patients 
hospitalised with AECOPD, is simple to apply at the bedside and predicts in-hospital 
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mortality using indices routinely available on admission.2 To develop the score a wide 
range of clinical, physiological and demographic variables were collected in 920 
consecutive patients admitted with AECOPD to either North Tyneside (NTGH) or 
Wansbeck (WGH) general hospitals between December 2008 and June 2010. 
Exclusion criteria were few and included the presence of co-morbidity likely to limit 
survival to less than one year or home ventilation. To ensure the maximal capture of 
patients and data, daily screening of patients’ medical records, and review of hospital 
coding records was performed 
The hospitals have diverse catchment areas and community support. One hospital 
covers a predominantly urban population, whilst the other serves a large rural area, 
supported by several community hospitals.  
Patients with coexistent pulmonary consolidation were included, provided AECOPD 
was the primary diagnosis. This is consistent with the major UK audits of AECOPD 
150 and non-invasive ventilation 198 which included patients with pneumonia 
AECOPD. 
Patients with pneumonic AECOPD are treated similarly to those with non-pneumonic 
AECOPD, but differently to those with community acquired pneumonia and no 
underlying diagnosis of COPD. For example, patients with pAECOPD/ AECOPD are 
treated with corticosteroids, bronchodilators and, when appropriate, non-invasive 
ventilation. Compared to patients with non-pneumonic AECOPD, those with 
pneumonic AECOPD have similar sociodemographic details, severity of underlying 
COPD and range of organisms.67 This justifies the classification of “pneumonic 
AECOPD” as opposed to community acquired pneumonia. 
In the DECAF study, dyspnoea was assessed using both the traditional Medical 
Research Council Dyspnoea score and the extended MRCD (eMRCD) score. The 
eMRCD score divides the most severe category (MRCD 5 = housebound) into those 
who do not require assistance with washing and dressing (5a) and those who do 
(5b). This modification improves the discriminatory power for predicting mortality.1 
The eMRCD is described in more detail in section 1.1.5. 
To ensure the prognostic tool was simple to administer, continuous variables were 
dichotomised. Independent predictors of in-hospital mortality were identified by 
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logistic regression analysis and the five strongest prognostic indices were selected to 
form the DECAF score, shown previously (Table 1.1). Zero, one or two points are 
scored for the eMRCD score, and one point is scored for the presence or absence of 
Eosinopenia, chest X-ray Consolidation, Acidaemia, or atrial Fibrillation. 
Higher DECAF scores were associated with higher inpatient mortality, ranging from 
0.5% in the DECAF 0 group to 70% in the DECAF 5 group. We assigned DECAF 
scores 0 and 1 as conferring low risk, 2 as moderate risk and 3 or more as high risk 
of mortality (Table 1.3). Compared to the British Thoracic Society audit in 2008,150 
mortality (after adjustment for the relative proportion of pneumonic exacerbations), 
length of stay and readmission rates were similar. In our study there was a higher 
proportion of patients requiring ventilation,1 suggesting that our hospitals do not have 
a lower threshold for admission than other centres. Furthermore, a high percentage 
(86%) of patients with an eMRCD score 5b and acidaemia received non-invasive 
ventilation. 
Risk group Score n % mortality 
Low risk 
0 201 0.5 
1 291 2.1 
Intermediate risk 2 226 8.4 
High risk 
3 125 24 
4 57 45.6 
5 20 70 
6 0 N/A 
Table 1.3: Percent inpatient mortality by DECAF score 
The predictive strength of the DECAF score was compared to other tools that have 
been used to predict mortality in AECOPD, though not all were developed for this 
purpose. Prognostic strength was assessed by measuring the area under the 
receiver operator characteristic (AUROC) curve, and were compared to other tools by 
the method of Delong et al.199 DECAF was compared to the Acute Physiology And 
Chronic Health Evaluation (APACHE II) score,200 the Blood urea nitrogen, Acute 
mental status change, Pulse rate and age 65 (BAP-65) score,201 the COPD and 
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Asthma Physiology score (CAPS),202 and the Confusion, Urea, Respiratory rate, 
Blood pressure and age 65 (CURB-65) score.203 
DECAF was superior to APACHE II (AUROC = 0.78, p<0.0001), BAP-65 AUROC = 
0.68, p<0.001), CAPS (AUROC = 0.71, p<0.0001) and CURB-65 for both patients 
with consolidation (AUROC = 0.77 vs. 0.66, p = 0.003, n = 299) and without 
consolidation (AUROC =0.87 vs. 0.72, p = 0.002, n = 621). It is important to note the 
developed score, in this instance DECAF, will be favoured when comparing it to other 
scores in its derivation cohort. 
The 2014 UK National COPD audit recommended that the DECAF score be 
documented in all patients admitted with an AECOPD but noted that validation was 
required 11 which is essential to prove the generalisability of a prognostic score.204 In 
chapter 7 we present the results of the validation of the DECAF score and compare 
its performance to other prognostic tools.  
1.3.2 Other prognostic scores used to predict acute mortality 
There are a number of severity scores that have been assessed in patients with 
AECOPD.205  
APACHE II 200 is a revised version of the APACHE score. It comprises of: a) 12 
physiological measurements divided into up to eight categories; b) five categories of 
risk for age; and c) three categories for prior immunocompromised state and 
comorbidity. APACHE II was validated in many patients and hospitals, and 
demonstrated good performance in the prediction of in-hospital mortality in 
unselected patients admitted to an intensive care unit. 
The performance of the APACHE score has been assessed in COPD patients 
admitted to a general medical ward.206 ICD-9 codes were used to retrospectively 
identify 277 patients, of whom 101 met the their criteria for an AECOPD. Using 
coding to identify AECOPD is inaccurate,207 and spirometric data was not available to 
confirm the diagnosis of COPD. The APACHE II score was combined with several 
covariates (smoking and pCO2) to predict death at three years; the AUROC curve 
was 0.76. Missing values were considered normal. The gold standard for missing 
data in this situation is multiple imputation (section 4.2.2). The original APACHE II 
score was developed using the most severe measure of individual indices in the 
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previous 24 hours, but in this study admission indices were used, which may have 
reduced prognostic power. 
A study by Connors et al.79 modified the APACHE II score and included other indices 
such as functional status and cor pulmonale, to predict mortality at six months. The 
cohort included 1,016 patients from five hospitals, all of whom had an AECOPD and 
a PaCO2 of 50mmHg or more. The AUROC was 0.73, but this has not been 
externally validated. 
The BAP-65 score was developed in a retrospective study of 88,074 patients with an 
AECOPD between 2004 and 2006.208 The four valuables used in the model are 
Blood urea nitrogen, Altered mental state, and Pulse rate greater than 109 per 
minute, and age greater than 65 years. The model was internally validated using 
bootstrapping. The AUROC for hospital mortality was 0.72 and 0.71 for the derivation 
and validation cohort (the need for mechanical ventilation at 48 hours was a 
secondary outcome). Patients were identified using coding which is inaccurate, and 
the diagnosis of COPD was not confirmed by spirometry. Those with acute 
respiratory failure and pneumonia were not included, which are two of the strongest 
predictors of death. It is unclear why pH was not included as a predictor. The raw 
data suggests that pH is a strong predictor, as those in the derivation and validation 
cohort had a mortality of 12.1% and 11.7% (10 fold higher than the baseline risk) if 
their pH was < 7.2, and 6.7% and 6.6% if the pH was > 7.21- 7.30. 
The performance of the score was confirmed in a validation dataset of 34,699 
admissions which showed an AUROC curve was 0.77 for in-hospital mortality.209 
Patients were identified using coding data which is unreliable, and smoking history 
and confirmation of airflow obstructive was not obtained. Subsequently, Tabet et al. 
have assessed the BAP-65 score to predict mortality and the need for mechanical 
ventilation in 980 patients admitted with an AECOPD to two Lebanese hospitals over 
an eight-year period.210 There is no mention of missing data, the study was 
retrospective (and so accurate recording of the Glasgow Coma Score was relied 
upon as part of usual practice) and only 980 patients were identified over an eight 
year period, suggesting that consecutive recruitment of patients did not occur. There 
is no mention of smoking history or spirometric confirmation of COPD. 
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CAPS was developed in a retrospective cohort of 8,527 patients with obstructive 
airways disease who were admitted to intensive care units or high dependency 
units.202 Consequently, it was not designed to be applied to general admissions of 
patients with AECOPD. Eight physiological variables were included in the final model 
using logistic regression to determine the optimum number and type of variable to 
predict in-hospital morality. The AUROC curve was 0.72 in the derivation and 
validation cohort showing consistent performance, though discrimination was lower in 
patients with COPD and no history of asthma in the validation cohort (0.70). Rates of 
missing data are clearly reported, with missing data between 1 and 32% for variables 
included in model development. Urea, glucose, albumin and bilirubin had the highest 
missing data rates, reported as being between 14 and 32%, however, bilirubin and 
glucose were not included in the final model. Data is not provided on missing data for 
the overall score. Missing data was assumed to be normal which may negatively 
impact on the accuracy of risk assessment. The model was superior to the APACHE 
II and APACHE III scores. 
The CAPS score was expanded upon in a prospective cohort study looking at 
asthma and COPD exacerbations requiring admission to the intensive care unit or 
high dependency unit.197 This added eight more variables to the score, including 
diagnosis (COPD, asthma or both), gender, level of physical function, age and GCS 
(Glasgow Coma Score). The outcome was 6 month mortality with a AUROC curve of 
0.75. A key strength of the research is that they measured the ability of clinicians to 
predict outcome, which is the default approach in the absence of a prognostic score. 
Clinicians had worse discrimination and markedly worse calibration than the model 
(see “4.2.11 Model assessment” for explanation of terms). The diagnosis of COPD 
was not confirmed by preadmission spirometry results, and smoking history is not 
reported. The performance of the model requires external validation to demonstrate 
the generalisability of the results. The complexity of the score may limit its use 
outside of the high dependency unit / intensive care unit. 
The CURB-65 score is a retrospective study first developed and validated in patients 
with pneumonia. Data from three large prospective studies were combined, in which 
pneumonia had been confirmed with chest x-ray. Overall, patients with chronic lung 
disease comprised 35% of the entire cohort of 1,068 patients. The CURB-65 score 
has been assessed in patients with non-pneumonic AECOPD.211 The study was 
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performed prospectively, which allowed for the collection of complete CURB-65 data 
in 252 consecutive admissions. Only 3 of 252 patients did not have outcome data, 
and were not included in the analysis. CURB-65 was a good predictor of 30 day 
mortality with a AUROC curve of 0.73, but was not a predictor of one year mortality. 
Most patients (74%) had COPD confirmed with preadmission spirometry, but the 
need for obstructive spirometry was not part of the eligibility criteria. A small number 
of patients had abnormal spirometry on follow up, but analyses with and without 
these patients were no different. 
Roche et al. developed and validated a tool to predict in-hospital death.43 All patients 
were reviewed by respiratory physicians to confirm the diagnosis of COPD. Patients 
requiring ICU monitoring and/or NIV were not included. The score included several 
clinical signs, including use of inspiratory accessory muscles and expiratory use of 
abdominal muscles. Such signs are subjective, and may require specialist expertise. 
The seniority and specialty of the clinician who assessed these signs is not provided. 
Despite this, the score showed good discrimination across 103 emergency 
departments in both validation and derivation cohorts, which shows that these signs 
can be reliably assessed. The population sample was randomly split into derivation 
and validation cohorts. This approach will tend to give over-optimistic results as the 
two datasets are very similar; non-random splitting is preferable to random splitting 
(though neither demonstrate external validity which requires an external validation 
cohort).212 The score has not undergone external validation. 
Stiell et al.213 conducted a prospective cohort study in six emergency departments. 
Using multivariate analysis, high risk indices were identified which included acute 
ECG features of ischaemia and radiographic pulmonary congestion. It is 
questionable if such patients had a primary AECOPD, as these features suggest an 
alternate diagnosis. No validation study has been performed. 
Quintana et al. performed a prospective study in 16 hospitals.214 The derived score 
showed good discrimination, but no validation study has been performed. The score 
included subjective recognition of “use of inspiratory accessory muscles or 
paradoxical breathing”, so may be less universally applicable, especially in 
healthcare settings which lack specialist review within 24 hours of admission.11, 151 
Recruitment was lower than equivalent audit data 151 due to the need for written 
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patient consent which disproportionately excludes the lowest and highest risk 
patients.  
1.3.3 Scores that predict readmission and long term mortality in patients with an 
AECOPD following discharge 
Clinicians are unable accurately to identify patients at particular risk of 
readmission.215 A simple and accurate prognostic tool would help identify those who 
may benefit most from additional health and social care services, and this hopefully 
would translate into improved outcomes for patients and more efficient use of scarce 
resources. A condition-specific score to predict this outcome following hospitalisation 
for AECOPD has not been developed. 
In this section, studies will be reviewed that aimed to predict readmission or death (or 
readmission alone) in patients following hospitalisation for AECOPD. Inclusion of 
studies that look for “death without readmission” as a combined outcome with 
“readmission” is appropriate because, in patients who die outside hospital, earlier 
recognition of deterioration is likely to have led to readmission. 
Within the CODEX study,216 the ADO, BODEX, CODEX and DOSE scores were all 
assessed for their performance at predicting the combined outcome of readmission 
or death without readmission in patients with COPD (Table 1.4). However, most were 
originally developed to predict death (ADO 217 and BODEX 218) or health status 
(DOSE 219) and all offer only modest prediction of readmission/ death without 
readmission. The performance of CODEX was superior to the updated ADO and 
BODEX score, with a trend towards better performance than DOSE, but this 
comparison was in the CODEX derivation population.216 Derivation studies bias 
results in favour of the derived tool, in this instance CODEX, and so comparison in an 
external validation cohort is required. 
ADO was developed to predict death in two cohorts: a group of patients post 
rehabilitation in secondary care, and a group of patients admitted to hospital due to 
an AECOPD.217 It requires only three indices to score: age, breathlessness, and the 
degree of airflow obstruction. Obtaining recent data on FEV1 to score ADO may be 
challenging. In the 2015 British Thoracic Society (BTS) national audit, only 46% of 
patients had spirometry recorded in the notes in the last five years.11 This score was 
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subsequently validated, and adjusted, in a large international study of 10 cohorts in 
primary, secondary and tertiary care looking at three year mortality.220 Its 
performance at predicting 90 day readmission or death was assessed in the CODEX 
study. It performed poorly, though it is worth reiterating that it was not designed to 
predict readmission. 
The BODEX score was developed in a prospective study of 185 patients who were 
followed up, on average, for 36 months.218 It measures BMI, airflow obstructive, the 
degree of breathlessness and exacerbation frequency and has been adapted from 
the BODE index. The BODEX had an AUROC curve of 0.74 for predicting all-cause 
mortality, and showed similar prognostic power to the BODE index. BODEX may be 
easier to calculate than the BODE index; the latter requires measurement of exercise 
capacity which may be difficult to assess whilst a patient is exacerbating. The 
number of patients in this study was relatively small, and no power calculation was 
provided; the study may have been underpowered to look at all-cause mortality, 
though this is less of an issue for readmission which is a more frequently occurring 
outcome. 
Table 1.4: Tools that have been used to predict readmission in AECOPD 
 Measured indices Study population and primary outcome 
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ADO217 √   √ √       √ Both Both Death 0.58 
BODEX21
8  √  √ √  √     √ Stable Outpatients Death 0.61 
CODEX21
6# √  √ √ √  √     √ AECOPD 
Mostly 
admitted 
Death or 
readmission 0.67 
DOSE219    √ √ √  √    √ Unclear Outpatients Health status¶ 0.64 
LACE221   √      √ √ √ X n/a Admitted Death or readmission 0.68◊ 
*Charlson comorbidity index, †mMRC dyspnoea score, ‡Forced expiratory volume in one second per cent predicted, xPaƟent reported 
AECOPD in previous year, §AECOPD in previous year requiring admission or ED attendance, llElective or emergency admission, #uses age 
adjusted Charlson index, ¶measured by the clinical COPD questionnaire, ◊30 day death or readmission. ED= Emergency Department  
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The AUROC curve for BODEX in predicting 90 day readmission or death was 0.61 in 
the CODEX study. 
The CODEX study was developed in several hospitals, the population is clearly 
described, and it is superior to ADO and BODEX, with a higher AUROC than DOSE, 
for 90-day readmission or death. CODEX was developed and validated in previous 
cohort studies, but the gold standard for derivation studies is prospective cohort 
studies. The validation cohort comprises a single hospital, and it is unclear if this site 
was included in the derivation study. Only geographical validation (validation at sites 
not included in model development) demonstrates the generalisability of a score.212 
The aim of the CODEX study was to create a tool for patients discharged from 
hospital, but 11.5% were not admitted. In the derivation study, only 91.9% had death 
data at 3 months, and the original ESMI paper (from which the model was created)222 
reports readmission data in “484 surviving patients” (84% of survivors). It is unclear 
how missing data was handled. Information is lacking on model development and the 
selection of indices. The predictors of death reported on multivariate regression from 
the original ESMI study do not include all CODEX indices, and no multivariate 
analysis is reported related to readmission.216, 222 Model performance is appropriately 
assessed, but there is no mention of calibration, and, as with the LACE index, 
CODEX required patient consent, and included the Charlson index, compromising 
ease of use at the bedside. For 90 day readmission or death, the performance of 
CODEX in its derivation cohort was superior to the updated ADO and BODEX, with a 
trend towards better performance than DOSE amongst inpatients with AECOPD. 
The DOSE index was derived in 375 patients with COPD in primary care to predict 
health status. It comprises of four indices: Dyspnoea, airflow obstruction, smoking 
status and exacerbation frequency. Exacerbations were reported by patients, and 
confirmed from primacy care records. This differs from the BODEX and CODEX 
score that only score for exacerbations that require hospital admission. The tool was 
validated in datasets from Holland, London and Tokyo. In this study, there was no 
relationship between the DOSE index and hospital admission, though data was only 
available in 175 patients. In the CODEX study, DOSE was shown to be a modest 
predictor or readmission or death. 
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LACE was developed in all emergency and elective admissions 223 and was 
developed for 30-day (and not 90-day) outcome. There are several generic tools to 
predict readmission, most of which are not considered here. The LACE score was 
selected as it showed better discrimination than other generic tools that can be used 
in the acute setting, and is used in some UK hospitals. In principle, a generic tool is 
preferable to a specific tool if it offers equal performance.  
The study population is adequately described, follow-up was good (95.6% 
population), model development robust and validation was performed in a separate, 
large cohort. The main limitations of the LACE index are: a) that readmission is self-
reported; b) it requires the full Charlson index to be calculated (which includes many 
indices and is complex to calculate at the bedside); and c) the analysis was 
performed in a previous multicentre prospective cohort study for which patients had 
to give informed consent, have a telephone, be cognitively intact and not be a 
nursing home resident, reducing the generalisability of the results.  
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 Review and meta-analysis of Hospital at Home 
compared to usual hospital care. 
Chapter introduction 
The DECAF implementation study undertaken as part of this thesis compared 
Hospital at Home (HAH) to usual care for patients with low risk AECOPD (Chapter 7). 
Prior to the initiation of this study, we performed a systematic review and meta-
analysis to assess the safety, efficacy and cost of Early Supported Discharge (ESD) 
and HAH which forms this chapter. 
2.1 Background 
Hospital at Home (HAH) “provides active treatment by health care professionals in 
the patient’s home for a condition that would require acute hospital inpatient care.” 224 
Early Supported Discharge (ESD) 225-227 aims to shorten length of stay. However, the 
definition of HAH and ESD varies across healthcare systems; in some settings HAH 
refers exclusively to admission avoidance,228 whilst elsewhere HAH simply implies a 
higher level of care than ESD.229 In published RCTs in COPD, the terms HAH and 
ESD are variably used to refer to similar services, and individual studies often include 
schemes aimed at both admission avoidance and shortening length of stay. Such 
schemes also vary substantially in the level of clinical and social support provided. 
Loan equipment, such as oxygen concentrators and nebulisers, is typically available 
and patients are supported by visiting respiratory specialist nurses, with medical 
supervision. Some services will provide intravenous therapy and short-term social 
services input. 
ESD/HAH may encourage greater mobility and independence, and should include 
education on self-management, which may improve outcomes. Contrary to national 
guidelines, the 2008 UK national audit showed that most hospitals in the UK do not 
offer ESD/HAH.150 The 2015 UK national audit did not report the proportion of 
patients receiving ESD, and only presented the proportion discharged under the care 
of COPD / ESD or equivalent scheme.11 In AECOPD, previous meta-analyses 
concluded that ESD/HAH is safe.158, 188, 230 Two recent meta-analyses were published 
at similar times, but differed in their conclusions in regard to readmission risk, 
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reflecting differences in trial selection and interpretation of the event rates and risk of 
bias.158, 231 
It is advised that treatment reviews and meta-analyses are updated bi-annually.232 
Our meta-analysis includes an RCT published subsequent to earlier reports and 
compares the efficacy of ESD/HAH to usual care with respect to mortality, 
readmission and cost. We describe how the benefit of ESD/HAH depends on 
whether return to hospital during the period of acute care is considered a 
readmission. In contrast to other studies, in our primary analysis we excluded 
patients lost to follow up. Including such patients assumes their event rate is zero 
and introduces bias, particularly when there are substantial differences in the 
proportion lost to follow up between arms. Some RCTs included patients who did not 
present through accident and emergency (A&E) departments (or equivalent) 233 or 
were not triaged for admission at the time of randomisation (i.e. patients in UC were 
discharged directly from A&E).234 Such patients are likely to be experiencing milder 
exacerbations and may have been well enough for immediate discharge from A&E; 
to ensure consistency and avoid bias they have been excluded. 
We also review the structure of ESD/HAH schemes, and assess costs, whilst 
recognising the problems of comparing cost across different countries and healthcare 
structures. 
2.2 Methods 
2.2.1 Selection criteria and outcome measures 
RCTs of ESD/HAH compared to UC in patients with a primary diagnosis of AECOPD, 
presenting to A/E or equivalent and triaged for admission, were considered for 
inclusion. Studies were only included if, without ESD/HAH, all patients would have 
been admitted; patients could receive ESD/HAH directly from A&E provided this 
criterion was met. The reported outcomes are: number of patients experiencing one 
or more readmissions, mortality and cost. 
2.2.2 Search strategy and selection of studies 
The pre-planned search strategy included combining search terms COPD, pulmonary 
disease, lung disease, respiratory disease, airway disease, airway obstruction, 
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airflow obstructive, hospital at home, home care, home base, home support, early 
supported discharge, early discharge, hospitalisation, hospital base, hospital care, 
usual care and acute care. Searches using all available date ranges were conducted 
on databases including Medline, Embase, Amed, Cinahl and HMIC and in web-based 
libraries (e.g. British Library, United States National Library of Medicine and Institute 
of Health Economics), relevant national organisations (e.g. NICE), BTS, Global 
Initiative for Chronic Obstructive Lung Disease) and current research registers (e.g. 
Clinical Trials Register, Current Controlled Trials Register, Centre for Health 
Economics). Hand-searching of relevant journals was performed to ensure abstracts 
and conference proceedings were retrieved and the bibliography of each trial was 
screened to identify any additional RCTs not retrieved in the initial search. All 
searches were completed by November 2014. Abstracts were screened and, if 
potentially eligible, full papers reviewed. All reports identified were independently 
assessed by three reviewers. Disagreements were resolved with discussion. 
2.2.3 Methodological quality assessment (Risk of bias) 
Bias was assessed and reported using The Cochrane Collaboration six core risks of 
bias 235. Bias was assessed independently by at least 2 reviewers for all trials. 
2.2.4 Data extraction 
Data were extracted onto a data abstraction table. When available, characteristics of 
the trial (e.g. author, year of publication and journal citation, country, setting, design, 
methodology), study population (e.g. total number enrolled, patient characteristics, 
age, other important baseline characteristics), interventions (ESD/HAH and UC 
details), risk of bias in trials, duration of follow-up and outcomes (including outcome 
definition, unit of measurement) were recorded. Where possible, all data extracted 
were those relevant to an intention-to-treat analysis. The time points at which 
outcomes were collected and reported were noted. All authors were contacted to 
clarify reported data. 
2.2.5 Statistical analysis 
Trials with similar outcome measures were pooled in meta-analyses. For time to 
event (hospital readmission) data, it was not possible to extract the log of the hazard 
ratio [log(HR)] and its standard error from trial reports or approximate using the 
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methods of Parmar et al.236 Consequently, we analysed readmission outcomes at the 
specific time points reported to estimate the risk ratio (RR). A fixed effect risk ratio 
was calculated for each trial using the Mantel-Haenszel approach (RRMH) and these 
were pooled in sub-groups of trials with similar durations of follow up. Fixed effect 
models were chosen (unless otherwise stated) as most trials were similar in 
methodology, setting and population.  
Ninety-five percent confidence intervals (CI) were calculated for the summary effect 
size and p<0.05 was deemed statistically significant. Heterogeneity between trials 
was assessed by visual inspection of forest plots and estimation of the percentage 
heterogeneity between trials that cannot be ascribed to sampling variation.237 If there 
was evidence of substantial heterogeneity, potential reasons for this were assessed. 
2.3 Results 
From the literature search, 1,689 references were screened. Including hand-
searching, we identified 52 unique references that were retrieved in full. Eight RCTs 
were included, all published within the last fifteen years. The majority of excluded 
studies were not RCTs or did not involve a comparison of ESD/HAH and usual care. 
Seven RCTs 159, 225-227, 229, 238, 239 were included in the mortality and readmissions 
review. Four trials included a cost analysis.159, 226, 240, 241 One RCT published 
separate clinical 227 and cost 241 analyses. The process of trial selection is shown in 
the Figure 2.1. 
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Figure 2.1: Results of the search strategy and reasons for excluding trials form the review 
2.3.1 Description of selected studies 
Four RCTs were conducted in the UK,225, 226, 229, 238 two in the Netherlands,227, 239, 241 
one in Australia 240 and one in Italy.159 The inclusion and exclusion criteria are 
summarised in Table 2.1. All trials randomised patients to ESD/HAH or UC and 
provided some description of the ESD/HAH service offered. Clinical responsibility for 
patients in the ESD/HAH arm remained with the hospital team until discharge from 
the scheme, with the exception of one trial in which the General Practitioner provided 
care out-of-hours and for “other medical problems”.225 Reported outcomes include 
mortality,159, 225-227, 229, 238, 239 readmissions,159, 225-227, 229, 238, 239 cost,159, 226, 240, 241 
length of in-hospital stay for UC 225, 226, 229, 238, 239 and ESD/HAH,159, 225, 239 total length 
of care (in hospital and at home) for ESD/HAH,159, 225, 226, 229, 239 patient preference,226, 
229 and service satisfaction.159, 226, 229, 240 
  
57 
 
2.3.2 Methodological quality of included studies 
Seven trials 159, 225-227, 229, 238, 239 reported the method of randomisation. Two trials 226, 
227 employed computer-generated random numbers and three trials used random 
numbers.159, 225, 239 Four trials reported allocation concealment using sealed 
envelopes.227, 229, 238, 239 
Blinding of participants and treating clinicians is not possible. Only one RCT was 
single blind (Ricauda et al.);159 clinicians who performed baseline assessments and 
the researcher assessing outcomes were unaware of allocation. For subjective 
outcomes (e.g. quality of life) the risk of bias was considered moderate for Ricauda et 
al., and high in the remaining trials. Mortality is an objective outcome with low risk of 
bias regardless of blinding.235 Readmission was regarded as objective in the 
Cochrane 2012 meta-analysis.158 On balance, we agree, although subjective 
influences may affect patient behaviour.  
Six trials 159, 225-227, 229, 238 included patients who were lost to follow up, withdrew 
consent or were excluded from analysis (e.g. due to incorrect diagnosis). In total, 726 
and 688 patients were included in the mortality and readmission analyses 
respectively. 
The baseline characteristics of patients and risk of bias, other than blinding, in the 
included trials are shown in Table 2.2. The recruitment process and structure of 
ESD/HAH services is outlined in Table 2.3.  
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Study Additional AECOPD inclusion criteria 
Exclusion criteria 
Clinical indices Co-morbidities Demographic and social  
Cotton 
2000 Not reported 
Acidaemia (H+>45 nM) 
Pneumonia or lung cancer on CXR 
Other medical conditions, including: Chest 
pain suggesting MI or PE 
Anaemia 
Gastrointestinal or endocrine disorders 
Musculoskeletal disease 
Nausea, vomiting and dehydration 
Non-Glasgow resident 
Homeless or Hostel dwellers 
Unable to consent 
No telephone 
Discharge already planned 
Primary social admission 
Davies 
2000 
FEV1<80% predicted 
FEV1/FVC<70% 
HR<100, SBP>100 
pH>7.35, PaO2>7.3, PaCO2<8 
WCC 4-20x10g/l 
MMSS>7 
Marked use of accessory muscles Uncontrolled 
LVF 
Acute changes on echocardiogram 
Need for intravenous therapy 
Suspected malignancy, pneumothorax, or 
pneumonia on CXR 
Asthma Require full-time nursing care 
Skwarska 
2000 Not reported 
Impaired LOC or acute confusion 
pH<7.35 
Acute changes on CXR 
Other serious medical conditions, e.g.: 
Ischaemic cardiac pain 
Cardiac failure 
Social reasons 
Ojoo 2002 
FEV1/FVC<70% 
Previous FEV1 reversibility to 
salbutamol<15%. 
Acidosis or new type 2 respiratory failure 
Cor pulmonale 
Acute changes on CXR 
Concomitant medical conditions requiring 
medical admission. 
Age >18; no telephone 
Resident >15 miles from hospital Poor 
home support or lives alone 
Nissen 
2007 
FEV1<80% 
FEV1/FVC<70% with lack of 
reversibility 30 mins after 
bronchodilator therapy PaO2>7.3 
Need for intravenous therapy 
Need for NIV or ventilation 
ECG changes 
Pneumonia on CXR 
Unstable heart failure 
Confusion 
Other severe medical disorder 
 
Inadequate social conditions 
No telephone 
Lives outside the hospital area 
Previously participated in the study 
Participant in another study 
Ricauda 
2008 Not reported 
PaO2<6.7; pH<7.35 or >7.55 
Suspected PE or MI 
MMSS<14 (severe dementia) 
Severe renal impairment 
Cancer (not skin) 
Hepatic failure 
No family or social support 
Age<75; no telephone 
Living outside catchment area 
Utens 
2012 
10 pack years of smoking 
 
Impaired LOC or acute confusion 
Indication for admission to ICU or NIV 
Acute ECG changes; pneumonia on CXR 
By day 3: no decrease in physical complaints 
IV therapy or newly prescribed oxygen therapy 
BM ≥15 mmol/l (and unable to self-regulate) 
Major uncontrolled co-morbidity including 
heart failure and malignancy 
Mental disability including dementia 
Active alcohol and/or drug abuse 
 
Age <40 
Lives outside care region 
Inability to understand 
Lack of home care 
By day 3, independent toileting 
Key: AECOPD – Acute exacerbation of COPD; FEV1 – forced expiratory volume in 1 second; MMSS – Mini mental state score; FEV1/FVC – FEV1/forced vital capacity; HR – heart rate; SBP 
– systolic blood pressure; PaO2 - partial pressure of oxygen in arterial blood; PaCO2 – partial pressure of carbon dioxide in arterial blood; WCC – white cell count; LOC – level of 
consciousness; LVF – left ventricular failure; CXR – chest x-ray; MI – myocardial infarction; PE – pulmonary embolus; ICU – intensive care unit; NIV – non-invasive ventilation. 
Table 2.1: Inclusion and exclusion criteria for trials included in the mortality and readmission analysis 
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   Study 
Number of 
patients 
Age FEV1 PaO2 PaCO2 Risks of bias 
 
Cotton 
2000 
ESD/HAH 41 65.7 (1.6)* 0.95(0.08) 41 (3)*% 8.5 (0.4)* 6.0 (0.3)* Follow up method varied. Some patients had 
face-to-face contact, others did not. More 
withdrawals in ESD/HAH. UC 40 68.0 (1.2)* 0.94(0.06) 44 (3)*% 9.2 (0.4)* 5.5 (0.2)* 
Davies 
2000 
ESD/HAH 100 70(8) 0.82(0.37) 36.1(17.2)% 9.7 (2.9) 5.2 (1.0) Methods of sequence generation and follow 
up not reported. Higher rate lost to follow up 
in usual care group. UC 50 70(8) 0.76(0.28) 35.1(14.7)% post bd 9.0 (1.2) 5.2 (0.8) 
Skwarska 
2000 
ESD/HAH 122 68.5 0.77 >7 (91.6%) Not reported Allocation concealment unclear. Unequal 
proportions lost to follow-up. 
 UC 62 69.9 0.66 >7 (90%) Not reported 
Ojoo 
2002 
ESD/HAH 30 69.7 1.0 (0.38) Not reported Not reported Random sequence generation method not 
reported. 
 UC 30 70.1 0.85 (0.34) Not reported Not reported 
Nissen 
2007 
ESD/HAH 22 69 (10.3) 1.5 at admission 40.1 (17.7)% 9.2 (1.4) 5.5 (0.7) Sequence generation not described in article; 
author confirmed sealed envelopes were used. 
UC 22 69 (10.1) 1.4 at admission 
33.7 (10.0)% 
8.9 (1.3) 5.5 (0.81) 
Ricauda 
2008 
ESD/HAH 52 80.1 (3.2) 0.92(0.4) 9.2 (2.5) 5.9 (1.6) Education only provided within the ESD/HAH 
arm. 
UC 52 79.2 (3.1) 1.04(0.5) 8.7 (1.9) 6.1 (1.6) 
Utens 
2012 
ESD/HAH 70 68.3 (10.3) Not reported 9.0 (1.1) 5.2 (0.7) Unequal proportions of patients lost to follow 
up. 
UC  69 67.8 (11.3) Not reported 9.4 (1.8) 5.0 (0.8) 
Values are given as means (standard deviations). Key: *  – standard error; † – 8 weeks post discharge; FEV1 – forced expiratory volume in 1 second; PaO2 – partial pressure of oxygen in 
arterial blood; PaCO2 – partial pressure of carbon dioxide in arterial blood; ESD/HAH – early supported discharge/ hospital at home; UC – usual care; bd – bronchodilator. 
Table 2.2: Baseline characteristics of patients and risks of bias in trials included in the mortality and readmission analysis 
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Study 
ESD/ HAH recruitment structure Structure of ESD/ HAH services 
When? Where from? Who by? Intervention Additional services provided 
Cotton 
2000 
Monday to Friday 
mornings Discharge 
next working day after 
recruitment 
Medical Wards 
Respiratory specialist 
nurse, respiratory middle 
grade doctor 
Nurse visited morning after discharge and then as required: 
median 11 visits over median 24 days.  
GP out of hours care. 
Nebulised bronchodilators, oxygen 
cylinders. 
(Additional social support or community 
physiotherapy not provided). 
Davies 
2000 
Monday to Sunday 
08.00 to 18.00 
Accident and 
Emergency 
Respiratory specialist 
nurse; 
Respiratory Doctor 
Nurse escorted home, visited mornings and evenings for first 
3 days, then as required: mean (SD) 11 (3) home visits. 
District nurse cover evenings and overnight. 
Social support (cleaning, shopping, W&D, 
MOW, day and night-sitters). Nebulised 
bronchodilators, oxygen concentrator. 
Skwarska 
2000 
Monday to Friday 
09.00 to 17.00 
Accident and 
Emergency; 
Medical 
Admissions Unit 
Medical Registrar; 
Acute Respiratory 
Assessment Service; 
Respiratory Consultant 
Nurse visited next day and then 2–3 day intervals: mean 3.8 
nurse visits. Weekly meeting with consultant. Medical advice 
available daily from on-call respiratory team 
Nebulised bronchodilators, oxygen 
concentrator. 
Ojoo 2002 
Monday to Thursday 
09.00 to 17.00 
Discharge within 48hrs 
Medical Chest 
Unit 
Respiratory outreach 
nurses 
Nurses complete daily progress and symptoms score charts. 
The medical chest unit were available out of hours by phone. 
Oxygen therapy and nebulised 
bronchodilators. 
Nissen 
2007 
Discharged from 
hospital within 48 hours 
of admission 
Not reported Project nurses 
Chest physiotherapy (assumed provided in hospital). Mean 
2.6 (1-6) home visits; mean 1.5 hours nurse visit; mean 2.1 
(0-6) phone contacts; mean phone time 15 mins; average 
time per patient= 4 hours 15 mins. 
Oxygen therapy. No additional social 
support. 
Ricauda 
2008 
Monday to Sunday. 
Mean time in 
emergency 
department=15.5 hrs 
Emergency 
department Not reported 
3 Geriatricians, 13 nurses, 3 physiotherapists, 1 social 
worker, 1 counsellor. Daily meetings. 7 day service. Physician 
and nurse visit day after discharge, then daily nurse visit 
(mean=14.1) and physician visit every 2–3 days (mean=9.9). 
Oxygen therapy, nebulised 
bronchodilators, intravenous antibiotics 
and steroids. 
Utens 2012 
Screened for inclusion 
day 1. Randomised day 
3 of admission, home 
on day 4 
Not reported Community nurses; Respiratory Physician  
Community nurses visited or contacted patient at least once 
daily on day of discharge and for 3 consecutive days. 
24 hour telephone access to hospital 
respiratory ward for emergencies. 
Key: GP – General Practitioner; W&D – washing and dressing; MOW – meals on wheels. 
Table 2.3: Recruitment process and structure of care for ESD/ HAH services in trials
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2.3.3 Organisational structure of ESD/HAH schemes 
Two trials offered ESD/HAH from Monday to Friday only 225, 226 and two trials 
provided a seven day service.159, 238 Utens et al.,227 Nicholson et al.240 and Ojoo et 
al.229 provided telephone support seven days a week, but it is unclear if patients were 
visited at the weekends. Patients were recruited from the A&E department,159, 238, 240 
or from general or speciality wards.225-227, 229, 239 
In most trials, patients returned home within 24 159, 226, 238 to 48 229, 239 hours of 
hospital admission. Patients were usually visited at home within 24 hours of 
discharge,159, 225-227, 238 though Nicholson et al.240 and Nissen et al.239 were unclear in 
this regard. 
Most ESD/HAH services involved home visits from hospital-based nurses with 
respiratory experience, but not physicians.225, 226, 229, 238 In one trial of patients aged 
75 years and over, home visits were performed by both geriatricians and nurses; 
although not respiratory specialists, they are experienced in delivering HAH 
treatment.159 In other trials, visits were performed by “generic community nurses”227 
or community based nurses and General Practitioners.240 Within most ESD/HAH 
services, the nurses could obtain medical advice from respiratory physicians.225, 226, 
238, 240 Out of hours support varied, and included district nurses,238 out of hours GP,225 
the on call respiratory team / medical chest unit / respiratory ward,226, 229, 242 or the 
HAH team (which included nurses and physicians);159 in one study this information 
was unclear.239 Five trials 159, 225, 226, 238, 239 reported the number of home visits, which 
ranged from a mean of 2.6 visits,239 to 14.1 visits from nurses and 9.9 visits from 
geriatricians.159 The trial with the least number of nurse home visits also offered a 
telephone support service. The mean (SD) number of telephone calls from patient to 
nurse was 0.76 (1.34) and from nurse to patient was 1.56 (1.31). 
Two trials offered patient and carer education.159, 229 including recognition and 
management of AECOPD, to the ESD/HAH group only. Other support offered 
includes social support,159, 238 physiotherapy,159, 239 and counselling and occupational 
therapy.159 
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2.3.4 Mortality 
Meta-analysis of seven RCTs,159, 225-227, 229, 238, 239 assessing 726 participants showed 
a trend towards lower risk of death within 2 to 6 months favouring ESD/HAH (RRMH = 
0.66, 95% CI: 0.40-1.09, p = 0.10; Figure 2.2). The percentage of the variability in 
effect estimates due to heterogeneity rather than sampling error (chance) was not 
important (I2 = 0%). 
 
Figure 2.2: Forest plot comparing ESD/HAH to usual care for mortality 
The results using a random effects model were similar (RRMH = 0.67, 95% CI: 0.40-
1.11, p = 0.12), which suggests a small amount of between trial variation. To 
investigate the possibility of publication bias, the analysis was performed only 
including the largest trials, which did not reduce the treatment effect but widened the 
confidence interval (0.60, 95% CI: 0.28-1.25, p = 0.29).226, 227, 238 We performed a 
sensitivity analysis excluding the trial with the most select population (patients aged 
75 and over) (RRMH = 0.60, 95% CI: 0.32-1.16, p = 0.13).159 Finally, the analysis was 
repeated including all patients lost to follow-up (assuming zero event rate) to allow 
comparison to previous meta-analyses which adopted this approach (RRMH = 0.67, 
95% CI: 0.41-1.10, p = 0.11).158, 231 
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2.3.5 Readmissions 
Meta-analysis of seven RCTs,159, 225-227, 229, 238, 239 assessing 688 participants, 
assuming return to hospital during ESD/HAH was not a readmission, showed 
ESD/HAH was associated with a lower risk of readmission within 2 to 6 months than 
UC (RRMH = 0.74, 95% CI: 0.60-0.90, p = 0.003). This, and the time periods for 
readmission, are shown in Figure 2.3. 
 
Figure 2.3: Forest plot comparing ESD/HAH to usual care for proportion of admissions with return to 
hospital not classed as a readmission 
The percentage of the variability in effect estimates that was due to heterogeneity 
rather than chance was I2 = 26%. An analysis with random effects was similar (RRMH 
= 0.72, 95% CI: 0.57-0.92, p = 0.010). 
The results were not robust to a sensitivity analysis that excluded the trial of 
Aimonino Ricauda et al.159 in which patients were limited by age (greater or equal to 
75 years) (RRMH = 0.83, 95% CI: 0.65-1.05, p = 0.11, I2 = 0%). 
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The benefit was also not seen when including all trials with return to hospital during 
the period care within ESD/HAH classed as a readmission (RRMH = 0.84; 95% CI 
0.69-1.01, p = 0.07; Figure 2.4). 
 
Figure 2.4: Forest plot comparing ESD/HAH to usual care for proportion of readmissions including 
return to hospital as a readmission 
Finally, the analysis was repeated including patients lost to follow up. Once again 
ESD/HAH was associated with fewer readmissions (RRMH = 0.75, 95% CI: 0.61-0.93, 
p = 0.007), but not if return to hospital during ESD/HAH was considered a 
readmission (RRMH = 0.88 95% CI: 0.72-1.07, p = 0.21). 
A detailed description of the numerator and denominator used for the readmission 
and mortality risk is shown in Table 2.4.
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Study Readmitted / at risk 
patients  
Died / at risk 
patients 
Notes Further information provided by author? Lost to 
follow up? 
ESD/ 
HAH 
UC ESD/ 
HAH 
UC 
Cotton 
2000 
12 / 41 
12 / 41 
12 / 40 1 / 41 2 / 40 Readmission and mortality data analysis as reported in study. Clarification on definition of readmission, and exclusions and withdrawals. 
Nil reported  
Davies 
2000 
35 / 93 
37 / 95 
17/ 45 9 / 95 4 / 45 
Two patients died within 14 days in ESD/HAH, both developed 
pneumonia, not visible on admission CXR, and returned to 
hospital before death. Denominator reduced in ESD/HAH and UC 
for patients with missing data for readmission and mortality. 
Confirmed 14 day period defined as the period of 
acute care and additional details regarding 
mortality. 
5 in 
ESD/HAH 
5 in UC 
Skwarska 
2000 
27 / 108 
39 / 120 
21 / 61 4 / 122 7 / 62 
In UC one patient died in acute period so removed from 
denominator for readmission. In ESD/HAH, twelve patients 
readmitted during hospital at home period, who were not 
analysed as readmissions so subtracted.  
Mortality and readmission data confirmed with 
author. On review of the data, author confirmed 
that two patients in ESD/HAH were not included in 
the readmission analysis (subtracted from 
denominator).  
Nil reported 
Ojoo 2002 
9 / 27 
11 / 29 
12 / 27 1 / 27 3 / 27 
In UC readmission rate reported as 44.4% (12/27). ESD/HAH 
readmission rate 33.3%. As 27 followed up, number of events= 
9. Of three patients excluded from ESD/HAH analysis, authors 
report two patients returned to hospital during ESD/HAH. 
No. 
3 in 
ESD/HAH 
3 in UC 
Nissen 
2007 
4 / 22 
6 / 22 
8 / 22 1 / 22 0 / 22 No deaths during the acute period. No patients lost to follow up. 
Detailed information provided on readmission and 
return to hospital data. Two patients who were 
admitted during ESD/HAH were included in the 
analysis, and were not readmitted during follow 
up, so denominator not adjusted. 
Nil reported 
Ricauda 
2008 
17 / 41 
20 / 41 
34 / 39 
 
9 / 50 12 / 51 
Three patients returned to hospital during ESD/HAH, not termed 
readmissions. Unable to clarify if these 3 patients were 
readmitted during follow up period. 
No. 
2 in 
ESD/HAH  
1 in UC.  
Utens 2012 
17 / 66 
18 / 66 
17 / 56 1 / 66 1 / 56 Patients died during the follow up period, not acute period, so denominator not adjusted. 
Detailed information provided on follow up. UC- of 
16 lost to follow, 3 known to be readmitted. 
ESD/HAH- of 6 lost to follow up, 2 known to be 
readmitted prior to being “lost”. 
4 in 
ESD/HAH 
13 in UC 
 
In some instances, patients who returned to hospital during EDS/HAH were not included in the authors’ analysis, so they have been removed from both the numerator and denominator. Patients 
who died during the acute period are not at risk of readmission and have been removed. The numbers in bold (readmission column) describe readmissions including return to hospital during 
ESD/HAH. Patients who were lost to follow up have been removed. 
Table 2.4: Readmission and mortality rate in trials 
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2.3.6 Service costs 
Three trials performed cost analyses,159, 226, 240 and one trial performed cost-
effectiveness and cost utility analysis.241 There is substantial variation in the costs 
that were included in the analyses, and how these costs were assessed. 
Although the trials were conducted in different countries with different healthcare 
systems, the cost per episode of healthcare associated with ESD/HAH was 
consistently lower than UC (UK ESD/HAH = £877, UC = £1753;226 Italy ESD/HAH = 
$1,175.9, UC = $1,390.9;159 Netherlands ESD/HAH = €1,219, UC = €1,463;241 and 
Australia ESD/HAH = Aus$745, UC = Aus$2543).240 
Only one trial assessed costs beyond the acute event; both healthcare and societal 
costs were reported over three months 241. Healthcare costs for the acute period (the 
period receiving in hospital or home treatment)) and the acute and follow up periods 
combined (ESD/HAH = €4,129, UC = €4,297) marginally favoured ESD/HAH. 
However, during the follow up period alone, usual care was less expensive 
(ESD/HAH = €2,910, UC = €2,834). The largest costs during the follow up period 
were due to community nursing and readmissions. Readmission costs were equal in 
both arms (€941), however in the usual care arm a larger proportion of patients were 
lost to follow up. This may have underestimated the readmission cost in UC by 
underestimating the readmission rate. UC patients had a marginally lower mean 
change in their Clinical COPD questionnaire, reflecting a smaller deterioration in 
symptoms. The UC group had marginally higher QALYs, though the difference was 
small and statistically non-significant. Therefore, from a healthcare perspective HAH 
was associated with a savings per QALY lost of €31,111. This is not consistent with 
other studies which tend to show improved quality of life with ESD/HAH though do 
not report in-depth economic evaluations. When costs from a societal perspective 
were also considered, including formal and informal carer costs and production 
losses for the patient, over the acute and follow up periods combined, ESD/HAH was 
more expensive than UC (ESD/HAH = €6,304, UC = €5,395). 
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2.4 Discussion 
2.4.1 Principal findings 
Compared to UC, ESD/HAH was associated with a trend towards lower mortality in 
trials reporting outcome between two and sixth months after discharge from hospital 
or ESD/HAH. 
ESD/HAH was associated with a lower rate of all-cause readmission than UC at two 
to six months provided all trials were included and that return to hospital during the 
period of acute care within ESD/HAH was not considered a readmission. Of 
importance, the trial by Ricauda et al.159 was age restrictive, education was only 
routinely provided in the ESD/HAH arm and there was a high event rate in the UC 
arm (after correction for age and co-morbidity). If this trial is excluded from the 
analysis, the difference in readmission rates is no longer significant. However, this 
trial 159 provides strong evidence that patients aged 75 and over may be safely 
included in ESD/HAH schemes. Most patients hospitalised with AECOPD are elderly 
150 and older patients are most at risk of readmission,243 and death.43, 243, 244 
Conceptually, if patients receiving ESD/HAH remain fully under the care of the 
specialist hospital based team, return to hospital during the period of acute care may 
be regarded as a transfer to a higher level of care within the same episode, rather 
than a readmission. This may also be of interest to commissioners and inform service 
tariffs. Whilst the distinction between HAH and ESD is blurred, return to hospital 
during a period of ESD is more typically regarded as a readmission. Regardless of 
the service description and level of care provided, the patient and their carers may 
regard return to hospital as a failure of ESD/HAH and the event as a readmission, 
which may have a negative impact on quality of life and service satisfaction. If this 
approach is adopted, readmission rates were similar for ESD/HAH and UC. 
Compared to UC, ESD/HAH is associated with a shorter in-hospital stay, although 
the total period of care tends to be longer. This does not necessarily mean that 
patients receiving ESD/HAH are kept under review unnecessarily. Pressures to 
reduce length of stay in hospital may have led to patients being discharged earlier 
than is optimal. If return to hospital is regarded as a readmission, this favours UC 
because UC patients cannot be ‘readmitted’ during their inpatient stay. Conversely, 
as the total period of care is longer in ESD/HAH, and the risk of readmission is 
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highest in the early discharge period, not defining return to hospital as a readmission 
may favour ESD/HAH. In common with earlier reviews,158, 231 we estimate that 23% of 
patients could be safely treated at home. Service costs relating to health during the 
initial treatment phase favour ESD/HAH over UC. For most studies, a description and 
breakdown of the cost calculations are not provided. Due to this, and heterogeneity 
of studies, identifying the most cost-effective model is not possible. Goossens et 
al.241 provide a detailed cost analysis, and when considering health and social costs 
combined, ESD/HAH was more expensive. In this study all patients spent three days 
in hospital, and so this model is closer to ESD than HAH, and the results may have 
been different if the patients had returned home soon after admission or hospital 
admission was avoided. 
Patient preference favours ESD/HAH over UC, whilst service satisfaction appears to 
be similar although further robust trials are required. 
2.4.2 Strengths and weaknesses of meta-analysis and comparison of included 
studies 
This review and meta-analysis has provided an up-to-date analysis of ESD/HAH 
compared to UC for AECOPD prior to our RCT of HAH selected by low risk DECAF 
score. It includes a trial 227 not published at the time of previous reviews.158, 231 We 
employed a comprehensive search strategy and contacted the corresponding 
authors to verify data when necessary. 
The included trials were conducted in different countries with different healthcare 
systems. The diagnostic criteria for AECOPD were similar, but there were important 
variations in inclusion criteria and the structure and organisation of ESD/HAH 
services. Some trials did not offer enrolment at the weekends,225, 226, 229 reducing both 
the cost of, and the number of patients who could access, ESD/HAH. In two trials 159, 
238 patients were recruited directly from A&E or the Emergency Department, 
facilitating quicker discharge home, whilst in other trials 225-227, 229, 239 patients were 
recruited from wards, allowing a period of stabilisation and observation as an 
inpatient. It is likely that offering both pathways, tailored to the individual patient, 
would optimise costs and the proportion of patients suitable to access the service. 
The structure of ESD/HAH services varied, including the healthcare professionals 
involved, the number of home visits, telephone support, access to medical services 
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such as home oxygen, and provision of temporary social support. Differences in 
selection criteria and service structure may, in part, explain the striking variation in 
the level of support provided in the ESD/HAH arm; the mean number of home visits 
ranged from 2.6 nurse visits 239 to 14.1 nurse and 9.9 physician home visits.159 
Amongst patients with AECOPD who require in-hospital or ESD/HAH treatment, 
those with more severe exacerbations and/or poor performance status may require 
greater clinical and social support at home. A more comprehensive service, offering 
frequent visits from professionals, home oxygen therapy and temporary social 
services if required, will allow inclusion of a broader spectrum of patients. Although 
this will increase the cost of ESD/HAH, it may still be less expensive than UC. 
In some trials there were differences in the elements of care provided in each arm. 
For example, in one trial, education, including exacerbation self-management, was 
provided to patients and carers in the ESD/HAH group, but not to the UC group.159  
The period of follow up varied; this influenced the event rate. To address this, we 
initially planned to analyse results using hazard ratios, but the data required were not 
available and could not be estimated using Parmar’s methods,236 therefore risk ratios 
were calculated. 
Differentiating between ESD and HAH is challenging, and in this review we have 
considered both together. HAH is an appropriate term for patients that have their 
entire episode treated at home, without admission. The term HAH is also used in 
some healthcare systems for patients who are assessed in the medical admission 
unit and return home for treatment the same day or the following morning if admitted 
overnight. For patients who deteriorate at home, during the period of care under 
ESD/HAH, an overnight stay in hospital is often defined as a readmission. However, 
equally this may be considered an escalation in level care within a single acute 
episode, and alternatively defined as “return to hospital”. We have analysed the data 
separately, where possible, to reflect this variation. Some patients may have a brief 
assessment in an emergency department or ambulatory setting without an overnight 
stay; this would typically not be considered a readmission, and we consider that the 
RCTs described were consistent in this respect. 
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2.4.3 Comparison with previous meta-analyses 
Trial selection 
Two meta-analyses comparing ESD/HAH and UC published in 2012 came to 
different conclusions with regards to outcome. Cochrane 158 reported moderate 
quality evidence that ESD/HAH was associated with lower readmission risk than UC 
(RR 0.65, 95% CI 0.59-0.99, p = 0.04),158 which was further strengthened following 
exclusion of the trial deemed to have the highest risk of bias (CI 0.58 to 0.91; p = 
0.006), and moderate evidence of a trend towards a reduction in mortality. In 
contrast, McCurdy 231 found no significant difference in readmission and mortality 
rates. The evidence was regarded as low to very low in quality, with a need for 
further research.  
Two trials included by Cochrane failed to meet our selection criteria. We did not 
include the study by Nicholson et al.,240 which primarily compares costs, in our meta-
analysis of readmission. This RCT included patients referred by the outpatient 
department. No information was provided on baseline function, the randomisation 
process, allocation concealment, mortality or readmissions. Data on readmissions 
was obtained at the time of the Cochrane review, but the period of follow up is 
unclear. In the ESD/HAH arm the risk ratio for readmission was high compared to 
other trials,225, 226, 229, 234, 238 however due to the small number of subjects, the 
confidence intervals are wide (RR = 2.77, 95% CI 0.69 to 11.17). Cochrane also 
raised concerns and excluded this paper in a sensitivity analysis. 
We excluded Hernandez et al.,234 which was included by Cochrane, because patients 
attending A&E with an AECOPD without the need for admission were considered 
eligible; 38.6% of the patients in the UC arm were discharged directly from A&E. A 
similar proportion of those treated within ESD/HAH would be expected to not 
otherwise require admission, thus this structure of care does not meet the definition 
of ESD/HAH for all included patients. Whether or not this group of patients benefit 
from home support is of importance, but is not the subject of this review. 
Patient events 
McCurdy differs from Cochrane in the number of events because McCurdy classes 
return to hospital during ESD/HAH as a readmission. Neither adjusted their analyses 
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for patients who die prior to discharge, yet such patients are not at risk of 
readmission. 
McCurdy discusses the issues surrounding missing data, but, like Cochrane, did not 
make any adjustment in the analysis. Both performed an intention to treat analysis, 
but included those patients lost to follow up in whom outcome data was not available. 
This assumes their event rate is zero, though other RCTs suggest that patients with 
missing data have a higher event rate than the population with complete data 245. The 
ideal approach to missing data is multiple imputation, but this requires raw trial data. 
We analysed readmission rates with and without return to hospital counting as a 
readmission and with and without patients lost to follow up. We are grateful to all 
authors who clarified data. 
2.4.4 Implications for clinicians and policymakers 
AECOPD are associated with substantial morbidity, mortality and healthcare costs. It 
is imperative that clinically and cost effective methods to reduce admissions and 
readmissions are considered and implemented. In selected patients presenting with 
AECOPD, ESD/HAH schemes substantially reduce length of stay, with similar or 
lower mortality and readmission rates compared to conventional inpatient care. 
Despite this, many Trusts currently do not offer such services. 
2.4.5 Future research 
We recommend that future RCTs of ESD/HAH clearly define readmission, and 
provide data on patients who return to hospital during ESD/HAH and whether these 
same patients are readmitted during the follow up period.  
The optimal selection criteria and structure of care for ESD/HAH services are 
unclear. Selection of patients should be based on their chance of surviving the acute 
episode, among other factors. The application of a robust prognostic tool for use in 
AECOPD would potentially be very useful in this respect.2 It is likely that a tailored 
approach to ESD/HAH, depending on the clinical and social dependency and 
performance status of each patient would be most efficient. Compared to basic 
ESD/HAH schemes primarily reliant on specialist respiratory nurses, multi-disciplinary 
interventions including higher levels of clinical support, temporary social support and 
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input from occupational therapists and physiotherapists may allow a broader 
spectrum of patients to access ESD/HAH. 
Incorporating services such as early pulmonary rehabilitation and education for both 
patients and carers within ESD/HAH is likely to confer additional benefits. The clinical 
outcomes and costs associated with different models of ESD/HAH warrant further 
study. A better understanding of patients’, carers’ and clinicians’ views of ESD/HAH 
may help inform the refinement and expansion of these services. Cost analyses 
should be based on actual costs rather than tariff and include all direct and indirect 
costs, including temporary social care, primary care and readmission costs. 
ESD/HAH schemes may foster greater independence and reduce the risk of 
subsequent readmission, particularly if combined with education, including self-
management. Consequently, ESD/HAH could be provided for readmissions as well 
as the index admission, and costs analysed across all episodes. 
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RESEARCH AIMS AND METHODS 
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 Aims and objectives 
3.1 Validation of the DECAF and eMRCD scores 
1. To validate the DECAF prognostic tool internally in a cohort of patients admitted 
consecutively with an AECOPD over a different time period to the derivation cohort. 
2. To validate the DECAF prognostic tool externally in other UK NHS trusts. 
3. To validate the eMRCD score in an internal and external validation cohort 
The DECAF score was developed in 920 consecutive admissions of patients with an 
AECOPD to two UK hospitals, and was an excellent predictor of inpatient mortality 
with an AUROC curve of 0.86.2 Prior to wider implementation of clinical prediction 
tools, validation and implementation studies should be performed. We aimed to 
validate the DECAF score at a different time point, but in the same population (also 
known as internal validation or temporal validation) and to validate DECAF in a 
separate population in the derivation and internal validation study (also known as 
external validation, or geographical validation; this study also took place at a different 
time from the derivation study). 
The eMRCD score 1 was developed from the same cohort 2 in which the DECAF 
score was derived. Of the DECAF indices, the eMRCD score was the strongest 
predictor of inpatient death on multivariate analysis. We aimed to reassess the 
prognostic strength of the eMRCD score for inpatient mortality, as well as in 
predicting long-term mortality and readmission risk. 
3.2 Hospital at Home in patients with a low DECAF risk, implementation and 
impact assessment 
1. To assess the cost and clinical outcome of treating patients admitted with low-risk 
DECAF AECOPD with Hospital at Home compared to usual care. 
AECOPD are one of the commonest reasons for hospital admission, and in the 
DECAF derivation study, over half of the admitted population had a low risk DECAF 
score and a median length of stay of 4-5 days. Such patients could return home with 
Hospital at Home within 24 hours, potentially reducing length of stay, costs and 
avoiding complications associated with inpatient stay. We intend to perform an RCT 
of HAH versus standard inpatient care for patients with AECOPD and at low risk of 
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death by DECAF score, assessing clinical outcomes, patient preference and health 
and social care costs. We will also evaluate barriers to HAH as directed by DECAF 
using semi-structured interviews of patients, carers and health professionals. These 
interviews will inform future implementation of HAH in the event of a successful trial. 
3.3 Readmission prediction in AECOPD, the PEARL score 
1. To develop and validate a score to predict 90 day readmission or death in the 
DECAF derivation, internal validation and external validation cohorts in survivors to 
discharge. 
Patients admitted with AECOPD have high readmission rates. Risk stratification may 
allow allocation of resources to at risk patients. There are a number of tools that have 
been assessed with regards to the risk of readmission or death in either unselected 
patients or those admitted with AECOPD. However, these tools only offer modest 
performance, which is unsurprising as they were either not derived in the COPD 
population (LACE 221), or were primarily developed to predict death (ADO,217 
BODEX,218 CODEX 216) or health status (DOSE 219). In other words, there was no 
method such as multivariate regression analysis performed to identify the strongest 
independent predictors. 
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 The derivation and validation of prognostic models 
Chapter introduction 
Methods which are common to different studies are included here. The specific 
statistical tests used to compare data are included in tables in the results section. 
To identify the appropriate statistical test, the distribution of data was assessed by 
visual inspection of the histogram. Further assessment of normal distribution was 
performed by analysing the mean, standard deviation, kurtosis and skewness and 
the median and interquartile range. 
Data were analysed using IBM SPSS statistics 22, SigmaPlot 12.3 and Microsoft 
excel. All reported p values are two-sided and confidence intervals are at 95% unless 
stated otherwise. 
This work belongs to a larger programme of research, which included the derivation 
of the DECAF score. The following section describes methods used to validate the 
DECAF score, and to derive and validate the PEARL score. For simplicity, in this 
section the terms “derivation cohort”, “internal validation cohort” and “external 
validation cohort are used”. For the DECAF internal and external validation study, 
this includes all patients, and for the PEARL study this includes all patients that 
survived to discharge; the methods are the same for each study, unless stated 
otherwise. 
Methods related to the DECAF derivation study are not described here, as this was 
part of a previous study.2 Data from the DECAF derivation study was used to develop 
the PEARL score. 
4.1 Ethical considerations and ethical approval 
In the original DECAF study, and in the internal and external validation studies, the 
ethics committee agreed that written patient consent was not required. Without this 
decision, the methodological rigour of the study would have been detrimentally 
affected. The need for consent would have resulted in the loss of patients that were 
admitted to hospital, and discharged shortly afterwards, or those that were too unwell 
(or died prior to) giving patient consent. This is analogous to trying to assess the 
fairness of a die without being able to roll a one or a six. 
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According to the Mental Health Act, 2005, adults are presumed to have capacity 
unless it can be established to the contrary. MCA 2005 s30 relates to capacity and 
research; research is intrusive “if it is of a kind that would be unlawful if it was carried 
out: a) in or in relation to a person who had capacity to consent to it; but b) without 
consent”. Accessing patients’ medical records usually requires consent, without 
which there is a breach of confidentiality, unless the person accessing the notes is 
part of the care team. BMA Medical Ethics today says, “Some record based research 
is carried out in parallel with the provision of treatment by health professional who 
already have access to the records as part of their duty of care. In such cases, where 
researchers are working on data form their own patients, there is no breach of 
confidentiality, as only those who already have access to the information use it for 
research.” This is the same principle that is used to justify accessing patients’ notes 
to collect data for national audit. 
The indices proposed for collection in the validation study are routinely measured in 
normal clinical practice, and it was planned that the patients would not undergo any 
extra investigations. Data would be collected, and anonymised, by the usual care 
team. The definition of “usual care team” is broad, and it can include staff such as 
radiologists and pathologists that may never see the patient, and the respiratory team 
meet this definition. 
In ensuring only the usual care team access patient notes, and that data extracted 
was anonymised, the validation study posed minimal risk to individual patients. There 
are a number of potential benefits. In AECOPD, HAH and ESD services have been 
shown to be safe and effective, with endorsement by the National institute of Clinical 
Excellence (NICE). As described in Chapter 2, these may reduce healthcare costs, 
and improve patient care. NICE recognise that patients should be considered for 
such services, but acknowledged the (previous) lack of a prognostic tool. 
Ethics approval was awarded by NRES committed North East- Sunderland on 3rd 
December 2012. 
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4.2 Developing and validating a prognostic Tool 
There has been a marked increase in the number of published prediction models. For 
example, the TRIPOD statement 246 and CHARMS checklist,204 are guides for 
assessing the quality of such studies. The latter reports that there are over 100 
models for outcome following brain trauma, 60 for breast cancer prognosis, and 45 
for cardiovascular outcome in diabetics. Systematic reviews of prognostic scores 
often conclude that there is widespread use of poor methods.247 The following 
section discusses the rationale for the selected methods, including the strengths and 
weaknesses of alternative approaches. 
4.2.1 Power calculation 
DECAF 
Based on an expected sensitivity of 70%, a standard error of the estimate of 
sensitivity of 5% required a minimum of 840 patients in both the internal and external 
validation cohorts.248 
PEARL 
The derivation cohort was adequately powered based on the minimum expected 
events per index.249 For the internal and external validation cohorts, the sample size 
required was 227 for an expected sensitivity of 70%, a standard error for this 
estimate of 5% and an event rate of 37%.248 
4.2.2 Dealing with missing data 
Missing data is unavoidable, and may bias the results of clinical and epidemiological 
research.250 The consequence of missing data depends on the pattern of missing 
data. Missing data is described as: a) missing completely at random (MCAR); b) 
missing at random (MAR); and c) missing not at random (MNAR). 
For data MCAR, there is no difference between the missing values and the observed 
values. For example, the mean and standard deviation would have been the same if 
the values had been included. The assumption that data is MCAR can be tested and 
if the assumption is fulfilled, complete case analysis can be performed. In practice, 
data is almost never MCAR. 
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It is more likely that data is MAR or MNAR, though proving that data are missing at 
random (MAR), as opposed to missing not at random (MNAR), is generally 
impossible.246 
If data is MAR or MNAR, complete case analysis can lead to biased results 
depending on the rate of missing data. If missing data is less than 5%, it is generally 
agreed that estimates using complete case analysis may not be biased. Complete 
case analysis refers to analyses that only use available data- cases with missing data 
are removed. This is a problem in prognostic research, as even a small amount of 
missing data per index can result in the exclusion of a large number of participants. 
The rate of missing data per index and per patient needs to be considered. 
Steyerberg 251 gives an example in which a model is being developed using five 
predictors, in 500 patients 20% of whom experience the outcome of interest. If each 
predictor has 10% missing data, the complete case analysis may result in the 
exclusion of 50% of the participants. Not only is this inefficient, but estimates will be 
biased; if large numbers of patients are excluded, it is not possible to establish if any 
resultant association is due to correlation between the predictor and the outcome, or 
due to patient selection. Furthermore, missing data may prevent the meaningful 
comparison of models, as the populations with complete data for each model may be 
different. 
Simple measures to account for missing data may result in biased estimates. For 
example, imputing the mean as the missing value is unlikely to be correct. This 
assumes that the characteristics of patients with missing data are the same as those 
without missing data. Also, this will lead to a narrowing of the standard error of the 
mean, which may result in false positive results when comparing data. 
“Missing at random” does not mean that values are “randomly missing” (which 
describes data missing completely at random) but rather that systematic differences 
between missing data and observed data can be explained by observed data. For 
example, haemoglobin and haematocrit measurements correlate well with each 
other.252 If haemoglobin data were missing for a patient, but the haematocrit were 
available, then the missing haemoglobin value could be calculated.  
For data MNAR the missing data depends on the missing value or on other 
predictors that have not been measured (in other words, we have not measured 
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haematocrit). Patients not attending clinic due to the severity of their illness may be 
an example of data missing not at random. 
There may be multiple indices that have been measured that predict the missing data 
index. Regression models can be used to calculate missing data points from other 
indices. As with mean imputation, this can result in a reduction in the standard error, 
which may bias results.253 
Multiple imputation is a method that uses linear and logistic regression to calculate 
the value of missing data points for data that is MAR. To prevent the reduction in the 
standard error, multiple data sets are created, with multiple imputed values. Table 4.1 
is a hypothetical example to illustrate the principle. Patient C has missing data for 
haematocrit. Based on the relationship between haemoglobin and haematocrit for 
patient A and B, three values have been created for patient C. This value is a more 
accurate result than the mean of the other haematocrit values. 
Patient Haemoglobin (g/dl) Haematocrit 
A 12.3 0.372 
B 11.1 0.340 
C 14.4 Missing 
Patient imputed values: 
C1 14.4 0.427 
C2 14.4 0.431 
C3 14.4 0.436 
Table 4.1: Hypothetical values to illustrate data Missing at Random 
Actual datasets would require far more patients, and at least five or more datasets, 
depending on the rate of missing data. In order to use this data in analysis, the 
values in the dataset are pooled by Rubin’s method.254 
Multiple imputation by Rubin’s method 
To explain this approach, a specific example from the DECAF validation study is 
used in which the AUROC curve for the APACHE II score is calculated and 
compared to the AUROC for the DECAF score. The comparison of AUROC curves in 
multiple datasets cannot be done in SPSS nor SigmaPlot. Therefore, the latter 
stages of Rubin’s approach was calculated manually in Microsoft Excel. This required 
a detailed knowledge of the process and is therefore described here in detail. The 
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described approach was used for all AUROC comparison in the internal and external 
validation analyses. 
It is unlikely that missing data rates of only a few percent will bias results. In this 
situation, complete case analysis may be used. However, missing data rates of 1 to 
2% per index can result in large overall missing data rates for a score such as the 
APACHE II which measures 12 physiological variables, age and comorbidity. In the 
validation study overall missing data were 26.8%; multiple imputation is not reliable 
for indices with more than 20% missing values. Therefore, multiple imputation was 
used for individual indices rather than prognostic tools. 
Data were imputed using the Markov Chain Monte Carlo method on IBM SPSS 
Statistics 22, with linear and logistic regression for continuous and categorical 
variables.254 Multivariate regression is discussed later in this chapter. 
As many indices as possible should be included in multiple imputation,254 though 
there may be computational limitations to the number of indices. A large number of 
variables (n = 67) were used as predictors for variables with missing data. Before the 
first imputation, 10,000 iterations were performed which converge to a stationary 
distribution. Following this, five datasets were imputed and the AUROC curve for the 
APACHE II score was calculated for each dataset as well as the mean (Table 4.2). 
To compare the APACHE II score to DECAF the 1) between imputation variance and 
2) within imputation variance must be calculated to find 3) the total variance. The 4) 
overall standard error, 5) degrees of freedom and 6) t statistic can then be calculated 
to provide a p value using the t distribution. 
1) To calculate the between imputation variation †: 
a) The mean of the five ROC curve areas (*) is subtracted from the individual 
ROC curve areas (“AUROC area A to E”), which is squared “(AUROC area 
minus Mean)2 A to E”. 
b) The five results “(AUROC area minus Mean)2 A to E” are divided by the 
number of datasets (five) minus one. 
Mathematically stated, the between imputation variation is (where m is the 
number of datasets): 
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  AUROC area A to E (AUROC area minus 
Mean)2 A to E 
 
APACHE II ROC curve A 0.785 4.09^-06  
APACHE II ROC curve B 0.786 8.24^-06  
APACHE II ROC curve C 0.779 2.26^-05  
APACHE II ROC curve D 0.783 1.55^-08  
APACHE II ROC curve E 0.783 6.83^-08  
Mean 0.783 * 8.76^-06 † Between imputation 
variance 
Table 4.2: AUROC and imputation variance for APACHE II imputed datasets 
2) To calculate the within imputation variation ‡: 
Using SigmaPlot 12.3, the AUROC curve for all five APACHE II curves were 
compared to the DECAF score (which had complete data and did not require 
imputation) to provide the standard error for the difference in the areas (Table 
4.3). The mean of the square of the standard error gives the within imputation 
variance. 
Mathematically stated, the within imputation variation is: 
 
  Standard error APACHE II 
versus DECAF A to E standard error^2 
 
APACHE II ROC curve A 0.020 0.000417  
APACHE II ROC curve B 0.020 0.000415  
APACHE II ROC curve C 0.021 0.000450  
APACHE II ROC curve D 0.021 0.000429  
APACHE II ROC curve E 0.020 0.000417  
Mean 0.021 0.000426 ‡ Within 
imputation 
variance 
Table 4.3: Standard error and calculation of within imputation variance for APACHE II imputed 
datasets 
3) To calculate the total variance: 
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The total variance is calculated by the within imputation variance ‡, plus 1.2 
multiplied by the between imputation variance †.  
0.000426+((1+1/5)*(8.76x10-6)) = 0.000436 
Mathematically stated, the total variance is: 
 
4) The overall standard error is the square of the total variance: 
0.000436^-1/2 = 0.021 
5) To calculate the degrees of freedom: 
Four, multiplied by one plus the within imputation variance divided by 1.2 
multiplied by the between imputation variance squared. 
Mathematically stated, the degrees of freedom is: 
 
6) The t statistic is calculated by the mean of the AUROC curves divided by the 
overall standard error. The t statistic and the degrees of freedom can then be used to 
calculate the p value using the t distribution, which in this example is p < 0.0001. 
4.2.3 Comparison of patient characteristics 
Baseline population characteristics were described using proportions, means with 
standard deviations (SD) or medians with inter-quartile ranges (IQR), and compared 
using Fisher’s exact test, analysis of variance or Welch, and Kruskal-Wallis’s test. 
4.2.4 Study design 
Prospective cohort studies are regarded as the gold standard for diagnostic 
modelling studies.204 This ensures that data on predictors and outcome are reliable. 
Retrospective studies are conceived after some participants have had the outcome 
under investigation. Data may be collected prospectively, but this does not mean the 
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study is prospective. This is an important distinction, as the increased use of 
technology in healthcare has resulted in increasing volumes of routinely stored data. 
This makes retrospective studies easier and cheaper, but retrospective cohorts tend 
to have poorer data quality, and some important predictors may be missed. Some 
types of data may be accurate when collected retrospectively, such as the recording 
of blood tests at admission, although data such as patient-reported symptoms may 
be very unreliable. 
Retrospective study designs are regarded as acceptable in validation studies.212 
However, there is still a risk of bias depending how accurately and consistently the 
predictor indices were collected and whether the identified population is 
representative of the population of interest. 
For these reasons, the derivation and external validation study were performed 
prospectively. The internal validation study was conceived prior to any outcome, 
though the majority of patients were identified retrospectively. The derivation study 
was performed in the same hospitals as the validation study, in which usual care 
included the recording of key data, such as the eMRCD score, which minimises bias. 
At all sites in the internal and external validation studies, the eMRCD score was 
accompanied by clear guidance notes for consistent scoring, which have also been 
published so that it can be replicated in clinical practice.255 All sites had data 
collection guides which included clear definitions for collected indices. Furthermore, 
outcome data, such as death and readmission, are objective and are reliably 
recorded on NHS computer systems and in patient’s medical notes. 
Six UK hospitals participated between January 2012 and May 2014. Sites A and B 
formed the internal validation cohort and C to F formed the external validation cohort. 
The latter were selected to ensure wide variation in structures of care and population 
characteristics (COPD prevalence, socioeconomic factors and rurality). In 
participating hospitals, consecutive patients admitted with AECOPD were identified. 
In the internal validation cohort hospitals, the DECAF indices are recorded as part of 
routine practice. This allowed the period of the study to be extended retrospectively 
to enhance recruitment; patients were primarily identified from a broad coding 
records search (discharge codes). However, this was cross-referenced with existing 
records of patients identified by respiratory specialist nursing and physiotherapy 
teams. In the external validation cohort to identify consecutive admissions of patients 
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with AECOPD, all medical admissions were screened prospectively. This involved 
dedicated staff attending the medical admissions unit and base wards. Coding 
records were also reviewed to maximise patient capture.  
4.2.5 Population 
The study population should be representative of the population of interest to ensure 
that the score can be used in practice.256 To achieve this, consecutive admissions 
should be identified, though this is seldom performed and results in potential bias due 
to selective sampling.204 As with missing data, missed patients are not missed 
completely at random. The following are examples of methods which risk missing 
patients: a) not confirming the diagnosis of AECOPD and/or COPD; b) broad 
exclusion criteria; c) relying solely on coding records to identify patients; d) relying 
solely on the usual care team to identify patients; e) the need for consent; and f) the 
exclusion of patients without complete data. 
In the validation studies, patients were required to have a primary diagnosis of an 
AECOPD for inclusion. This was defined as symptoms of an AECOPD in a patient 
with proven airflow obstruction in whom an alternative diagnosis was not more likely. 
This included patients with COPD who for example received diagnoses such as 
lower respiratory tract infection or pneumonia, but met the criteria for an AECOPD. 
Preadmission spirometry from any time period was included. The difficulty of finding 
spirometry in medical notes is highlighted by the 2015 UK COPD audit, which 
showed that only 46% of patients admitted with an AECOPD had obstructive 
spirometry documented. In the validation studies, all paper and electronic records 
(including old volumes or notes, lung function databases, and GP records) were 
searched for spirometry records. Obstructive spirometry was defined as an FEV1 / 
VC of less than 0.7. The vital capacity was used rather than the FVC because some 
patients with severe COPD may have spirometry that is consistent with a restrictive 
pattern on a forced manoeuvre, but have severe airflow obstructive based on a 
relaxed VC. 
Eligibility criteria were few, to maximise inclusion of patients: 
Inclusion criteria 
1. Age greater than or equal to 35 years 
2. Smoking history greater than or equal to 10 pack years 
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3. Obstructive spirometry (FEV1 / VC < 70%) 
4. Primary diagnosis of AECOPD (nonpneumonic or pneumonic) 
Exclusion criteria 
1. Previous inclusion in the study 
2. Other illness likely to limit survival to less than one year 
These criteria were the same for the DECAF score and the PEARL score, except that 
the PEARL score cohort did not include those patients that died as an inpatient. 
Patients needed to be 35 years or older and have a smoking history of 10 cigarette 
pack years of more. This was to ensure that patients with a diagnosis of COPD were 
included; younger age and a relatively low cigarette pack year history may favour a 
diagnosis of asthma. 
Patients could only be included within the study once, usually for their first admission. 
If patients were admitted with suspected COPD, they could be included for a future 
admission due to an AECOPD once they had COPD confirmed by spirometric 
testing: to achieve this, all patients admitted with a provisional diagnosis of an 
AECOPD had all future admissions reviewed within the research time-frame for each 
site. A potential criticism of this approach is that it does not include patients with a 
new diagnosis of COPD, and therefore may reduce the generalisability of the results. 
However, this may lead to the inclusion of patients who turn out not to have COPD. 
Also, the inclusion of such patients will introduce immortal time bias as survivors to 
discharge and patients sufficiently well to perform spirometry during their 
exacerbation will be included whilst those that are very unwell or die during their 
admission will be missed.  
Patients with a survival of less than one year for a reason other than COPD were 
excluded. 
Relying on coding searches alone to identify patients coded with AECOPD is 
unreliable. There is no single code for AECOPD, and AECOPD are both over- and 
under-diagnosed by the current ICD-10 classification. Over-diagnosis of AECOPD is 
less of a concern than under-diagnosis, as the former can be identified by reviewing 
patient’s medical records. The “under-diagnosed” group are at risk of being missed 
completely. To avoid this, a broad coding search was developed and refined. 
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There were 24 codes identified which could be considered an AECOPD, or could 
represent the miscoding of an AECOPD. An initial search was performed for any 
diagnosis using the terms J10 to J18 (influenza and pneumonia), J20 to 22 (other 
acute lower respiratory infections), J40 to J47 (chronic lower respiratory diseases), 
J96.0, J96.1, J96.9 and/or J98.2 (acute and chronic respiratory failure not elsewhere 
classified and interstitial emphysema) over an eight month period. 
The search retrieved over 11,000 patient episodes. For this group, discharge letters 
were reviewed and patients classified into definite, probable or no AECOPD for one 
month of data. This was then compared to medical notes which showed that for this 
time-period, discharge letters were 100% accurate at excluding an AECOPD (no 
AECOPD classification based on the discharge letters), but could not be relied upon 
to confirm an AECOPD without looking at the medical notes. 
Patients were also categorised into their primary diagnosis (asthma, bronchiectasis, 
pneumonia, COPD, etc.) to establish how often patients with AECOPD receive these 
as their primary diagnosis and how often COPD is included as a non-primary code. 
The search was subsequently refined to: patients aged 35 and over, with a primary 
diagnosis of J10 to J18, J20 to 22, J40 to J47, J96.0, J96.1, J96.9 or J98.2, and a 
secondary diagnosis of any J44 code. 
In the external validation cohort, consecutive patients with AECOPD were identified 
prospectively. This involved a dedicated research person or team visiting admission 
units and wards Monday to Friday to screen all admissions (screening on Monday 
included identifying patients admitted over the weekend). Coding records were also 
reviewed to ensure all consecutive patients were identified. Prospective identification 
of patients at sites captured approximately 90-95% of patients with AECOPD. Those 
that were missed and identified by coding were more likely to have been discharged 
sooner (the most well) or died soon after admission (higher DECAF scores are 
associated with a shorter time to death).3 Similarly, for patients whose medical 
records were difficult to obtain, death rates were higher. Missing these patients would 
narrow the risk range and bias results: it would be analogous to trying to assess the 
fairness of a die without being able to roll a one or a six on some occasions. 
In the internal validation study, most patients were identified retrospectively. 
However, the usual care team routinely aims to review all patients with an AECOPD, 
which when combined with a broad coding search allowed for the identification of 
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consecutive patients. This was confirmed by comparing two months of dedicated 
prospective identification of patients by two members of the research team, 
compared to using the coding search and information from the clinical team. The 
research team identified patients missed by the usual care team, which shows that 
having staff solely dedicated to identify patients improves recruitment. Furthermore, 
only one patient was missed by the coding search that was identified prospectively 
over a two month period (by the research and clinical teams). Recruitment rates in 
the internal validation study were similar to the original prospective DECAF study, 
which supports complete capture of patients. 
In the validation study, patient consent was deemed unnecessary by the ethics 
committee. Studies that require patient consent risk excluding large numbers of 
patients who are too unwell to provide consent, and subsequently die. As such 
patients are not MCAR this introduces bias affecting the assessment of the tool 
performance in the whole population. For example, in a study by Quintana et al.,214 
recruitment was substantially lower than in equivalent audit data. 
Patients who did not survive to discharge were appropriately excluded from analyses 
that looked at readmission risk. In the validation cohort, those that did not have 
complete data for all DECAF indices were not included in the analysis, to allow 
assessment of how the score would perform in clinical practice. This is a potential 
source of bias, as study data are often missed in a selective and biased way. This 
pragmatic approach was supported by measures to ensure that missing data would 
be at a minimum: only 1% of the population were not included, mainly patients that 
had oxygen saturations sufficiently low to warrant arterial blood gas analysis but that 
declined this investigation.  
4.2.6 Study sites 
Six UK hospitals were included in the study. North Tyneside General Hospital 
(NTGH) and Wansbeck General Hospital (WGH) were the sites of the internal 
validation study, and the same sites at which the decaf derivation study was 
performed. The external validation study was performed at the Royal Victoria 
Infirmary (RVI) in Newcastle, the University hospital of North Tees (UHNT), the Royal 
Cornwall Hospital (RCH), and the Northern General Hospital (NGH) in Sheffield. 
 89 
  
Study sites were selected for the variation in the hospitals and in the population that 
they serve to maximise the generalisability of the results. 
4.2.7 Outcome 
DECAF validation 
The primary outcome was in-hospital mortality prediction, with comparison of DECAF 
risk groups between the derivation and validation cohorts. Secondary outcomes 
included assessment of the optimal thresholds for pH and eosinopenia, prediction of 
30-day mortality by DECAF, and comparison to other prognostic scores (APACHE 
II,200 BAP-65,209 CAPS,202 and CURB-65 203). Length of stay was compared across 
DECAF scores. 
PEARL 
The primary outcome was prediction of 90 day readmission or death without 
readmission in patients discharged from hospital following admission with AECOPD. 
Secondary outcome included assessment of other prognostic scores with 
comparison to the newly developed tool (PEARL), 30 day readmission or death 
without readmission, prediction of readmission alone, time to death or readmission 
and readmission frequency. 
In common with previous studies (Table 1.4), we selected “death without 
readmission” as a combined primary outcome with “readmission”. This is justified as 
patients who die without readmission are likely to have been readmitted had the 
clinical deterioration been recognised in time, and death without readmission and 
readmission share similar predictors. Furthermore, readmission alone as the 
outcome would mean that those who die without readmission appear in the 
“favourable” outcome group. 
We selected a 90 day timeframe for our primary outcome as this covers the high risk 
period. In patients hospitalised due to AECOPD who survive to discharge, one third 
are re-admitted within 90 days131 and the risk of further exacerbation and 
readmission over the 8-12 weeks post-discharge outweighs the risk over the 
subsequent year.25, 130 Such events are associated with substantial risk of death, 
adverse qualify of life112, 127-129 and high healthcare costs.5  
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4.2.8 Data collection 
Data collection of the derivation cohort was collected as part of a separate thesis, 
and is described in detail elsewhere.2 
For the validation cohorts, data collection guides were provided to all sites and 
included information on sources of data, the definitions of diseases and terms, and 
time-points for collection. This allowed for precise and consistent data collection. 
Socio-demographic and clinical data were collected on admission. The eMRCD scale 
was provided with written instructions on scoring.255 The presence of consolidation 
on x-ray was based on the consultant’s ward round review (or most senior doctor 
review). Atrial fibrillation was diagnosed by the admission electrocardiogram or 
known history. A diagnosis of left ventricular failure and cor pulmonale was based on 
clinical findings or echocardiogram: reliance on echocardiography alone would limit 
the real-life application of the score. All blood tests (including eosinophil count and 
arterial blood gas results) were from admission. 
Ninety day readmission and mortality data were collected from medical records. 
Admission and readmission were defined as an admission to a hospital ward outwith 
the emergency department. Clinical assessments and care was not influenced by the 
research team, and no additional tests were performed.  
Data was only deemed to be missing once all data sources were exhausted, to 
minimise missing data. The data collection form included a checklist to search the 
patient’s clerking, GP letters, full medical notes (all volumes if required) and nursing 
notes. 
Clinical indices on admission, and demographic, survival and readmission data that 
were collected are shown in Table 4.4. 
In the DECAF derivation cohort,2 118 patients had oxygen saturation (SpO2) greater 
than 92% while breathing room air, of whom none had an arterial pH of less than 
7.30 (DECAF Acidaemia score = 1). In the internal and external validation cohorts, 
therefore, if the attending physician deemed that arterial blood gas (ABG) sampling 
was unnecessary and SpO2 was greater than 92%, it was presumed that the arterial 
pH was greater than or equal to 7.30 and therefore the patient did not score for the 
pH component of the DECAF score.167 
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Type Data point 
Demographics and 
admission information 
Admission age, gender, hospital site, social care prior to admission (nursing home, 
residential home, sheltered accommodation, need for carers), date and time of 
admission 
Inclusion criteria 
Primary diagnosis of AECOPD (nonpneumonic or pneumonic), age greater than or 
equal to 35 years, Smoking history greater than or equal to 10 pack years, 
Obstructive spirometry (FEV1 / VC < 70%) 
Exclusion criteria Previous inclusion in the validation study, Other illness likely to limit survival to less than one year 
Population descriptor 
Number of respiratory, non-respiratory and total admissions in past 6 and 12 
months, Number of respiratory, non-respiratory and total A&E visits in past 6 and 12 
months, exacerbation frequency past 12 months, smoking status, number of pack 
years and year quit smoking, previous pulmonary rehabilitation, previous treatment 
with NIV, NIV during admission, resuscitation status. 
Spirometry FEV1, FVC and ratio and date (preadmission, discharge and follow-up) 
Admission information 
CXR consolidation, eMRCD (independent in washing, dressing or feeding), 
effectiveness of cough, height, weight (measured weight on admission and 3 to 6 
months ago, reported and calculated weight loss, intentional or unintentional 
weight loss), BMI, nutritional intake preadmission, pulse rate, blood pressure, 
respiratory rate, temperate, confusion, GCS scale and pedal oedema. 
Co-morbidity 
Cor pulmonale (clinical or echo diagnosis), cognitive impairment, anxiety, 
depression, left ventricular dysfunction, aids, cerebrovascular disease, chronic 
pulmonary disease, asthma, congestive heart failure, connective tissue disease, 
dementia, hemiplegia, solid tumour, leukaemia, malignant lymphoma, myocardial 
infarction, ischaemic heart disease, atrial fibrillation, peripheral vascular disease, 
gastrointestinal ulcer disease, diabetes with or without end organ damage, liver 
disease (and severity), renal disease (and severity), 
Medication Long term prednisolone and dose, beta-blocker, long-term oxygen therapy, diuretic, statin, ACE inhibitor, ARB inhibitor 
Bloods (all admission) 
ABG (Fi02 on admission ABGs, pO2, pCO2, pH, bicarbonate, base excess), sodium, 
potassium, urea, bilirubin, creatinine, albumin, serum glucose and BM, troponin, 
CRP, haemoglobin, haematocrit, red cell distribution width, platelets, white cell 
count, neutrophil count, eosinophil count 
Outcome 
Death (date, place and cause up to one year), length of stay, readmission (and 
reason for readmission up to one year in the internal validation study and 90 days in 
the external validation). 
Table 4.4: Collected indices 
4.2.9 Predictors for 90 day readmission of death 
Indices that are known to predict death or readmission were selected by performing a 
systematic review of the literature and by clinical plausibility.257 Those predictors that 
are not routinely assessed or available at admission were not included for ease of 
use of the final tool. Predictors and outcome were clearly defined prior to data 
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collection. A potential limitation of the internal validation cohort is the retrospective 
identification of most patients. However, the risk of any consequent bias is low as the 
relevant indices had been recorded prospectively, and the researchers were blind to 
outcome at the time of data acquisition. This was not a risk in the derivation and 
external validation cohorts which were prospective. 
A complete list of indices included in the development of a tool to predict 90-day 
readmission or death (the PEARL score) are shown in Table 4.5.  
 
 
 
 
 
 
 
 
 
 
It is important to ensure that indices are not included which strongly correlate with 
each other to ensure stability in a prognostic model.258, 259 Predictors that are closely 
related do not offer independent information.256 This can be suspected in instances 
where indices measure similar phenomenon, such as haematocrit and haemoglobin. 
This can be quantified by paring all indices and measuring the correlation coefficient. 
If the correlation coefficient is greater than 0.7 this would support excluded one of the 
two indices. 
Sociodemographic details 
   Female 
   Age 
   Institutional care 
   Cigarette pack years 
Preadmission details 
   eMRCD 
   Admissions in previous year 
   Weight loss >5% 
   FEV1 % predicted 
   Long term oxygen 
   Long term prednisolone 
   Left ventricular failure 
   Cor pulmonale 
   Diabetes 
   Chronic Kidney Disease 
   Cerebrovascular Disease 
   Atrial Fibrillation 
   Asthma 
   Cognitive impairment 
Admission details 
   Length of stay 
   Radiographic consolidation 
   Ineffective cough 
Table 4.5: Candidate predictors of readmission or death without readmission 
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All indices were dichotomised or categorised by visual inspection of the ROC curve, 
a clinically relevant cut-off, or a median split.2 Where multiple appropriate cut-offs 
were apparent, the prognostic power of each cut-off was compared. 
It is recognised that for ordered categorical indices, such as the eMRCD, collapsing 
categories may be required.256 Generally speaking, transforming continuous indices 
into dichotomous indices is not advised, as it may result in a loss of predictive 
information. However, simplifying indices in this way allows a score to be 
remembered and easily calculated at the bedside without the aid of a computer or 
calculator. It is possible to compare models with a continuous index in the same 
index dichotomised to look for any loss of prognostic information. 
In the development of the PEARL score, the above indices were categorised: age 
<80 or 80+; cigarette pack years <45 or 45+; eMRCD score 1-3, 4, 5a or 5b; forced 
expiratory volume in one second (FEV1) %predicted <50 or 50+; previous 
admissions <2 or 2+; and length of stay as per the LACE study (0, 1, 2, 3 ,4-6, 7-13, 
or 14+ days).221  
4.2.10 Model development 
Logistic regression is a commonly used statistical technique for binary outcome in 
prognostic research in medicine. The model can include different types of predictors, 
such as continuous, categorical and binary indices. To understand the principles of 
logistic regression, it is useful to first consider the linear regression model. 
Linear regression models take the form: 
Y = β0 + βi * xi  
β0 refers to the intercept on the y axis, βi represents the regression coefficients for 
one or more predictors (xi). A model with two predictors would look like the following: 
Y = β0 + β1 * x1 + β2 * x2  
Where x1 and x2 are the first and second predictor. If x1 were a continuous index, 
such as age, then β1 represents the difference in Y for each unit of x1. As a 
hypothetical example, a one year increase in age (x1) might be associated with a one 
mmHg increase in systolic blood pressure (Y). A linear regression line can be fitted to 
these indices (Figure 4.1, “A”). If x2 were a binary predictor, such as diabetes, then 
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only a one unit change is possible from 0 to 1, where 0 represents no diabetes (and 
acts as the reference group), and 1 represents diabetes (and is the comparison 
group). β2 is then the risk associated with diabetes in addition to age. The exponent 
(eβ) provides the odds ratio, which is perhaps a more easily understood measure of 
risk than the beta-coefficient. The beta-coefficient associated with age alone will be 
different if diabetes or other indices are included in the model. When only one 
predictor is included in a regression model it is an unadjusted or univariate model.  
It is not possible to fit a linear regression line to the data points if the outcome is 
binary (such as death) rather than continuous (Figure 4.1, “B”). In this situation, 
logistic regression can be used. The outcome is considered in terms of the probability 
of its occurrence (P(y=1)). For example, the relationship between age and the 
probability of death (Figure 4.1, “C”) follows an S shaped curve: using the 
exponential function, the intercept, regression coefficients and predictors can be log 
transformed to provide a linear function (Figure 4.1, “D”): 
Logit(P(y=1)) = β0 + βi * xi 
 
Figure 4.1: Illustrative figure of A) a linear regression line, B) a continuous index and binary index, C) 
an S shaped curve for the probability of death and age, and D) the logit of the probability of death 
which transforms the curve into a straight line. 
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There is no agreed single approach for the development of a prognostic tool. In this 
study, binary logistic regression is used to develop predictive models. There are two 
common approaches: a) reducing the number of candidate indices by using 
univariate analysis prior to multivariate analysis; and b) including all indices in 
multivariate analysis. 
In the first approach, univariate analysis (such as univariate logistic regression, or the 
chi squared test) is used to look for associations between predictors and the 
outcome. To explain this approach and a potential weakness, the following 
hypothetical example is used. 
In an observational study, a group of adults of 65 or over are monitored over a ten 
year period. Over this period, 200 of the 500 men and 200 of the 500 women die (t, 
“A”). On univariate analysis gender is not a predictor of death (“A” odds ratio 1, 95% 
CI 0.78-0.129, p = 1), but smoking is strongly related (“B”; odds ratio 11.40, 95% CI 
7.50 to 17.34, p < 0.0001). The rates of death in male and female smokers are the 
same (“C”).  
  Died Survived Died / total % 
A 
Female 200  300 200 / 500 (20%) 
Male 200 300 200 / 500 (20%) 
B 
Smokers 150 30 150 / 180 (83.3%) 
Non-smokers 250 570 250 / 820 (30.5%) 
C 
Men who smoked 50 10 50 / 60 (83.3%) 
Woman who smoked 100 20 100 / 120 (83.3) 
Table 4.6: Illustrative data to show limitations of using univariate analysis to exclude indices 
However, the overall rates of smoking were twofold higher in women than men, and 
so a higher death rate would be expected in women. As this did not occur, it 
suggests that being male is associated with death. This is confirmed when 
performing multivariate analysis, which shows both smoking and male gender are 
independent predictors of death: smoking odds ratio = 12.35, 95% CI 8.05 to 18.94, p 
< 0.0001; male gender odds ratio = 1.39, 95% CI 1.05 to 1.85). 
In order not to reduce the chances of missing important predictors on univariate 
analysis, a p value of 0.1 or 0.2 may be selected, rather than 0.05. However, the 
above example shows that it is still possible to miss predictors with this approach.  
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To avoid this problem, all variables can be included in model development.256 There 
are various ways this can be performed, and the approach taken in this study for the 
development of the PEARL score is described.  
All candidate indices shown in Table 4.5, except for weight loss, were included in the 
initial model and the removal criteria were set (p = 0.1). There is no requirement to 
use a p value of 0.05, which is the case in hypothesis testing and estimation. The 
strength of the association with the outcome is of more relevance in prognostic 
research and it may be appropriate to include an index with a p value higher than 
0.05. This is described by Steyerberg 251 who explains that non-significance is not 
evidence for a zero effect of a predictor; indices that occur infrequently may not meet 
statistical significance without a very large sample size. Furthermore, the inclusion of 
indices in a model that have no association with the outcome lead to a minimal 
decrease in prognostic power within simulation studies. 
Weight loss was not entered into the model due to the relatively high rate of missing 
data and labour intensity in collection, a problem which would likely recur in clinical 
practice.256 The index with the highest p values was removed, and the model was 
then re-fitted to the remaining indices. This process, known as backwards 
elimination, is repeated until only indices with a p value of less than 0.1 remain.  
Previous studies have demonstrated a relationship between both anxiety and 
depression and readmission.260, 261 Methods of recording anxiety and depression vary 
substantially between clinicians and across healthcare settings. Due to the lack of 
objective data regarding these variables, they were not included in model 
development. 
Once all of the independent predictors of outcome have been identified on 
multivariate logistic regression, the final indices need to be selected. The number of 
indices in a model follows the law of diminishing returns, in that additional indices 
have less impact on prognostic power. For example, in the DECAF derivation study, 
the full model of ten indices had an AUROC of 0.89 compared to 0.86 for the five 
strongest indices which appear in the DECAF score. The removal of independent 
predictors is a pragmatic decision: smaller models are easier to interpret and use in 
practice, and the loss of prognostic power may be minimal. The coefficients of the 
remaining predictors will be different once other indices are removed, and should be 
re-estimated. 
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This selection of fewer prognostic indices is a pragmatic decision as such scores are 
easier to calculate at the bedside. Similarly, converting beta coefficients into 
weightings allows for bedside calculations without the aid of a computer.262 This is 
the approach we followed in the development of all scores. 
Overfitting in regression models 
In developing a model, there is an assumption that the derivation population are 
representative of the underlying population (all patients admitted with an AECOPD). 
This should allow for accurate predictions in a new population based on the analysis 
in the derivation cohort. However, even if a derivation study is robustly performed, 
and data collection is accurate and complete, the predictors may not apply to new 
subjects due to “idiosyncrasies of the sample”.251 If a developed model includes such 
idiosyncrasies then the model may be overfitted. A model that is overfitted will not 
perform well in a separate validation cohort. 
One reason for this difference in performance is regression to the mean.251 In a 
derivation study, many indices are included, and the best performing candidates may 
be selected. There is a greater likelihood of selecting indices which are performing at 
their best. The model may therefore include indices in which the strength of the 
association (beta coefficient) has been over-estimated. The more indices included in 
the original model, the greater the risk of overfitting. It is even possible for indices to 
be selected by chance that have no true association with the outcome. This risk can 
be reduced by having a larger sample size and by only including indices with 
relatively large effects. 
Predictions for future subjects can be improved by adjusting regression coefficients. 
In a linear regression model, this involves reducing the mean squared error, which 
will slightly increase bias but increase precision (by reducing variance). A similar 
approach may improve prediction within logistic regression models too. 
Shrinkage after estimation is a method that reduces regression coefficients towards 
zero. The shrinkage factor is based on the likelihood ratio for the model and the 
degrees of freedom (the number of indices in the model). A model can also be re-
adjusted based on analysis in new cohorts; in this situation the beta coefficients can 
be adjusted towards the new estimate, rather than towards zero. 
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4.2.11 Model assessment 
In linear regression models, the variation between predicted values and observed 
values can be measured with R2. This is a measure of the distance between 
predictions and observed outcome, with a score of 1 indicating that the model is a 
perfect fit to the data. Whilst R2 is a useful measure for linear regression models, it 
cannot be performed for binary logistic regression models 
We report the Nagelkerke’s R2, which can be used in logistic regression models. This 
measure is severe for instances in which a patient with the outcome has a very low 
prediction, and Nagelkerke’s R2 values tend to be lower than are seen with R2 values 
in linear models.263  
There are two key aspects to measuring overall performance of a clinical score: 
discrimination and calibration. Discrimination is a measure of how accurately 
predictions discriminate between those patients with the outcome compared to those 
without the outcome. Calibration is a measure of the agreement between predicted 
outcomes and the actual (observed) outcomes across the full range of predicted 
outcomes (risk groups). 
Sensitivity, specificity and discrimination 
The c statistic is a measure of concordance used to assess the discrimination of a 
generalised linear model.263 For a binary logistic regression model, the c statistic is 
identical to the area under the receiver operating characteristic (AUROC) curve. 
The AUROC curve plots the sensitivity (the true positive rate) against 1 – specificity 
(false positive rate). In order to do this, patients need to be classified as positive or 
negative based on different cut-offs. The following example uses the DECAF score.2 
The starting point assumes that all patients are classified as positive. This means 
that the false positive rate is zero, and represents the farthest top right point on the 
curve with a sensitivity of 1 and specificity of 0 (Figure 4.2). The curve then shifts 
though different cut offs (which in this example are based on the DECAF scores of 
patients) towards the bottom left hand corner of the curve which represents a 
sensitivity of 0 and specificity of 1. 
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Figure 4.2: DECAF, APACHE II, CAPS and CAP-65 ROC curves from DECAF derivation study 
Sensitivity= true positive / (true positive + false negative). This calculation is 
performed for all DECAF cut-offs, with all patients that died above the cut-off labelled 
as true positives and all those that died below the cut-off labelled as false negatives. 
For example, for a DECAF score of 3 (which represents a cut-off of 3.5) the 
sensitivity is calculated as follows. All those patients with a DECAF score of 4 or 
more who died are labelled as true positive (n = 70, Table 4.7). The false negative 
value is those who died who had a DECAF score of 3 or less (n = 26). 70/(70+24) = 
0.73.  
Specificity= true negative / (true negative + false positive). This calculation is 
performed for all DECAF cut-offs, with all patients that survived above the cut-off 
labelled as true negatives and all those that survived below the cut-off labelled as 
false positives.  
For example, there were 132 patients who survived with a DECAF score of 4 or 
more, and 692 with a DECAF score of 3 or less. 132 / (132+162) = 0.16. This value is 
subtracted from one to give the 1 – specificity which is plotted on the graph with the 
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corresponding sensitivity (point C, Figure 4.2). Table 4.7 shows the different values 
which are calculated to plot the AUROC curve for the DECAF score. 
DECAF Group, 
n 
Died, 
n 
True 
+ve 
False 
-ve 
Sensitivity True -
ve 
False 
+ve 
Specificity 1 - 
specificity 
Point on 
graph 
0 201 1 
  
1 
  
0 1 Top right 
1 291 6 95 1 0.99 624 200 0.76 0.24 A 
2 226 19 89 7 0.93 339 485 0.41 0.59 B 
3 125 30 70 26 0.73 132 692 0.16 0.84 C 
4 57 26 40 56 0.42 37 787 0.04 0.96 D 
5 20 14 14 82 0.15 6 818 0.01 0.99 E 
6 0 n/a 
  
0.00 
  
0 1 Bottom 
left 
Table 4.7: Example tables showing how to calculate sensitivity and 1-specificity for ROC curve 
analysis 
Once these points have been plotted, the area under the curve can be calculated. 
The area under the curve is the probability that a patient with the outcome, in this 
example death, is given a higher probability by the score than a randomly chosen 
patient without the outcome. The nearer the AUROC curve area is to 1, the better the 
prognostic score (Figure 4.3). A perfect predictive score will have a AUROC of 1, 
whilst a score with no predictive power- such as the toss of a coin- would score zero.  
 
Figure 4.3: Graph showing better prediction with higher AUROC values 
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The usefulness of a clinical score in practice depends on more than discrimination 
and calibration. To establish clinical usefulness, a cut-off is required which can be 
termed the “decision threshold”. The choice of cut-off depends on the context of the 
medical decision. For example, in identifying patients with an AECOPD who are 
suitable for home treatment, a DECAF score of 0-1 would be appropriate, as only 7 in 
492 patients died. The low number of false negatives is reflected in the high 
sensitivity. A prognostic score could show good discrimination, but be unsuitable at 
identifying low risk patients. This can be seen with the CURB-65 score in patients 
with pneumonic AECOPD (6.3 Validation of the DECAF score). Though the 
discrimination of CURB-65 was good, there was a high risk of death in the low risk 
group. This illustrates the importance of showing measures such as the sensitivity 
and specificity for each cut off, as well as calculating discrimination and calibration. 
Calibration 
There are several different ways of assessing the agreement between observed 
outcomes and predictions, also known as calibration. For a logistic regression model, 
the Hosmer-Lemeshow goodness-of-fit test 264 divides patients into risk groups. 
Hosmer and Lemeshow recommended that the number of risk groups selected 
should be one or more than the number of covariate in the model, though typically 
ten groups are used. Too few groups may not detect mis-calibration. The test 
calculates the observed number of outcomes (the proportion of patients in that group 
experiencing the outcome) to the predicted number of outcomes (the mean risk of all 
patients in that risk group). The null hypothesis for the test is that the model is fit to 
the data. A Hosmer-Lemeshow goodness-of-fit test less than p = 0.05 rejects the null 
hypothesis that the model does not fit the data well. However, it does not show that 
the model is a good fit to the data. 
Calibration can be displayed visually on a calibration plot, which graphs the predicted 
risk on the x axis and the observed risk on the y axis (Figure 4.4). This again divides 
patients into risk groups based on observed and predicted outcomes. One approach 
is to plot the observed outcome into deciles of prediction, which is a graphical 
representation of the Hosmer-Lemeshow test.251  
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Figure 4.4: Graph showing excellent calibration with measures of observed and predicted risk (dots) 
close to perfect (blue line) 
Rather than use deciles of risk, for a weighted model with a binary outcome, the 
observed and predicted risks can be calculated based on the weighted scores.221 To 
explain this approach, Table 4.8 shows the results for a hypothetical readmission 
score from a derivation cohort. Only patients that scored a 2 have been included, and 
their individual risk calculated (“Patient risk of admission”) from a regression 
equation. The mean risk is then calculated, which is 0.2, and can be plotted against 
the observed risk, which is the proportion of patients that were actually admitted 
(“Readmitted”- also 0.2). This can be repeated for each score, and the predicted and 
observed risks can be plotted.  
Patient Patient risk of admission 
(predicted risk) 
Readmitted 
(observed risk) 
1 0.18 No 
2 0.19 No 
3 0.2 No 
4 0.21 Yes 
5 0.22 No 
Table 4.8: Predicted risk and observed risk for patients scoring 2 for a hypothetical readmission score 
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The predicted risk for the derivation cohort can be plotted against the observed risk 
by PEARL score for the derivation cohort, internal validation cohort and external 
validation cohort. For a well calibrated score, the observed risk should be close to the 
predicted risk, and lie near the 45 degree line (Figure 4.4). 
Another form of calibration compares the observed risk by risk score across each 
cohort. The proportions of patients (with the outcome / total) can be compared across 
all cohorts by risk score using Fisher’s exact test. A p value greater than 0.05 would 
show that there is no significant difference in the observed proportions.  
Comparing prognostic tools 
It is possible to compare prognostic tools using the method of DeLong.199 This is a 
nonparametric approach to compare the AUROC curve between two models within 
the same data set. It is a paired comparison, so it is important that missing data has 
been dealt with appropriately prior to analysis, for example using multiple imputation. 
Novel prognostic indices can be added to pre-existing tools. Using binary logistic 
regression, the additional prognostic benefit of a new index in an existing model can 
be assessed. In this situation it is inappropriate to use the DeLong method to 
compare the old model to the new model, which tends to provide conservative 
estimates. A preferred approach in this situation is to compare the Akaike Information 
Criterion (AIC).204 The AIC is based on the -2 log likelihood calculated for the model 
from the regression analysis, with an adjustment for the number of indices in the 
model. 
4.2.12 Model implementation 
The gold standard in creating a prognostic score involves three steps: 1) 
development, 2) validation and 3) assessment of its impact on patients with respect 
to health and cost outcomes when used in practice.265 The deficits in prognostic 
studies are well described. There are many models that have been developed, but 
fewer that have been validated. Most of these studies that have been validated are 
done so in the same (split) cohort of patients, which does not assess the external 
validity of the derived model. Furthermore, published analyses of the impact of a 
prognostic model are rare: a recent review only identified two published analyses of 
the impact of a prognostic model.265 
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In order to assess the impact of a model an intervention and control arm is required. 
For the DECAF implementation study, we performed a randomised controlled trial of 
usual care compared to Hospital at Home in patients with a low risk DECAF score (0-
1). 
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 DECAF implementation study. Randomised Controlled Trial 
of Hospital at Home compared to usual care for patients admitted with 
a low risk AECOPD 
Chapter introduction 
This chapter focusses on the research aims and methods of our RCT which 
compared HAH to standard inpatient care in patients admitted to hospital with a low 
risk (DECAF 0 or 1) AECOPD. Throughout this chapter, standard inpatient care will 
be described as usual care or abbreviated to UC. 
 5.1 Ethical approval 
Eligible patients were approached in the admission units by a member of the 
respiratory team. Patients provided written consent for inclusion in the trial: patients 
who had diminished capacity were not approached. It was made clear to patients that 
non-participation in the trial would not affect their care. The existing literature shows 
that HAH/ESD is a safe intervention, and, in some instances, superior and preferable 
to standard inpatient care. Previous studies did not have the benefit of an accurate 
prognostic score to aid patient selection, which we used to identify low risk patients. 
Conversely: a) many of the previous studies were of ESD (rather than true HAH), in 
which patients are sufficiently well to return home; b) the DECAF score identifies a 
larger proportion of patients as low risk then were included in previous ESD/HAH 
studies; and c) a low risk DECAF score can include those with coexistent pneumonia 
who were typically excluded from previous studies.2, 3, 255 
Written patient consent was obtained in all patients. Ethics approval was awarded by 
NRES committee North East- Sunderland on 22nd October 2013. 
5.2 Study monitoring and safety 
An independent data monitoring committee reviewed data on serious adverse events 
with the authority to stop the trial, but no interim efficacy analysis was planned. 
Previous research showed that patients with a DECAF score of 0 or 1 have an in-
hospital mortality of approximately 1.4%.255 Based on this figure, one or two deaths in 
the acute period (14 days from admission) is expected. Given that the death rate in 
the acute period was expected to be low, the data monitoring group examined the 
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details of any deaths in this time period. Three or more deaths in the HAH was 
regarded as sufficiently high to trigger a review of the procedures around HAH, with 
four grounds for recommending discontinuation of this arm. 
Number of deaths Probability of death 
One or more 0.39 
Two or more 0.086 
Three or more 0.013 
Four or more 0.0014 
Five of more 0.00012 
Six or more 0.0000086 
Table 5.1: Number and probability of expected deaths at 14 days (provided to the data monitoring 
group) 
5.2 Study design and participation 
The study took place at Northumbria NHS healthcare trust and the surrounding 
community as part of the HAH arm. The target population was consecutive patients 
triaged for admission with a primary diagnosis of AECOPD. 
Inclusion criteria      
1. Age ≥35 years      
2. Smoking history ≥10 pack years   
3. Obstructive spirometry (FEV1/VC <70%) 
4. Primary diagnosis of AECOPD    
5. DECAF score 0 or 1    
6. Lack of ability to give informed consent. 
Exclusion criteria 
1. Other illness likely to limit survival to <1 year 
2. Long term ventilation 
3. Coexistent secondary diagnosis which necessitates admission 
4. Acute confusion precluding discharge 
5. Assessment more than one overnight stay after admission 
We planned to recruit 140 patients over 20 months. Eligible patients were provided 
with verbal and written study information, and those that consented were randomised 
to HAH or standard inpatient care and followed-up for 90 days. The estimated 
recruitment period was based on recruitment to, and outcome of, the DECAF 
derivation study, which was conducted in the same hospitals as the RCT. We 
 107 
  
allowed for acceptance and attrition rates of 60% and 15% respectively. We 
estimated that 585 patients would be assessed for eligibility, 445 of whom would be 
excluded for the following reasons: 
 DECAF score >1, n=293 
 Failure to meet remaining inclusion and exclusion criteria: n=59 
 Decline to participate: n=93 (40%) 
140 patients were to be randomised to HAH (n=70) or standard inpatient care (n=70). 
It was estimated that 12 patients per group would withdraw consent or be lost to 
follow-up resulting in 58 in each arm. All analyses were conducted on an intention to 
treat basis. 
Risk stratification was performed by the DECAF score. Those admitted with a 
DECAF score of 0-1 (low risk) were eligible. All patients with an AECOPD who are 
low risk and meet the eligibility criteria were offered inclusion in the trial. If a patient 
was judged as “unsafe” for home treatment by any member of the healthcare team, 
but met all study entry criteria (which included having a low risk of acute death by the 
DECAF score), the patient was still offered inclusion. However, the final decision to 
allow the patient to return home with Hospital at Home was with the respiratory 
consultant in charge of the patient’s care; they could decide to keep the patient in 
hospital and treat them with usual care. Such patients were analysed in their 
allocated group (Hospital at Home) and all protocol violations were reported in the 
published study. 
Patients remained in their allocated group for 90 days following the index admission. 
Those that received HAH for their index admission could also receive HAH for any 
future admissions with AECOPD within 90 days, provided the further AECOPD was 
low risk by DECAF score. Patients and healthcare professionals were not be blinded 
to the treatment.  
 
5.3 Our model of Hospital at Home 
HAH is the provision of care to support a patient at home during an illness normally 
requiring hospital admission. HAH as described here differs from supported 
discharge schemes, which are a part of standard usual care in some hospitals: 
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Patients will typically be discharged sooner, and will have access to more intensive 
treatment and clinical and social support in HAH. 
HAH may help to maintain normal activities, foster greater independence and avoid 
hospital acquired infections. Education, including self-management, may be more 
successful if delivered in the home to the patient and their primary carer, rather than 
in the busy ward environment. Eligibility for HAH and the degree of support was 
assessed in hospital; whilst receiving HAH, the patient remained under the care of 
the hospital team. In our RCT, HAH treatment comprised once to twice daily 
respiratory specialist nurse visits supervised by a respiratory consultant, with 
additional input from physiotherapy, occupational therapy and formal social care as 
required. Telephone support was available with an on-call RSN 24 hours a day, 
seven days a week. Routine phone calls took take place every evening, with other 
extra calls on an ad hoc basis. Telephone calls were in addition to, and not a 
replacement for, home visits. Patients’ observations, such as respiratory rate and 
pulse oximetry, were recorded. Other equipment, such as nebulisers and oxygen 
concentrators, were provided as needed. In those patients who had high care needs, 
a pendant alarm was available via social services which allowed direct contact to a 
named individual. One of the aims of this model of care was to allow patients to gain 
confidence managing their AECOPD at home, in a supported environment. The 
range of healthcare disciplines and level of support available were greater than many 
other services, reflecting the inclusive selection criteria, but tailored to the patient to 
ensure use of resource is appropriate. 
Those randomised to HAH returned home with support from the specialist team as 
soon as possible, provided that the initial arterial pH ≥7.35 and PaCO2 ≤6kPa. 
Patients with PaCO2 >6 kPa without acidaemia returned home, provided they were 
improving, at 24 hours and patients with acidaemia were considered for transfer to 
HAH 24 hours after the acidaemia had resolved (Figure 5.1). 
All patients, had an assess of their mobility, home circumstances and any additional 
social care needs (help with shopping, cleaning, personal care, meals on wheels), 
and transfer to HAH was dependent on adequate social support being in place. 
Urgent additional, same-day social input was available. 
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Figure 5.1: Flowchart showing planned timings to return home based on arterial blood gas sampling 
5.4 Standard inpatient care 
It is important to emphasise that standard inpatient care included the usual measures 
which are taken to ensure prompt discharge of patients with AECOPD, including 
supported discharge by specialist respiratory nurses. For the standard treatment 
group we anticipated that median stay would be similar to UK audit data and our 
previous local figures (median ~5 days).150 The decision to discharge patients in the 
standard care group was made by the attending clinician, and not influenced by the 
research team. 
5.5 Statistical methods 
5.5.1 Randomisation and minimisation 
One to one randomisation was performed by minimisation, with a 30% chance of 
randomisation by random number sequence. This was provided by an external, 
independent agency. To allocate patients to groups, the researcher entered 
minimisation criteria into a web-based system. This ensured that the allocation 
sequence was unpredictable and blinded to the entire research team, including the 
person enrolling patients into the study. Baseline data, including quality of life scores, 
were collected prior to allocating patients to treatment groups. This was done to 
avoid the risk of bias which can result when collecting baseline health related quality 
of life scores in patients who have just been told that they are not receiving their 
preferred treatment. The minimisation criteria were selected based on their 
association with readmission and/or death (using a logistic regression model on 
DECAF 0 or 1 patients from previous DECAF studies) which are the major 
determinants of cost (Table 5.2). 
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ABG (Management pathway) CO2≤6 pH ≥7.35 pCO2>6 pH ≥7.35 pH < 7.35 
Hospital admissions previous year 0 1 2 or more 
Prior social care (private or social services)  None Social care 
eMRCD score  1-4 5a 
Cerebrovascular disease  Yes No 
Table 5.2: Minimisation criteria 
5.5.2 Power calculation 
The estimated standard deviation of costs was £1,143, based on tariff costs received 
by the trust for 373 patients admitted with DECAF 0-1 AECOPD. This was based on 
the best available data, which was limited to health costs for the index admission. 
Based on tariff costs received by the trust for 373 patients admitted with DECAF 0-1 
AECOPD, the estimated standard deviation of costs was £1,143, and a non-inferiority 
limit of £150 was chosen. We estimated that Hospital at Home would be £-470 per 
patient cheaper than usual care. If the true difference between groups was £-470, 
118 patients would be required to be 90% sure that the lower limit of a one sided 
95% confidence interval was above the non-inferiority limit of £150. This calculation 
was based on the standard approach described by Chow, Shao and Wang.266 All 
participants provided consent for their data to be monitored electronically in the event 
that they withdraw from the study. This allowed for complete collection of data for 
health and social costs.  
Bed days were analysed over the acute period (defined as the first 14 days from 
admission), follow up (end of acute period to 90 days) and the whole 90 day period. 
For hospital bed days over 90 days, including readmissions, in the standard care arm 
the estimated mean bed days as 7.8 days and for HAH 3.1 days, with a standard 
deviation of 7.8 days. We needed two groups of 58 patients to detect a difference in 
mean scores of 4.7 (7.8 days v 3.1 days) with 90% power assuming a type 1 error 
rate of 5%. 
5.5.3 Missing data 
Data completion rates will be provided for outcome and the number of patients lost to 
follow up will be reported. 
Patients who die in a study may have lower costs than those that survive. In the 
event that equal numbers of patients die, costs were to be included up to the point at 
which they died. We planned a sensitivity analysis excluding those that die in the 
event that death rates were different between arms. 
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Multiple imputation was used on missing data as described by Rubin (as described in 
4.2.2 Dealing with missing data).254  
5.5.4 Populations analysis 
Baseline characteristics, including severity of COPD and minimisation criteria are 
shown by treatment group and overall. This included: age, gender, minimisation 
indices (Table 5.2), markers of AECOPD severity (including DECAF indices, such as 
CXR consolidation), social circumstances, income, academic qualifications, smoking 
history, FEV1 per cent predicted and co-morbidity. 
The inclusion or exclusion of patients in the final analysis who were randomised in 
error was, where possible, decided without knowledge of their allocated group and 
prior to any outcome. 
The main two study populations compared were: 1) patients allocated to Hospital at 
Home treatment, and 2) patients allocated to usual care. Analyses were intention to 
treat, and in a sensitivity analysis multiple imputation was used for missing data to 
allow the inclusion of all patients.  
A third patient group, those that declined to take part in the study, will be described. 
Descriptive data will be shown on patient age, gender, severity of AECOPD ad co-
morbidity. This helps with the generalisability of the results to clinical practice by 
indicating if patients who declined were more or less well than included patients.  
5.6 Treatments received 
All patients with an AECOPD who were low risk and met the eligibility criteria were 
offered inclusion in the trial. If a patient was judged as “unsafe” for home treatment 
by any member of the healthcare team, but met all study entry criteria (which 
included having a low risk of acute death by the DECAF score), the patient was still 
offered inclusion. However, the final decision to allow the patient to return home with 
Hospital at Home was with the respiratory consultant in charge of the patients’ care, 
who could decide to keep the patient in hospital and treat them with usual care. Such 
patients were analysed in their allocated group (Hospital at Home).  
Patients remained in their allocated group for 90 days following their index 
admission. Those that received HAH for their index admission could also receive 
HAH for any future admissions with AECOPD within 90 days, provided the further 
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AECOPD was low risk. Patients and healthcare professionals were not blinded to the 
treatment.  
5.7 Overview of outcomes 
The primary outcome was the total cost of health and formal social care over 90 days 
from presentation (informal carer costs are not shown). Secondary outcomes were 
cost-effectiveness, survival, readmission rates, bed days, patient preference, COPD 
exacerbations, hospital anxiety and depression scores (HADS), COPD assessment 
tool (CAT) scores and the EQ-5D-5L score44 measured at 14 and 90 days. 
Resource use and associated costs were calculated at the patient level and average 
costs per treatment arm and variance were estimated. Data collection was the same 
in both arms, except for resource collection during HAH treatment. All visiting health 
and social care staff recorded time spent with the patient and travel time. 
Over 90 days, patients in both arms maintained a diary of all health and social care 
visits, and attendances (such as accident and emergency, GP, and outpatient 
appointments). Patients were phoned every two weeks to prompt completion and 
obtain a back-up record of activity. These data were cross-referenced with primary, 
secondary and social care records, and were reviewed at the 90 day home visit. To 
ensure complete capture of information for the primary outcome, additional consent 
was sought for remote monitoring of health and social records if the patient withdrew 
from the trial. 
For primary care, resource use included all medications, GP appointments, and 
home visits by doctors and allied healthcare professionals. Secondary care inpatient 
resource was recorded for the index admission and for all readmissions (including 
return to hospital) and included staff time, diagnostic and laboratory tests, 
medication, and length of stay. Hospital costs and capital costs were obtained from 
NHS trust finance department, and the cost of a day on a ward was micro-costed. All 
outpatient visits and accident and emergency attendances were recorded. 
Social care resource use, including formal social care and equipment costs, were 
obtained from individual social care records.  
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Unit costs were obtained from a variety of national and local sources and are 
reported in Chapter 7 for the financial year 2015 (pounds sterling). Average costs per 
patient were calculated by multiplying unit cost by resource use. 
For secondary health-related quality of life measured by the EQ-5D-5L instrument, 
data were recorded in hospital at baseline and at home visits at 14 and 90 days. 
5.7.1 Primary cost analysis 
All costs were calculated at the patient level, unless stated otherwise. The study was 
costed from an NHS and personal social services perspective. 
The data collection method or tool are listed below:  
1) staff resource use questionnaires (data from medical and electronic 
records); 
2) time and motion questionnaires for Respiratory Specialist Nurses; 
3) a baseline health and resource use proforma; 
4) post-discharge health economics questionnaires completed by patients; 
and 
5) post-discharge social services costs spreadsheet. 
NHS - Primary care and community care costs 
Following discharge from their index episode, patients recorded all health and social 
care costs and were phoned on a two weekly basis to ensure data were completed. 
Data were reviewed at the 90-day visit and triangulated with data from medical 
records which included GP records. 
NHS - Secondary care costs 
Some patients with AECOPD have all of their investigations and initial treatments in 
accident and emergency, whilst others have some of these performed in the 
admissions unit. If all aspects of care were costed from admission, patients who had 
identical investigations and treatments could be costed differently. Therefore, for 
consistency, all investigations and treatments in accident and emergency were 
included in the cost of admission. This is appropriate, as in many hospitals the main 
route of admission for GP admissions is direct to the admissions unit. All other costs 
were calculated from the time of admission. 
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NHS costs Data collection method 
 Primary care  
   GP visits- surgery 1 and 4 
   GP visits- home 1 and 4 
   GP telephone calls 1 and 4 
   Practice nurse visits 1 and 4 
   Medications 1 and 4 
   Investigations 1 and 4 
 Community care  
   District nurse 1 and 4 
   Physiotherapy 1 and 4 
   Occupational therapy 1 and 4 
   Dietician 1 and 4 
   Psychology 1 and 4 
   Investigations 1 and 4 
 Secondary care  
   A + E attendances 1 
   Length of stay by ward 1 
   Medications 1 and 3 
   Investigations 1 
   Physician time 1 
   Respiratory Nurse time 2 (and 1) 
   Physiotherapy  1 
   Occupational therapy 1 
   Dietician 1 
   Psychology 1 
Social care resource use  
   Social worker 3, 4 and 5 
   Home help 3, 4 and 5 
   Adaptations 3, 4 and 5 
Table 5.3: Resource use and data collection (numbers correspond to list p113) 
The cost of the time on a ward was micro-costed to give a cost per day. This was 
used to calculate the hospital bed stay and staffing costs associated with the 
patients’ in-hospital stay. This approach was used for HAH and usual care patients 
for the time spent in hospital.  
All patient reviews by healthcare staff such as doctors (including level of seniority), 
pharmacist and physiotherapy was recorded. 
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During Hospital at Home episodes, the Respiratory Specialist Nurses completed time 
and motion forms on a selection of patients. This included the collection of data on all 
aspects of care related to the patient, including administration duties. For all patients 
in the Hospital at Home arm, visits and travel time undertaken by health and social 
care staff were recorded. 
The cost of all inpatient medication was calculated from the patients’ medication 
chart. The cost of medication supplied as an inpatient was based on the tariff costs 
from the British National Formulary. The costs of all investigations was calculated, 
and included add-on costs. 
Social care resource use 
Patients and their carers kept a record of all social services resources use. Records 
of social service resource use was triangulated with social services social records at 
the patient level. 
Valuation of NHS and informal care giving resource use  
For each trial participant, all components of treatment costs stratified by category of 
resource use were computed by multiplying units of resource use by their unit costs. 
These were then summed over all resource use categories to obtain a total cost for 
each participant both from an NHS and personal social services perspective. This 
was then used to generate the average cost per patient in each arm of the trial. 
The unit costs for resources used for the costs of the HAH intervention includes short 
term in-hospital costs, staff time, medications and costs of investigations. The cost of 
the ward stay was micro-costed from the Trusts finance department and included 
nursing staff costs and hospital bed stay costs and was presented as an average 
cost per day. With the exception of the costs of a respiratory ward stay, all unit costs 
were derived from multiple sources including NHS Reference Costs (2015) 
(Department of Health 2015)267 and the Personal Social Services Research Unit’s 
Unit Costs of Health and Social Care 2015 cost compendium.268 All unit costs are 
expressed in GBP (£) and valued at 2015-16 prices.  
Cost analysis 
The primary outcome was the difference in health and social costs between both 
treatment groups at 90 days. Our null hypothesis is that Hospital at Home treatment 
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is inferior to usual care treatment for health and social costs at 90 days. For the 
primary analysis, a one sided 95% confidence interval was used to calculate the 
inferiority analysis. For all other comparisons, a two-sided significance level of p<0.05 
was be used. 
A bootstrap approach was used to compare the mean difference in costs between 
the groups and estimate the one sided 95% confidence interval for the non-inferiority 
analysis. In non-inferiority studies, it is considered good practice to show a graph of 
the confidence interval and the non-inferiority limit to explain the results.269 If the 
confidence interval lies entirely above the inferiority margin, then the null hypothesis 
can be rejected (lines A and B, Figure 5.2). If the confidence interval crosses the 
non-inferiority margin (line C, Figure 5.2) or lies entirely below it, then the null 
hypothesis has not been rejected. The non-inferiority limit is £150 (Δ, Figure 5.2).269 
 
 
Figure 5.2: Relationship between confidence interval and outcome 
Sensitivity analyses of costs 
In a sensitivity analysis, the costs in the usual care group was calculated using data 
on length of stay prior to the start of the study. Within the study, low risk DECAF 
patients who were due to go home the day they were identified by the research team 
were not recruited. By definition, HAH is a treatment without which the patient would 
require in-hospital care. Therefore, the length of stay in the usual care arm can 
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increase compared to historical controls. However, the trial may reduce length of stay 
in the usual care group by reassuring clinicians and patients that earlier discharge is 
appropriate.  
5.7.2 Effectiveness 
Calculation of health utilities and Quality Adjusted Life Years (QALYs)  
In line with NICE recommendations (NICE 2013) on outcomes in economic analyses, 
QALYs were measured. Data used to estimate QALYs was collected using the EQ-
5D-5L. This was used to collect information about participant’s health related quality 
of life (HRQoL) at baseline, 14 days and 90 days. The EQ-5D-5L allows HRQoL to 
be valued on a scale where perfect health and death are 1 and 0 respectively (1.1.6 
EQ-5D-5L). 
Mean QALY differentials between the groups were generated from the utility values 
derived from responses to the EQ-5D 5L during the follow-up period using the 
regression approach, controlling for baseline utility.270 This area under the curve 
approach (Figure 5.3) puts a time weight onto each utility score which allows us to 
generate QALY values for each participant.  
 
Figure 5.3: Illustration of the area under the curve approach 
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Cost Utility Analysis 
A cost-utility analysis was performed based on incremental costs per QALY gained of 
the HAH intervention over usual care.  
If an intervention results in improved outcomes and cost savings relative to normal 
care, then the intervention would, according to the economic evaluation, be regarded 
as the dominant option (South-East quadrant, Figure 5.4). A dominant study is the 
holy grail of economic evaluations. More typically, positive studies are more effective 
but more costly (North-East quadrant, Figure 5.4). 
The incremental cost per QALY gained will be calculated, showing the rate of return 
of QALYs gained based on additional resources invested. The Incremental cost 
effectiveness ratio (ICER) is calculated by the incremental cost divided by the 
incremental change in QALYs. The results of the analyses will be presented as point 
estimates of mean incremental costs and QALYs 
 
Figure 5.4: Cost-effectiveness plane 
1000 bootstrapped samples will be undertaken to express the uncertainty around the 
incremental cost per life year gained/QALY ratio based on mean costs and 
outcomes. The results of the bootstrapping simulations will be presented on the ‘cost-
effectiveness plane’, which highlights the preferred treatment option (Figure 5.4). If 
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the results lie in the north-west (NW) or south-east (SE) quadrants the preferred 
treatment is clear, as one option dominates the other. If the results lie in the north-
east (NE) or south-west (SW) quadrants the decision as to which is the preferred 
treatment is less clear (i.e. one option may be less costly but also less effective, or 
more effective but at greater cost); the ICER may aid this decision. 
A cost-effectiveness acceptability curve (CEAC) based on the net benefit approach 
271 will be used to present the probability of the intervention being cost-effective, 
based on a range of values for society’s willingness to pay for a unit of outcome. 
Base case results will utilise data with complete information, the ‘complete cases’ for 
both costs and effects. 
 
Figure 5.5: Cost Effectiveness Acceptability Curve 
5.7.3 Other secondary outcomes 
HADS, CAT and utility score 
The change in quality of life scores from baseline at 14 days and 90 days was 
calculated. For HADS and CAT, negative values represent improvements in health 
from baseline, whilst for utility scores, positive values represent improvements from 
baseline. The per cent of patients improving by the minimum clinically important 
difference (MCID) was also calculated. 
 120 
  
Bed days 
Bed days over 90 days were compared using a two-sample t test for 90 days. 
Separately, the number of days under Hospital at Home care (days in hospital and 
days treated at home) is presented with the number of days treated in usual care for 
the index admission. 
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RESULTS 
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 The validation of the DECAF score 
6.1 Patient characteristics 
Data were obtained for 880 and 845 patients in the internal and external validation 
cohorts respectively. Across both cohorts, mean (SD) age was 73.1 (10.3) years, 
54.3% were female, and most had severe airflow obstructive; mean (SD) FEV1 45.5 
(18.3) %predicted. The median DECAF score was 2 (IQR 1 to 3), 28.3% had 
radiographic consolidation and 18.9% had an acidaemic exacerbation (pH < 7.35). 
In-keeping with the UK national audit,11 rates of co-morbidity were high, notably 
ischaemic heart disease and diabetes (table 2). 
Significant differences between sites included: the proportion requiring institutional 
care, radiographic consolidation, age, gender, DECAF score, severity of airflow 
obstruction, the number of previous hospital admissions and the proportion with 
significant weight loss. Sites were broadly similar for co-morbidity, though the 
proportions with left ventricular dysfunction, anxiety or depression differed. 
Patients with a survival of less than one year for a reason other than COPD were 
excluded. For the internal validation cohort, patients were not eligible as follows: 
survival less than one year n = 27 (12 lung cancer, 3 end stage dementia, 3 
metastatic cancer, 2 metastatic bladder cancer, 2 idiopathic pulmonary fibrosis, 1 
metastatic renal cancer, 1 metastatic bower cancer, 1 metastatic rectal cancer, 1 
oesophageal cancer, and 1 mesenteric cancer patient), less than ten pack year 
smoking history n = 24, spirometry not obstructive = 42. Ten patients had no ABG 
results, but had supplemental oxygen or oxygen saturations that were too low to 
assume a DECAF acidaemia score of zero. One patient had no eosinophil count.  
6.2 Missing data 
There were no missing mortality or DECAF data. The percentage of complete data 
for each risk score was: BAP-65 97.2%, CURB-65 96.5%, CAPS 85.9% and 
APACHE II 73.2%. For individual variables, missing data were PaO2 12.6%, albumin 
12.2%, pH 12.1%, GCS 11.7%, potassium 3.3%, confusion 2.6%, temperature 2.6 %, 
mean arterial blood pressure 1.8%, respiratory rate 1.8%, systolic BP 1.7 %, diastolic 
BP 1.7%, heart rate 1.4%, haematocrit 1.2%, creatinine 0.5%, white blood cell count 
0.2%, urea 0.1% and sodium 0.1%.  
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Table 6.1: Baseline characteristics by site 
 Internal validation n= 880 External validation n= 845  
All sites 
N= 1725 
P value Site A 
n= 459 
Site B 
n= 421 
Site C 
n= 307 
Site D 
n= 271 
Site E 
n= 171 
Site F 
n= 96 
Recruitment period 1/1/2012- 
31/5/2013 
1/1/2012- 
31/5/2013 
21/8/13- 
26/5/14 
1/7/13- 
30/4/14 
25/4/13-
14/2/14 
1/2/2014- 
28/4/2014 
1/1/12- 
26/5/14 
N/A 
Recruitment/day 0.89 0.82 1.07 0.89 0.58 1.12 0.86 N/A 
Died in-hospital, % 9.8 7.8 7.5 6.6 4.7 5.2 7.7 0.27 
DECAF 0-1, % 44.4 46.6 47.6 34.3 44.4 61.5 44.9 0.00018 
DECAF 2, % 30.9 26.6 29.6 28.0 32.7 21.9 28.9 0.33 
DECAF 3-6, % 24.6 26.8 22.8 37.6 22.8 16.7 26.3 0.00013 
Sociodemographics 
 
Age, years* 73.5 (9.9) 73.9 (10.3) 73.5 (10.4) 72.0 (9.8) 72.4 (10.7) 70.7 (11.4) 73.1 (10.3) 0.025 
Female, % 56.4 58.0 56.4 40.6 58.5 53.1 54.3 0.00012 
Smoking pack-yrs, n† 41 (30-58) 40 (30-55) 44 (30-60) 40 (30-56) 45 (30-60) 40 (30-59) 40 (30-59) 0.71 
Current smoking, % 38.2 40.9 39.7 36.2 36.1 47.4 39.1 0.41 
Institutional care, % 8.9 5.0 2.9 2.6 4.1 5.2 5.2 0.0018 
Markers of disease severity 
 
eMRCD score 1-4, % 44.7 49.2 49.5 35.1 44.4 68.8 46.4 <0.0001 
eMRCD score 5a, % 39.7 36.6 30.3 24.7 42.1 24.0 34.3 <0.0001 
eMRCD score 5b, % 15.7 14.3 20.2 40.2 13.5 7.3 19.3 <0.0001 
Hospital admissions 
in previous year, n† 
0 (0-1) 0 (0-1) 1 (0-1) 1 (0-2) 1 (0-2) 1.5 (0-3) 0 (0-1) <0.0001 
FEV1% predicted* 47.8 (19.4) 48.5 (18.5) 44.8 (18.2) 40.6 (14.9) 40.5 (15.4) 46.6 (20.4) 45.5 (18.3) <0.0001 
LTOT, % 15.7 16.2 13.4 17.7 26.8 17.7 16.9 0.014 
Cor pulmonale, % 5.9 7.4 10.4 8.5 8.9 2.1 7.5 0.052 
LT prednisolone, % 8.1 6.7 5.5 10.0 9.0 7.3 7.6 0.38 
Co-morbidity 
 
IHD, % 27.5 32.3 31.9 27.7 26.6 27.1 29.4 0.46 
CVD, % 13.3 12.4 13.1 13.7 5.9 11.5 12.3 0.14 
Diabetes, % 11.3 11.9 15.0 13.0 14.8 17.7 13.1 0.40 
Atrial fibrillation, % 14.8 20.7 16.9 17.7 16.4 14.6 17.2 0.33 
LVD, % 8.1 9.3 18.2 10.0 4.7 3.2 9.9 <0.0001 
Cognitive 
impairment, % 
5.0 5.0 6.8 8.5 3.6 1.0 5.5 0.049 
Anxiety, % 13.9 13.3 37.6 20.3 7.1 9.4 18.1 <0.0001 
Depression, % 23.3 18.3 33.6 25.5 19.4 9.4 23.1 <0.0001 
Admission clinical data 
 
Acute confusion, % 12.9 12.9 8.7 8.9 6.6 6.3 10.6 0.060 
Respiratory rate, n* 26.5 (6.8) 25.7 (6.0) 21.8 (4.5) 24.1 (6.2) 23.9 (6.2) 23.5 (6.3) 24.7 (6.3) <0.0001 
Pulse rate, n* 104.9 (21.0) 102.8 (22.8) 97.1 (18.3) 102.2 (20.5) 104.7 (21.6) 99.7 (18.4) 102.3 (21.0) <0.0001 
sBP, mmHg* 136.5 (30.3) 145.2 (26.6) 130.8 (22.0) 135.0 (26.5) 134.5 (22.9) 133.6 (24.2) 137.1 (26.9) <0.0001 
dBP, mmHg* 74.6 (17.0) 80.0 (19.0) 71.6 (15.8) 77.2 (18.5) 77.3 (19.6) 73.2 (13.7) 76.0 (17.9) <0.0001 
Temperature, 0C† 36.9 
(36.3-37.6) 
36.5 
(36.0-37.2) 
36.8 
(36.4-37.3) 
36.5 
(36.0-37.1) 
36.5 
(35.9-37.0) 
36.7 
(36.0-37.0) 
36.7 
(36.2-37.3) 
<0.0001 
Oxygen saturation† 92 (87-94) 93 (88-95) 94 (91-95) 93 (90-95) 93 (90-95) 92 (91-95) 93 (89-95) <0.0001 
Pedal oedema, % 25.8 21.6 26.8 27.0 32.7 5.3 24.9 <0.0001 
BMI, kg/m2 * 25.1 (6.8) 24.9 (6.8) 24.5 (6.4) 25.4 (6.4) 24.1 (6.5) N/A 24.9 (6.6) 0.28 
Weight loss >5%, % 14.2 10.6 21.2 24.7 12.9 2.4 15.3 <0.0001 
CXR consolidation, % 30.5 34.4 22.8 30.6 18.7 19.8 28.3 <0.0001 
Arterial Blood Gas values 
 
pH† 7.42 
(7.37-7.46) 
7.42 
(7.37-7.46) 
7.43 
(7.38-7.46) 
7.40 
(7.35-7.44) 
7.45 
(7.38-7.48) 
7.39 
(7.35-7.43) 
7.42 
(7.37-7.46) 
<0.0001 
PaO2, kPa† 8.0 (6.9-9.3) 8.0 (6.9-9.3) 8.6 (7.7-9.8) 8.4 (7.3-10) 9.4 (7.8-9.4) 8.3 (7.5-9.4) 8.3 (7.2-9.7) <0.0001 
PaCO2, kPa† 5.6 (4.8-7.1) 5.7 (4.8-7.3) 5.2 (4.4-6.2) 6.1 (5.3-7.5) 5.6 (4.8-7.6) 6.1 (5.1-7.1) 5.7 (4.8-7.1) <0.0001 
HCO3, mmol/L* 28.1 (6.0) 28.7 (6.8) 26.5 (5.5) 28.7 (5.4) 30.2 (8.9) 27.8 (5.0) 28.3 (6.4) <0.0001 
pH < 7.35, % 17.8 19.2 15.1 24.3 17.9 20.8 18.9 0.19 
Sites compared by Fisher’s (proportions), ANOVA or Welch (means), or Kruskal-Wallis’s (median) tests. *Mean (Standard deviation); 
†Median (Interquartile range). CXR= chest radiograph, CVD= Cerebrovascular disease, dBP and sBP= Diastolic and systolic blood pressure, 
HCO3= Bicarbonate, IHD= Ischaemic heart disease, LTOT= long term oxygen therapy, LT= Long Term, LVD= Left ventricular dysfunction. 
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6.3 Validation of the DECAF score 
The AUROCDECAF curve for in-hospital mortality was: internal validation = 0.83 (95% 
CI 0.78 to 0.87), external validation = 0.82 (95% CI 0.77 to 0.87), and overall = 0.82 
(95% CI 0.79 to 0.85). The discrimination of the DECAF score was significantly 
stronger than CURB-65, CAPS, APACHE II and BAP-65 for 30-day mortality. For 
inpatient mortality, the DECAF score was again superior, except in comparison to 
APACHE II where the higher discriminatory strength of DECAF was not significant 
(Table 6.2 and Figure 6.1).  
 
 
Figure 6.1: Receiver operator characteristic curves of prognostic scores for in-hospital (A) and 30-day 
mortality (B) 
In a complete case analysis (without imputation), the conclusions were unchanged 
for 30-day mortality; for in-hospital mortality, AUROCDECAF curve was again the 
highest, but was not statistically superior to CAPS (p = 0.068) or BAP-65 (p = 0.060). 
  
Prognostic score AUROC curve (95% 
CI) 
In-hospital death 
Comparison to 
DECAF, p value 
AUROC curve (95% 
CI) 
30-day death 
Comparison to 
DECAF, p value 
DECAF 0.82 (0.79-0.85) N/A 0.79 (0.75-0.83) N/A 
CURB-65 0.76 (0.72-0.80) 0.0057 0.73 (0.69-0.77) 0.0051 
CAPS 0.77 (0.73-0.81) 0.038 0.73 (0.69-0.77) 0.0083 
APACHE II 0.78 (0.74-0.82) 0.083 0.72 (0.68-0.77) 0.0039 
BAP-65 0.77 (0.73-0.81) 0.038 0.72 (0.68-0.76) 0.0021 
Table 6.2: Comparison of AUROC curves for DECAF and other scores (with imputation) 
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Table 6.3 shows mortality rates, sensitivity and specificity by DECAF score in the 
overall validation cohort, and mortality by DECAF risk group compared to our 
derivation cohort.2 
Compared with the derivation study, mortality overall and in the high risk group was 
lower. Higher DECAF scores were again associated with higher mortality, though 
absolute numbers were small for DECAF 5 and 6 groups. The model was a 
satisfactory fit to the data (Hosmer-Lemeshow statistic= 0.48, Nagelkerke R2= 24%). 
The previously assigned weightings of the DECAF score were confirmed on logistic 
regression (Table 6.4), and eMRCD score remained the strongest predictor. 
Index B OR (95%CI) P value Score 
Dyspnoea     
    eMRCD 1-4  1 <0.0001 0 
    eMRCD 5a 1.13 3.10 (1.78-5.40) <0.0001 1 
    eMRCD 5b 2.17 8.79 (5.13-15.03) <0.0001 2 
Eosinopenia (<0.05 x109/L) 0.90 2.45 (1.61-3.72) <0.0001 1 
Consolidation 0.90 2.45 (1.66-3.62) <0.0001 1 
Acidaemia (pH <7.3) 1.35 3.87 (2.38-6.31) <0.0001 1 
Atrial Fibrillation 0.85 2.35 (1.53-3.60) <0.0001 1 
Table 6.4: DECAF indices as predictors of in-hospital mortality 
Compared to the traditional MRCD scale,38 eMRCD had superior prognostic strength 
for in-hospital mortality: AUROCeMRCD = 0.74 (95% CI 0.70 to 0.78) v. AUROCtraditional 
MRCD = 0.68 (95% CI 0.64 to 0.72); p < 0.0001. In the subpopulation with a pneumonic 
exacerbation (n = 485), eMRCD was again superior to the MRCD scale: 
(AUROCeMRCD = 0.67, 95% CI 0.60 to 0.73 v. AUROCMRCD = 0.62, 95% CI 0.56 to 
0.69; p = 0.0070). 
DECAF 
score 
n Died in-hospital, 
n (%) 
Sensitivity Specificity Mortality by risk group, % P 
Validation Derivation  
0 255 0 (0) 1.00 0 
1.0 1.4 0.60 1 519 8 (1.5) 1.00 0.16 
2 498 27 (5.4) 0.94 0.48 5.4 8.4 0.14 
3 301 46 (15.3) 0.73 0.78 
21.4 34.7 0.00046 
4 113 35 (31.0) 0.39 0.94 
5 37 15 (40.5) 0.12 0.99 
6 2 1 (50.0) 0.0076 1.00 
Total 1725 132 (7.7) N/A N/A 7.7 10.4 0.016 
Table 6.3: DECAF score, in-hospital mortality, sensitivity and specificity 
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CURB-65 predicts 30-day mortality in patients with community acquired pneumonia, 
and is commonly applied to patients with a pneumonic exacerbation of COPD 
(pAECOPD). In the validation cohort, for the subgroup of patients with pAECOPD 
(n=489), the DECAF score was a non-significantly stronger predictor of 30-day 
mortality than CURB-65 (AUROCDECAF= 0.76, 95% CI 0.70-0.81 v. AUROCCURB-65= 
0.68, 95% CI 0.62-0.74; p=0.057) (Table 6.5 shows sensitivity and specificities for 
DECAF scores, and Table 6.6 shows 30 day outcome). 
 Validation cohorts Derivation and validation cohorts 
DECAF score Sensitivity 1 - Specificity Sensitivity 1 - Specificity 
0 N/A N/A N/A N/A 
1 1.00 0.84 0.98 0.82 
2 0.87 0.48 0.82 0.44 
3 0.55 0.20 0.54 0.17 
4 0.20 0.052 0.21 0.043 
5 0.014 0.0024 0.0078 0.0015 
6 0 0 N/A N/A 
Table 6.5: Sensitivity and specificity of DECAF in pneumonic exacerbations of COPD 
 
Inpatient death, n (%) 30-day death, n (%) 
Score DECAF CURB-65 DECAF CURB-65 
0 N/A* 3/55 (5.5) N/A* 4/55 (7.3) 
1 2/122 (1.6) 14/182 (7.7) 4/122 (3.3) 20/182 (11.0) 
2 21/267 (7.9) 31/264 (11.7) 25/267 (9.4) 39/264 (14.8) 
3 36/215 (16.7) 50/219 (22.8) 42/215 (19.5) 57/219 (26.0) 
4 43/129 (33.3) 24/57 (42.1) 48/129 (37.2) 24/57 (42.1) 
5 26/53 (49.1) 7/11 (63.3) 29/53 (54.7) 5/11 (45.5) 
6 1/2 (50) N/A 1/2 (50) N/A 
Total 129/788 (16.3) 149/ 744 (18.9) 
*The lowest possible DECAF score in those with pAECOPD is 1.  
Table 6.6: Inpatient and 30-day mortality by DECAF and CURB-65 score in those with pAECOPD, 
derivation and validation cohorts. 
When patients with pAECOPD were pooled across the derivation and validation 
cohort (n=788), DECAF was superior for 30 day (AUROCDECAF= 0.75, 95% CI 0.71-
0.79 v. AUROCCURB-65= 0.66, 95% CI 0.62-0.71; p<0.0001) and inpatient mortality 
(AUROCDECAF= 0.76, 95% CI 0.71-0.80 v. AUROCCURB-65= 0.70, 95% CI 0.65-0.75; 
p=0.024). The superior performance of DECAF is of particular importance for patients 
deemed at low risk by each score, who may be considered suitable for home 
treatment. Patients with a low risk DECAF score had a lower in-hospital mortality 
compared to those with a low-risk CURB-65 score: DECAF= 1.6% (2/122) v. CURB-
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65= 7.2% (17/237); p=0.026. There were similar differences for 30-day mortality: 
DECAF 0-1= 3.3% (4/122) v. CURB-65 0-1= 10.1% (24/237); p=0.022. 
The optimal thresholds for eosinophil count and pH were reassessed. On visual 
inspection of the ROC curve, the optimal cut off for eosinopenia was unchanged 
(0.05 x109/L).2 For pH threshold, both 7.30 and 7.35 offered similar discrimination. 
The 7.30 threshold identified in the derivation study was retained for consistency, and 
because, of 58 patients with a low risk DECAF score and non-scoring acidaemia 
(7.30-7.34), none died. Only three patients had a DECAF score of 1 due to a 
pH<7.30, all of whom survived. 
Patients with SpO2 > 92% without supplemental oxygen in whom ABG sampling was 
deemed unnecessary were assigned a score of 0 for the pH component of DECAF. 
Of 209 such patients overall, only 6 died (2.9%); this total included 0/52 with a 
DECAF score of 0 and 2/67 with a DECAF score of 1. 
Time to death in those who died during the index admission, and length of stay in 
those who survived to discharge, by DECAF score are shown in Table 6.7. Among 
survivors, higher DECAF scores were associated with longer length of stay. 
DECAF score Median time to 
death, days (IQR) 
Median length of 
stay, days (IQR) 
 
0 N/A 3 (1-5)  
1 4.5 (4-12.5) 4 (2-7)  
2 9 (5-16) 5 (3-10)  
3 10 (3.75-23.25) 7 (3-13)  
4 5 (1-11) 7.5 (5-18)  
5 2 (1-9) 10 (6-19.5)  
6 2 (2-2) 22 (22-22)  
Table 6.7: Time to death in patients who died during the index admission, and median length of stay in 
those who survived to discharge, by DECAF score 
6.4 Discussion 
In a large, multicentre study of patients admitted with AECOPD, we have confirmed 
that the DECAF score is a robust predictor of mortality that can be easily scored at 
the bedside using indices routinely available on admission. As in the earlier 
derivation study, DECAF was superior to other scores (BAP-65, CAPS, APACHE II, 
CURB-65) sometimes used to predict short-term mortality of patients with AECOPD.  
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We went to considerable lengths to capture consecutive patients, but a small number 
of patients who died or who were discharged shortly after admission may have been 
missed. In order to minimise any resulting bias and to maximise capture of all eligible 
patients, admission units were screened and a broad coding records search was 
performed. In the 2014 UK national audit,11 mean site recruitment of patients with 
spirometric confirmation of COPD was 0.36 per day. In our study, recruitment was 
substantially higher at all sites, which supports high case ascertainment rates. 
Investigators in site E reported problems obtaining spirometry results, which may in 
part explain their comparatively lower recruitment rate.  
The CHARMS checklist provides guidance on the appraisal of prediction model 
studies (see appendix 1).204 The main limitation of this study is that the internal 
validation study was, in part, performed retrospectively. Although retrospective 
collection of data may bias results, this risk was mitigated as the DECAF indices 
were collected as part of routine clinical practice in the participating hospitals, the 
researchers extracting data were blinded to outcome and case ascertainment and 
outcome were similar to the prospective external cohort. Of importance, the latter 
was individually adequately powered.  
Data were only regarded as “missing” once all data sources had been checked and 
rates of missing data were low. For key outcomes, analyses were repeated with and 
without multiple imputation. To improve data completeness for DECAF, patients with 
SaO2 > 92% breathing room air, and judged by a clinician not to require ABG 
analysis, scored 0 for the acidaemia component of DECAF; this was justified by the 
low mortality in this group, and supports a similar pragmatic approach in the clinical 
application of the score, reducing burden for both patients and clinicians. However, 
we do not advise that this assumption is used to lower clinician’s threshold for 
performing ABG sampling. 
There were important differences between site populations, in particular the receipt of 
institutional care, coexistent consolidation, degree of airflow obstruction and severity 
of DECAF score. This may in part reflect our efforts to select diverse sites for 
participation in the study, and the strong and consistent performance of DECAF, 
despite such differences in baseline characteristics, emphasises the external validity 
of the score. 
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Mortality varied between sites (from 4.7% to 9.8%) and between cohorts (internal 
validation = 8.9% v. external validation = 6.4%; p = 0.057). This largely reflects 
differences in baseline characteristics, notably the proportion of patients admitted 
from institutional care and with coexistent pneumonia. When these two sub-groups 
were excluded, mortality was 4.8% in both cohorts. Overall mortality was 7.7%, which 
is in keeping with the 2003 (7.7%) and 2008 (7.8%) UK national audits. In the 2014 
UK audit mortality was 4.3%, though the reason for the lower mortality rate is 
reported as unknown. In our study, case ascertainment, co-morbidity and the 
proportion of patients with consolidation or an MRCD score of 5 was higher than in 
the 2014 UK national audit.  
Since our 2012 DECAF derivation study, two further prognostic scores have been 
published.213, 214 In one,213 patients with acute ECG features of ischaemia and 
radiographic pulmonary congestion were included. Such patients are unlikely to have 
met our inclusion criterion of a primary diagnosis of AECOPD. 
In the second study, the derived score showed good discrimination, and validation is 
awaited.214 However, the score included subjective recognition of “use of inspiratory 
accessory muscles or paradoxical breathing”, reducing generalisability, especially in 
healthcare settings which lack specialist review within 24-hours of admission.11, 151 
Recruitment was lower than equivalent audit data,151 because written patient consent 
was required, which disproportionately excludes the lowest and highest risk patients. 
Our methodology mirrored UK national audits; only routine data were collected so 
patient consent was not required. 
Length of stay for AECOPD is falling, and early discharge, both supported and 
unsupported, is common place, with patient selection based largely on clinical 
judgement. However, clinical judgement of prognosis is poor 197 whilst the DECAF 
score has consistently shown a high sensitivity for identifying low risk patients. ESD 
and HAH services for patients with AECOPD are expanding.11 NICE recommend that 
patient selection for these services be based on mortality risk,4 but also highlight the 
(previous) lack of a robust prognostic score to guide decision-making. In the present 
study, DECAF 0-1 patients (including those with pneumonia or acidaemia) had an 
acceptably low mortality risk and comprised 45% of patients. The effect of treating 
this group with HAH or ESD requires a randomised controlled trial to assess clinical 
outcomes and associated costs. We have undertaken an RCT of Hospital at Home 
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compared to usual care in low risk patients, and this is described in Chapter 7. In our 
experience, the CURB-65 score is commonly applied in patients with pneumonic 
exacerbations of COPD to inform discharge planning and choice of antibiotics. Based 
on evidence from both the derivation and validation study, clinicians should not be 
reassured by “low risk” CURB-65 scores in such patients as the associated mortality 
is unacceptably high; we advise against its use in this population.  
A high risk DECAF score is associated with both a high risk of death and, in those 
who die, a short time to death. The latter is particularly true of patients scoring 
DECAF 5 or 6, in whom the median time to death was only 2 days. Such patients 
may be suitable for early escalation in care, or alternative palliative care, but the 
window for intervention is short. Among patients who survive to discharge, length of 
stay increases incrementally with DECAF score. 
In both the derivation and present study, dyspnoea severity measured by the eMRCD 
score was the strongest single predictor of mortality and a superior predictor to the 
traditional MRCD scale. In the 2014 UK national audit, “DECAF light” was scored 
retrospectively using the traditional MRCD scale (Figure 6.2). However, “DECAF 
light”, as opposed to the full DECAF score, was calculated only because eMRCD 
data was unavailable. We support the recommendation of the UK national audit that 
DECAF indices, including the eMRCD score, be collected on all patients admitted 
with AECOPD. Various versions of the traditional MRCD scale exist,38, 43, 272 which 
may lead to differences in scoring. We caution against such modifications to the 
eMRCD score unless supported by empirical evidence. 
In conclusion, we have shown that DECAF can be used in a variety of hospital 
settings in order accurately to stratify mortality risk in patients with AECOPD. Further 
research is required to quantify its impact on clinical practice, for example in the 
identification of patients for HAH or ESD services. 
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Figure 6.2: In-hospital mortality in the DECAF derivation and validation study, and “DECAF light” from 
the 2014 UK National COPD Audit 
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 Hospital at Home and DECAF 
7.1 Patient characteristics 
Emergency hospital admissions between June 2014 to January 2016 were reviewed 
to ensure all patients with AECOPD were identified. Of note, sixty-four patients with a 
DECAF 0-1 AECOPD were planned for same-day discharge before assessment by 
the research team and could not be included as, by definition, HAH is not appropriate 
for patients who are sufficiently well for discharge. 
Of 207 DECAF 0-1 AECOPD assessed for eligibility, 120 were randomised. Two 
patients were randomised in error, and were not included in the primary analysis. 
Three patients were randomised to HAH, but were intentionally treated by UC, and 
were analysed in their original allocation as per the intention to treat principle (Figure 
7.1). No patients allocated to UC received HAH. Groups were well matched with 
respect to minimisation criteria and most other baseline characteristics (table 3). 
 
Figure 7.1: Consort diagram 
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 HAH n=60 
UC 
n=58 
 
DECAF indices   
 
DECAF score 1, n (%) 43 (71.7) 31 (53.4)  
eMRCD Dyspnoea score 5a, n (%) repeat below 12 (20) 9 (15.5)  
Eosinopenia, % 15 (25) 8 (13.8)  
CXR consolidation, %  15 (25) 9 (15.5)  
Acidaemia (pH < 7.30), % 1 (1.7) 0  
Atrial Fibrillation, % 0 0  
Minimisation criteria   
 
ABG management, pH < 7.35 / pCO2>6 pH ≥7.35, % 7 (11.7)/ 40 (66.7) 8 (13.8) / 38 (65.5)  
Hospital admissions previous year 1 / 2, % 12 (20) / 21 (35) 12 (20.7) / 19 (32.8)  
Prior social care, % 3 (5) 1 (1.7)  
Cerebrovascular disease, % 9 (15) 9 (15.5)  
Sociodemographics  
 
Age, years* 71.0 (9.6) 68.7 (10.5)  
Female, % 32 (53.3) 30 (51.7)  
Smoking pack-yrs, n† 45 (35-50) 44 (30-60)  
Current smoking, % 27 (45) 25 (43.1)  
Reporting no qualifications on leaving school, % 46 (76.7) 41 (70.7)  
Most frequently reported family income per year, £†  5,200-10,399 10,400-15,599  
Markers of disease severity  
 
FEV1% predicted* 45.5 (18.4) 42.1 (16.3)  
LTOT prior to admission, % 7 (11.7) 2 (3.4)  
Cor pulmonale, % 11 (18.3) 5 (8.6)  
Co-morbidity  
 
IHD, % 14 (23.3) 12 (20.7)  
Diabetes, % 8 (13.3) 5 (8.6)  
LVD, % 1 (1.7) 3 (5.2)  
Anxiety, % 9 (15.0) 3 (5.2)  
Depression, % 12 (20.0) 9 (15.5)  
Admission clinical data  
 
Respiratory rate, per minute* 25 (4.5) 26 (5.1)  
Pulse rate, per minute* 103.9 (19.6) 104.9 (15.4)  
sBP, mmHg* 140.8 (21.1) 145.1 (24.3  
dBP, mmHg* 77.3 (12.2) 80.9 (14.5)  
Temperature, 0C† 36.6 (36.2-37.3) 36.5 (36.1-37.1)  
Oxygen saturation† 92 (89-94) 92 (88.5-95)  
Discoloured sputum, % 43 (71.7) 33 (56.9)  
Arterial Blood Gas values  
 
pH† 7.42 (7.39-7.45) 7.42 (7.38-7.44)  
PaO2, kPa† 7.6 (7.2-9.3) 7.9 (7.2-10.2)  
PaCO2, kPa† 5.5 (5-6.25) 5.3 (4.8-6.6)  
HCO3, mmol/L* 27.1 (4.3) 27.3 (4.7)  
pH < 7.35, % 7 (11.7) 8 (13.8)  
Baseline outcome measures   
 
Utility score (Eq-5D-5L), n* 0.517 (0.268) 0.501 (0.243)  
Hospital Anxiety and Depression Score A/ D, n† 6 (4-10.25) / 7 (4-9) 7 (4-10) / 5 (2-8.25)  
Copd Assessment Tool, n† 28.5 (21.75-33) 27 (23-32.25)  
Treatment   
 
AECOPD treatment prior to admissions, % 32 (53.3) 26 (44.8)  
*Mean (Standard deviation); †Median (Interquartile range). CXR= chest radiograph, CVD= Cerebrovascular 
disease, dBP and sBP= Diastolic and systolic blood pressure, HCO3= Bicarbonate, IHD= Ischaemic heart disease, 
LTOT= long term oxygen therapy, LVD= Left ventricular dysfunction. 
 
Table 7.1: Baseline characteristics of patients  
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Groups were well matched with respect to minimisation criteria, and most other 
baseline characteristics (table 3). In HAH, the proportions of DECAF 1 patients, and 
those with chest x-ray consolidation, cor pulmonale and/ or on long term oxygen 
therapy was higher. This is a potential source of bias in favour of usual care. 
7.2 Costs used in study 
The full breakdown of all costs are included in the appendix. 
7.3 Cost and cost-utility analysis 
The mean health and formal social care cost over 90 days was £1,016 lower in HAH 
than UC. These costs included admissions, readmissions and all HAH episodes, 
including costs for patients with multiple HAH episodes. However, there was a wide 
variation in cost, and the 95% confidence interval crossed the pre-specified non-
inferiority limit of £150 (Figure 7.2, “3 days”: CI -2343 to 312, p = 0.10). The cost 
difference and distribution were greater than anticipated, supporting an adjusted non-
inferiority limit of £340,266 which was achieved.  
During the index admission, median LOS in UC was three days, which was two days 
less than expected.255 If this model is implemented in other hospitals, the local cost 
differences will be influenced by current LOS. We therefore performed a sensitivity 
analysis to assess the effect of LOS in UC during the index admission on health and 
formal social care costs. One additional bed day without medical staffing costs would 
increase the mean cost difference to £-1262 with a one sided 95TH percentile of £66, 
achieving the non-inferiority limit of 150 and favouring HAH. Two bed days would 
have been £-1508 with a one sided 95th percentile of £-180. 
 
Figure 7.2: Length of stay and cost difference (£) between HAH and UC 
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The difference in cost was primarily related to inpatient and formal social services 
costs (Table 7.2). The cost differences for the index admission alone are shown in 
Table 10.3 in chapter 10, appendix C. Total QALY scores were non-significantly 
higher in HAH compared to UC (QALY HAH-UC= 0.005, 95% CI -0.14 to 0.25). The 
probability of HAH being cost-effective compared with UC was 90% at the NICE 
threshold of £30,000 per QALY. This is the proportion of dots beneath the diagonal 
line in Figure 7.3A and is represented by the vertical line in Figure 7.3B. The area 
under the diagonal line is comprised of instances in which: HAH is both more 
effective and cheaper than UC (area “1”); HAH is more effective and more expensive 
but within the NICE threshold (area “2”); and c) UC is more effective, but also more 
expensive and exceeds the NICE threshold (area “3”). HAH is therefore the dominant 
intervention compared to UC in that it is both cheaper and more effective for most 
patients treated (74% probability).  
 HAH, £ UC, £ 
Bootstrapped 
mean Difference 
(£) 
Bootstrapped 95% CI* 
of cost difference 
Overall costs     
Health and formal social care 3857.8 4873.5 -1015.7 -2735.5 to 644.8 
Healthcare 3819.2 4755.8 -936.6 -2645.4 to 709.9 
Oxygen therapy 38.4 18.3 20.1 -1.73 to 42.0 
Medication 422.5 458.9 -36.4 -150.1 to 75.7 
Hospital costs    
 
Bed stay 1540.8 2775.2 -1234.4 -2524.8 to -82.0 
Inpatient healthcare review 417.7 514.3 -96.7 -288.4 to 96.4 
Laboratory and diagnostic tests 375.1 358.7 16.4 -128.1 to 169.1 
NIV costs 44.4 158.2 -113.8 -255.4 to 8.12 
HAH costs    
 
HAH visits and travel time** 383.9 0.0 383.9 319.2 to 455.3 
Telephone calls costs 5.8 5.4 0.5 -3.57 to 5.33 
Community costs    
 
Formal social care 38.6 117.7 -79.0 -299.2 to 55.2 
Home visits after discharge 43.7 39.2 4.5 -19.2 to 31.8 
A+E and outpatient appointments 546.8 427.6 119.2 -22.6 to 243.0 
*The 95% confidence interval (CI) in the table is two sided (0.025 to 0.975) calculated with the bootstrap approach. For health and 
formal social care (the primary outcome) the one sided 95% CI (0.95) was £312. 
** 55% of time on HAH visits was spent with the patient. (45% on travel time) 
Table 7.2: Health and formal social care average costs at 90 days 
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Figure 7.3A: the cost effectiveness plane for HAH and UC, with the diagonal line representing the 
NICE cut-off at £30,000 per QALY. Area 1= HAH cheaper and more effective, 2= HAH more effective 
and more expensive but less than the NICE cut-off, and 3= UC is more effective, but more expensive 
and exceeds the NICE cut-off. Figure 3B: The probability of cost-effectiveness is shown over a range 
of willingness to pay for a QALY, to inform decisions to accept or reject new technologies. There is a 
90% probability HAH will be cost-effective at the NICE threshold (vertical line). 
The analysis was repeated using multiple imputation for missing data. This resulted 
in 78% of values in the dominant quadrant on the cost-effectiveness plane, and the 
probability of cost-effectiveness was essentially unchanged (Figure 7.4). 
 
 
 
 
 
 
 
 
 
Figure 7.3: Cost-effectiveness plane (A) and cost-effectiveness acceptability curve (B). 
A B 
Figure 7.4: Cost-effectiveness plane (A) and cost-effectiveness acceptability curve (B), multiple imputation. 
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7.4 Hospital at Home 
Of the 60 patients allocated to HAH, 53 (88.3%) had a zero or one day stay. Most 
patients incurring an overnight stay were admitted in the afternoon or evening. 
Patients received a median of 4 (IQR 2 to 5) overnight days HAH care per HAH 
episode. Including travel time, healthcare professionals spent a median of 7.2 hours 
(IQR 4.7 to 10.8) on home visits per HAH spell (median RSN visits = 7.1 hours, IQR 
4.4 to 10.1). There were 342 visits for 57 episodes: RSN = 327, physiotherapy = 13, 
psychology = 1, and respiratory support worker = 1. 
During HAH, two patients returned to hospital for assessment (which included a 
respiratory consultant review, repeat chest radiograph and blood testing) and 
returned home the same day. One patient returned to hospital and stayed overnight 
before returning home to complete their HAH spell. 
7.5 Other outcomes 
There were no deaths in the acute period (within 14 days) in either arm. Within 90 
days, there was one death in each arm. There was a statistically significant reduction 
in bed days over 90 days in those treated with HAH (HAH = 1, IQR 1-7 compared to 
UC = 5, IQR 2-12; p = 0.001). Readmission rates were similar in both arms with 22 
(36.7%) in HAH and 23 (39.7%) in UC. Further detail is provided in Table 10.4 in 
chapter 10, appendix C. There was a strong preference for HAH treatment at 14 days 
in both arms stated by 54 of 60 in HAH and 51 of 57 in UC. 
Table 5 shows the change in quality of life scores from baseline at 14 days and 90 
days. For HADS and CAT, negative values represent improvements in health from 
baseline, whilst for utility scores, positive values represent improvements from 
baseline. The per cent of patients improving by the minimum clinically important 
difference (MCID) is also shown. The improvements in health status in HAH 
compared to UC were clinically meaningful for HADS-anxiety score at 14 days and 
CAT at 90 days, but this could be a chance finding.37, 274 On multiple imputation the 
difference in the benefit of CAT at 90 days was 1.5, but the utility score at 14 days 
was 0.51 which is above the MCID (Table 7.3). 
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 HAH UC 
 Unit change* 
% 
MCID† missing 
Unit 
change 
% 
MCID missing 
HADS-A 14 day -1.0 48.3 0 0.5 33.9 2 
HADS-A 90 day 0 33.3 6 0 38.2 3 
HADS-D 14 day -1.0 38.3 0 0 26.8 2 
HADS-D 90 day -0.5 37.0 6 0 27.3 3 
CAT 14 day -4.0 61.7 0 -3.0 57.9 1 
CAT 90 day -3.0 51.9 6 -1.0 36.4 3 
Utility 14 day (EQ-5D-5L) 0.091 56.7 0 0.055 49.1 1 
Utility 90 day (EQ-5D-5L) 0.003 43.9 3 0.007 41.1 2 
*Values are median, except for utility which is mean. Unit change is the difference in absolute values between 
follow up and baseline. Improvements in health status are negative for HADS and CAT, and positive for utility 
scores. †The percentage of paƟents who improved by a Minimal Clinically Important Difference, which is 1.5 
for HADS-A and HADS-D, 2 for CAT and 0.051 for the EQ-5D-5L.  
Table 7.3: Changes in quality of life scores from baseline 
7.6 Patients declining participation 
As part of an audit of practice, baseline characteristics of patients who declined to 
participate in the HAH study were reviewed. Patients who declined enrolment were 
not more unwell than study participants based on co-morbidity and measures of 
disease severity (Table 7.4). 
 
 Decliners HAH UC 
Female 54.3 53.3 51.7 
Age (SD) 70.6 (9.8) 71.0 (9.6) 68.7 (10.5) 
Pack years (IQR) 40 (40-60) 45 (35-50) 44 (30-60) 
FEV1 % predicted (SD) 45.1 (19.6) 45.5 (18.4) 42.1 (16.3) 
DECAF 1, % 65.7 71.7 53.4 
eMRCD 5a, % 8.6 20 15.5 
CXR consolidation, % 25.7 25 15.5 
pH less than 7.35, % 2.9 10 10.3 
PaO2 kPa (SD) 8.0 (7.35 to 9.0) 7.6 (7.2-9.3) 7.9 (7.2-10.2) 
One previous admission 12 months, % 22.9 20 20.7 
Two previous admissions 12 months, % 25.7 35 32.8 
Prior social care, % 5.7 5 1.7 
IHD, % 25.7 23.3 20.7 
Diabetes, % 17.1 13.3 8.6 
LV dysfunction, % 5.7 1.7 5.2 
Anxiety, % 11.4 15 5.2 
Depression, % 14.3 20 15.5 
Table 7.4: Characteristics of decliners, and patients in HAH and UC 
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7.7 Discussion 
Hospital at Home is clinically more effective than usual care with a five-fold reduction 
in bed days over 90 days. AECOPD and inhospital stay are associated with a 
reduced quality of life, which may be improved by HAH treatment; there were 
clinically meaningful improvements in HADS-anxiety at 14 days and CAT score at 90 
days in the HAH group compared to UC group. Crucially, 90% of patients across both 
arms stated they would prefer HAH to UC for future exacerbations of similar severity. 
In an economic evaluation, extensive costs were obtained, and health-related quality 
of life was measured with the EQ-5D-5L. This showed that HAH was less expensive 
and more effective than usual care. AECOPD is one of the commonest reasons for 
hospital admission, and DECAF identifies approximately 50% of patients as low risk. 
Therefore, the potential clinical and cost benefits of the implementation of HAH is 
large. Furthermore, low risk patients can be identified objectively, consistently and 
safely with the DECAF score. This allows replication of our model of Hospital at 
Home, and may also lead to a reduction in length of stay in usual care. 
This study has several strengths. We assessed the impact of using the DECAF score 
to guide HAH treatment, replicating how we anticipate the tool will be used in clinical 
practice. The DECAF score is the only prognostic tool for COPD exacerbation that 
has undergone the gold standard of derivation, internal and external validation, and 
impact assessment; such studies are extremely rare despite being strongly 
recommended.265 We performed a detailed and extensive cost analysis, recording all 
important aspects of health and social care. Several sources of data capture were 
used, including patient diaries and primary and secondary care records, and patients 
were contacted every two weeks to ensure that data were accurate and as complete 
as possible. Rates of missing data were low for health-related quality of life data. 
Multiple imputation was used to demonstrate that the results were robust. 
Randomisation was performed by an external agency using minimisation, based on a 
regression analysis of DECAF 0-1 patients, to identify the strongest predictors of 
readmission or death 
One of the key limitations of the study was the choice of £150 as the non-inferiority 
limit. Data on the primary outcome, total health and social care cost over 90 days, 
was not available. The pre-specified non-inferiority limit was based on the estimated 
difference in healthcare costs for a single admission, which was £-470. This estimate 
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was less than half the actual difference in total health and social care costs over 90 
days of £-1016. A more appropriate non-inferiority limit would have been £340. The 
number of patients discharged prior to assessment by the research team, thus not 
eligible to participate, was larger than expected. This resulted in a more unwell and 
costly study population.  
Due to the under-representation of short stay patients, the median length of stay in 
UC should have been longer than the expected five days; the median LOS was 
actually two days shorter. Patients who declined participation were not more unwell 
than study participants. Those with a DECAF 0-1 exacerbation who met exclusion 
criteria may have had a longer length of stay. However, they were outnumbered by 
the groups above so their exclusion cannot account for the lower median LOS. A 
more likely explanation is that the use of the DECAF score and study participation 
reduced length of stay, as well as costs, within usual care. Only UC patients 
expressed disappointment with their allocated arm, and some requested discharge; 
such decisions lay entirely with the responsible clinicians. In an embedded qualitative 
study, clinicians reported that UC patients were probably discharged sooner than is 
typical. Bed pressures may have exerted additional influence. There were no acute 
deaths in UC, which suggests that low risk DECAF score may be used to inform safe 
early discharge.  
Another limitation is that the study was performed in three hospitals within one 
healthcare trust, potentially reducing the generalisability of the results. However, the 
structure of care, including availability of early supported discharge, differed between 
sites. We have previously shown that the DECAF score effectively identifies low risk 
patients in six different hospitals, with different populations and structures of care.255 
Some hospitals may currently lack the nursing infrastructure to deliver HAH selected 
by DECAF, but investment is justified as there is a 90% chance of this model being 
cost-effective with further possible cost savings through reduced LOS in UC. Training 
costs of nurses were included in our analysis. 
Meta-analyses of previous studies considered HAH and rarely supported discharge 
(ESD) together. These showed that HAH/ESD report reduced readmission rates and 
a trend towards a lower mortality with limited evidence for the effect on health related 
quality of life.3, 158 Three studies performed a cost analysis, showing that HAH/ ESD 
was less expensive, 159, 226, 240 but these were not economic evaluations. An 
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economic evaluation requires the measurement of costs and clinical effectiveness in 
two or more arms of a study. This approach is important as the benefit of the 
intervention can be estimated in terms of the cost per QALY. Measuring costs alone 
fails to identify the degree of clinical benefit or harm to the patient, and so there is no 
meaningful context for any expenses/ savings. Furthermore, such analyses should 
include health and social costs to ensure that apparent health savings are not simply 
transferred from to social care. Goossens et al. performed a detailed economic 
evaluation of health and social costs: at three months HAH/ ESD was 168 Euros less 
expensive than UC from a healthcare perspective, but 908 Euros more expensive 
when societal costs were included.241 As most of these previous studies are of ESD 
services rather than HAH, comparison to our study should be guarded. For example, 
in the study by Goossens et al., LOS in the ESD treatment arm was the same as our 
UC arm (three days for the index episode). Ricauda et al. compared an experienced 
HAH service to UC and showed cost savings, with a reduction in readmission rates. 
They only included patients of 75 and over, and excluded those with severe hypoxia, 
acidaemia, cancer and those without family and social support.159 
Previous studies of HAH/ ESD had extensive eligibility criteria to identify suitable, low 
risk patients and typically excluded those with co-existent pneumonia and acidaemia 
on blood gas.225, 226, 238 159, 227, 229, 239 Ordinarily, clinicians would be reluctant to allow 
these patients into HAH/ ESD services, but we treated such patients successfully 
with no difference in mortality between groups. This result is consistent with findings 
from the DECAF derivation and validation study, which showed that DECAF 0-1 
patients with pneumonia or acidaemia had a low acute mortality risk.2, 255 
In common with many previous studies, we did not include return to hospital during 
HAH treatment as a readmission, but rather an escalation in level of care. If return to 
hospital during HAH was counted as a readmission, the readmission rate would be 
biased in favour of UC patients as they are not exposed to this risk during their acute 
stay; we have previously discussed this important issue,3 though it does not affect 
our primary outcome.  
This randomised controlled trial shows that Hospital at Home selected by low risk 
DECAF score is safe, clinically effective, preferred by most patients, and cost-
effective compared to usual care. In combination with data from our derivation and 
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validation studies, this implementation study supports the use of DECAF in clinical 
practice to select low risk patients for HAH services. 
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 The PEARL readmission score 
8.1 Patient characteristics 
In the derivation, internal validation and external validation cohorts 824 (Dec 2008-
June 2010), 802 (Jan 2012-May 2013) and 791 (April 2013-May 2014) patients 
survived to hospital discharge of whom 309 (37.5%), 297 (37.0%) and 330 (41.7%) 
were readmitted or died within 90 days of discharge. The justification for this outcome 
is described previously (4.2.7 Outcome). The population characteristics of each 
cohort are shown and compared in Table 8.1. A diverse population of patients with 
AECOPD were recruited, exemplified by significant differences between cohorts in 
median eMRCD score, admissions in the previous year, and proportions with left 
ventricular failure and cor pulmonale. The population characteristics of individual 
hospitals are described elsewhere.2, 255 
  
8.2 Missing data 
Missing data for all indices, prognostic scores and patients are shown in Table 8.2.  
 Derivation Internal 
validation 
External 
validation 
P value  
Number of patients, n 824 802 791 N/A  
Sociodemographic details      
   Female, % 54.2 56.4 51.5 0.14  
   Age* 72.3 (9.9) 73.1 (10.2) 72.2 (10.4) 0.14  
   Institutional care, % 5.2 6.0 3.0 0.013  
   Cigarette pack years, n† 45 (32-60) 40 (30-56) 40 (30-60) 0.00015  
Preadmission details      
   eMRCD† 4 (3-5a) 5a (4-5a) 5a (4-5a) <0.0001  
   Admissions in previous year, n† 0 (0-1) 0 (0-1) 1 (0-2) <0.0001  
   Weight loss >5%, % 21.6 11.9 18.5 <0.0001  
   FEV1 % predicted* 44.5 (18.1) 48.4 (19.2) 43.0 (16.9) <0.0001  
   Long term oxygen, % 11.3 15.6 17.3 0.0015  
   Long term prednisolone, % 8.7 7.4 7.8 0.58  
   Left ventricular failure, % 7.4 10.7 12.3 0.0033  
   Cor pulmonale, % 9.8 6.1 8.0 0.022  
   Diabetes, % 14.7 11.6 14.3 0.13  
   Chronic Kidney Disease, % 5.7 11.3 13.4 <0.0001  
   Cerebrovascular Disease, % 12.6 12.7 11.0 0.52  
   Atrial Fibrillation, % 10.9 16.0 15.8 0.0034  
   Asthma, % 5.1 7.2 10.2 0.00042  
   Cognitive impairment, % 4.6 4.4 5.4 0.58  
Admission details      
   Length of stay, n† 6 (4-11) 5 (3-10) 4 (2-8) <0.0001  
   Radiographic consolidation, % 29.9 29.7 23.0 0.0041  
   Ineffective cough, % 9.3 9.6 3.4 <0.0001  
* Mean (Standard deviation); † Median (Interquartile range). P value compares proportions, means and 
median values across all three groups. 
 
Table 8.1: Demographics and candidate predictors by cohort  
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Table 8.2: Percentage of missing data per variable in each cohort 
Of the candidate indices shown in table 2, all had 1% or less missing data for each 
cohort except for pH (derivation 6.6%, internal validation 9.4% and external validation 
16.2%), weight loss (derivation 2.9%, internal validation 1.4%, external validation 
12.4%), admissions per year (derivation 0%, internal validation 0%, external 
validation 2.1%), and cough effectiveness (derivation 0%, internal validation 0.37%, 
external validation 1.5%). 
 Missing data, %  
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Number or patients, n 824 802 791  
Patients with missing data 2.9 3.6 16.9  
    Excluding weight loss 0 2.2 6.4  
Sociodemographic details  
   Gender 0 0 0  
   Age 0 0 0  
   Residence 0 0 0  
   Cigarette pack years 0 0 0  
Preadmission details  
   eMRCD 0 0 0  
   Admissions in previous year 0 0 2.1  
   Recent weight loss 2.9 1.4 12.4  
   FEV1 % predicted 0 0.75 1.5  
   Long term oxygen 0 0 0.38  
   Long term prednisolone 0 0 0.63  
   Left ventricular failure 0 0 0.25  
   Cor pulmonale 0 0 0.25  
   Diabetes 0 0 0.38  
   Chronic Kidney Disease 0 0 0.13  
   Cerebrovascular Disease 0 0 0.51  
   Atrial Fibrillation 0 0 0  
   Asthma 0 0 0.25  
   Cognitive impairment 0 0 0.38  
Admission details  
   Admission hospital 0 0 0  
   Length of stay 0 0 0.76  
   Radiographic consolidation 0 0 0  
   Cough effectiveness 0 0.37 1.5  
Variables from other prognostic with missing data  
   BMI 2.9 21.3 25.4  
   Exacerbations 11.9 61.5 18.2  
   Severe exacerbations 0 0 1.3  
   Current smoking status 0 0.62 0.38  
Missing data by prognostic score  
   PEARL 0 0 2.4  
   ADO (original and updated)   0 1.9 1.5  
   BODEX 2.9 22.1 26.2  
   CODEX 0 1.9 2.7  
   DOSE 11.9 62.6 19.1  
   LACE 0 0 1.9  
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8.3 Development of a predictive score 
The following indices were categorised: age <80 or 80+; cigarette pack years <45 or 
45+; eMRCD score 1-3, 4, 5a or 5b; forced expiratory volume in one second (FEV1) 
%predicted <50 or 50+; previous admissions (<2 or 2+ in the past year); and length 
of stay as per the LACE study (0, 1, 2, 3 ,4-6, 7-13, or 14+ days).221 The ROC curves 
for eMRCD score, admissions in the previous year and age as a continuous indices 
are shown in Figure 8.1. The arrows represent the cut-offs that were selected for 
categorisation of the indices. 
 
Figure 8.1: ROC curves for categorised indices that appear in PEARL score 
All candidate indices were analysed using backwards multivariate logistic regression 
(Table 8.1). Weight loss was not entered into the model due to the high rate of 
missing data. Indices with high missing data rates may provide biased estimates as 
the test may only be performed in select patients; furthermore, collecting this index 
was labour intensive, a problem which would likely recur in clinical practice.256  
The indices retained in the final model were: Previous admissions, eMRCD score, 
age 80 or more, cor pulmonale (“right ventricular failure”) and left ventricular failure, 
and were collectively named the PEARL score (Table 8.3 and Table 8.4). The 
PEARL regression equation was compared within the derivation cohort by Akaike 
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Information Criterion (AIC), entering age as a categorical and continuous variable: 
PEARLage catergorical AIC = 940.4, PEARLage continuous AIC= 940.8. This is the 
recommended approach to compare the relative quality of two related models,204 and 
shows no difference, supporting the categorisation of age for ease of application of 
the score. 
As continuous variables were dichotomised, primarily to ensure ease of use, the 
regression coefficients (the column entitled “B” in Table 8.3) show the relative 
contribution of each index. The coefficients were used to assign initial weights to 
each index in the derivation cohort. There are various approaches to adjust models 
to improve prediction and generalisability;246, 275 this can involve combining derivation 
and validation data sets.246 The assigned weights were re-evaluated after pooling all 
three cohorts. The original weightings assigned in the derivation cohort were 
appropriate, except “previous admissions”, which should optimally be weighted as 
three (Table 8.3).  
8.4 Performance and calibration of the PEARL score 
The AUROC for the PEARL score (Table 8.4) for 90-day readmission/ death without 
readmission was: derivation = 0.73 (95% CI 0.70-0.77); internal validation = 0.68 
(95% CI 0.64-0.72); and external validation = 0.70 (95% CI 0.66-0.73). In all three 
cohorts combined the AUROC for 90-day readmission/ death without readmission 
was 0.70 (95% CI 0.68-0.73). For 90-day readmission only (not including death) the 
AUROC was 0.69 (95% CI 0.67-0.71). 
  
 Derivation cohort All cohorts Updated 
Weighting PEARL indices B P value Odds ratio (95% CI) B 
Previous admissions (2 or more) 1.04 <0.0001 2.84 (1.98-4.07) 1.14 3 
eMRCD score 4 0.67 0.0017 1.96 (1.29-2.98) 0.37 1 
eMRCD score 5a 1.13 <0.0001 3.10 (1.89-5.10) 0.85 2 
eMRCD score 5b 2.02 <0.0001 7.51 (4.17-13.52) 1.09 3 
Age 80 or more 0.38 0.032 1.47 (1.03-2.08) 0.38 1 
Right ventricular failure 0.50 0.050 1.66 (1.00-2.74) 0.63 1 
Left ventricular failure 0.52 0.080 1.68 (0.94-3.00) 0.52 1 
Constant -0.78 <0.0001 0.46 (0.36-0.58) -0.95  
                           Maximum PEARL score 9 
 Hosmer-Lemeshow statistic= 0.83, Nagelkerke r square= 0.21 
 Table 8.3: Predictors of death or readmission, the PEARL indices  
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The risk of readmission or post-discharge death increases with higher PEARL scores 
(Table 8.5).  
Risk PEARL 
Score 
Derivation cohort, % 
(n) 
Validation cohort, % (n) All cohorts, % by risk 
group 
Lo
w
 0 15.1 (25/ 166) 16.4 (29/ 177) 
20.7 (184/ 890) 
1 23.6 (49/ 208) 23.9 (81/ 339) 
In
te
rm
ed
ia
te
 2 33.8 (48/ 142) 36.3 (116/ 320) 
42.1 (454/ 1078) 3 51.2 (44/ 86) 41.7 (111/ 266) 
4 59.1 (55/ 93) 46.8 (80/ 171) 
 
5 65.2 (43/ 66) 60.1 (95/ 158) 
66.4 (298/ 449) 
H
ig
h 
ris
k 
6 67.5 (27/ 40) 69.2 (63/ 91) 
7 72.2 (13/ 18) 70.2 (40/ 57) 
8 100 (4/ 4) 77.8 (7/ 9) 
9 100 (1/ 1) 100 (5/ 5) 
Total 37.5 (309/ 824) 39.4 (627/ 1593) 38.7 (936/ 2417) 
Table 8.5: 90 day death/ readmission without death probability by PEARL score 
Further details of all cohorts, and data on readmission and death as lone outcome 
are shown in the appendix (Table 10.1); across all three cohorts, risk was similar with 
all p-values >0.05 showing that predictions are consistent. We grouped scores into 
low (0-1), intermediate (2-4), and high risk (5+) PEARL scores. Sensitivity and 1-
Index  Score  
Previous admissions (2 or more within past year) 0 / 3  
Dyspnoea    
   eMRCD 1-3 0  
   eMRCD 4 1  
   eMRCD 5a 2  
   eMRCD 5b 3  
Age 80 or more 0 / 1  
Right ventricular failure (Cor pulmonale) 0 / 1  
Left ventricular failure 0 / 1  
Total PEARL score 9  
Table 8.4: The PEARL score 
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specificty for the PEARL score are shown in the online supplement (Table 8.6). In the 
low risk group (PEARL 0-1) only 2.5% (22/ 890) died post-discharge within 90 days. 
PEARL score Sensitivity 1 – Specificity 
0 1.00 1.00 
1 0.92 0.73 
2 0.76 0.42 
3 0.61 0.24 
4 0.46 0.15 
5 0.29 0.080 
6 0.15 0.035 
7 0.058 0.010 
8 0.016 <0.0001 
9 0.0032 <0.0001 
Table 8.6: PEARL score sensitivity and 1- specificity, derivation cohort 
Calibration was further assessed by plotting “expected probability” (calculated from 
the full regression equation) against the “observed probability”. Calibration tends to 
perform best in derivation cohorts, so the derivation and validation cohorts were 
plotted separately. Again, PEARL was well calibrated (perfect calibration would fall 
on the 45 degree line, Figure 8.2). 
 
Figure 8.2: Calibration curve showing predicted risk compared to observed risk by PEARL score.  
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8.5 Comparison to other prognostic scores 
ROC curves for each prognostic score are shown in Figure 8.3 for the validation 
cohorts combined. Comparison within the derivation cohort favours the developed 
tool, so the derivation cohort is not included within the graph. 
 
Figure 8.3: ROC curves for PEARL, ADO, BODEX, CODEX, DOSE and LACE for 90 day readmission 
or death, validation cohorts combined 
Table 8.7 shows the comparison between PEARL and all other tools for each 
individual cohort. PEARL was superior to ADO, BODEX, DOSE and LACE in all three 
cohorts, and to CODEX within the derivation and external validation cohorts. Results 
were unchanged with complete case analysis. 
Thirty day comparisons are shown online (Table 8.8). PEARL was also superior to 
the original ADO score, the eMRCD score (the strongest of the PEARL indices), and 
the DECAF score (appendix Table 10.2). 
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Table 8.8: 30 day readmission or death, AUROC curves, with data imputation 
8.6 Time to death or readmission, and readmission frequency 
Time to death or readmission was available to 90 days in all three cohorts and to one 
year in the derivation and internal validation cohorts. Higher PEARL risk groups were 
associated with a shorter time to death or readmission (Figure 8.4 and Table 8.9). 
Prognostic score Derivation Internal validation External validation 
PEARL 
0.73 
(0.70-0.77) 
0.68 
(0.64-0.72) 
0.70 
(0.66-0.73) 
ADO* 
0.67 
(0.63-0.71)† 
0.64 
(0.60-0.67)‡ 
0.58 
(0.54-0.62)* 
BODEX 
0.65 
(0.61-0.69)* 
0.64 
(0.60-0.68)x 
0.62 
(0.58-0.66)* 
CODEX 
0.69 
(0.65-0.73)‡ 
0.66 
(0.63-0.70)NS 
0.62 
(0.58-0.66)* 
DOSE 
0.63 
(0.59-0.67)* 
0.59 
(0.55-0.64)† 
0.61 
(0.57-0.65)* 
LACE 
0.65 
(0.61-0.69)* 
0.61 
(0.57-0.65)‡ 
0.65 
(0.61-0.68)x 
AUROC curves of each score compared to PEARL by method of DeLong: *<0.0001, †<0.001, ‡<0.01, x<0.05, NS not significant 
Missing data >20% for BODEX and DOSE. On complete case analysis, BODEX= 0.63 (0.59-0.67), DOSE= 0.60 (0.53-0.66) 
Table 8.7: 90 day readmission or death, AUROC curves, with data imputation 
Pr
og
no
st
ic
 sc
or
e 
De
riv
at
io
n 
Co
m
pa
ris
on
 to
 
PE
AR
L,
 p
 v
al
ue
 
In
te
rn
al
 
va
lid
at
io
n 
Co
m
pa
ris
on
 to
 
PE
AR
L,
 p
 v
al
ue
 
Ex
te
rn
al
 
va
lid
at
io
n 
Co
m
pa
ris
on
 to
 
PE
AR
L,
 p
 v
al
ue
 
PEARL 
0.70 
(0.66-0.74) 
N/A 0.64 
(0.60-0.69) 
N/A 0.64 
(0.60-0.69) 
N/A 
ADO 
0.63 
(0.59-0.68) 
0.0021 0.61 
(0.56-0.65) 
0.082 0.56 
(0.51-0.60) 
0.00047 
BODEX 
0.63 
(0.59-0.68) 
0.0027 0.61 
(0.57-0.66) 
0.16 0.58 
(0.53-0.62) 
0.0046 
 
CODEX 
0.65 
(0.61-0.70) 
0.014 0.62 
(0.58-0.67) 
0.28 0.59 
(0.54-0.63) 
0.0064 
 
DOSE 
0.61 
(0.57-0.66) 
0.00064 0.58 
(0.53-0.63) 
0.016 0.59 
(0.54-0.63) 
0.021 
LACE 
0.66 
(0.61-0.70) 
0.087 0.61 
(0.57-0.66) 
0.26 0.59 
(0.55-0.64) 
0.038 
AUROC curves of each prognostic score compared to DECAF by method of DeLong. 
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The cumulative risk up to 90 days for readmission or death without readmission was 
20.8*, 41.8% and 67.3% for low, intermediate and high risk groups respectively.  
PEARL risk group identifies those at risk of frequent admissions. For risk groups 0-1, 
2-4 and 5-9 the median (IQR) number of readmission was 0 (0-1), 1 (0-2) and 2 (1-3). 
When adjusted for death (time exposed to readmission), the risk was 0 (0-1.8), 1 (0-
3) and 3 (1-6) respectively. 
 
Figure 8.4: Time to readmission or death, by PEARL risk group: A) in all cohorts up to 90 days, B) in 
the derivation and internal validation cohort up to 365 days (comparison using the log rank test)  
8.7 Discussion 
We have developed and validated a model to predict 90-day readmission/ death 
without readmission in patients hospitalised with an AECOPD; the “PEARL score”. 
The tool was designed to be easily applied at the bedside using indices routinely 
available at admission, and performance was superior to alternative scores. The risk 
PEARL risk 
group 
PEARL 
score 
Days to readmission or death, % No readmission 
or death, % Total, n 
 
0 to 30 31 to 60 61 to 90 91 to 365  
Low 0-1 11.3% 6.5% 3.0% 25.9% 53.3% 664  
Intermediate 2-4 24.1% 10.0% 7.7% 29.2% 29.1% 702  
High 5-9 40.4% 15.4% 11.5% 22.3% 10.4% 250  
 Total 21.5% 9.4% 6.4% 26.8% 36.0% 1626  
Table 8.9: Time to readmission or death, by PEARL risk group, derivation and internal validation cohort 
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of readmission/ readmission without death was considerably higher in the first 90 
days than during the rest of the year, both overall and within the moderate and high 
risk PEARL groups, which justifies our chosen timeframe. Rates of readmission were 
similar to those seen in the European National Audit 2016.10 Our composite endpoint 
is more appropriate than readmission alone, as the latter would include both those 
who are neither readmitted nor die and those who die without readmission in the 
“favourable” outcome group. Accurate risk stratification of patients should help 
efficiently direct resources aimed to reduce readmissions, such as supported 
discharge services, pulmonary rehabilitation, education programmes, and possibly 
azithromycin therapy, though the impact of these strategies requires assessment. 
Furthermore, identification of patients who are at risk of death without readmission 
may allow services to be put in place to facilitate early recognition of deterioration, 
and readmission. 
The study has a number of strengths, most importantly consecutive recruitment of 
patients and high case ascertainment. This is supported by excellent recruitment 
rates at all sites which were substantially higher than the 2015 UK national COPD 
audit, as detailed previously.255 Generalisability is supported by consistent 
performance in three cohorts, including the prospective external validation cohort (the 
“gold standard” for assessing performance). The six hospitals which took part had 
different structures of care and varied populations, with respect to readmission 
avoidance schemes, COPD prevalence, socioeconomics, and rurality. Furthermore, 
data were collected by a variety of healthcare professional, including physicians and 
specialist nurses. 
The eligibility criteria were inclusive; few patients were excluded due to poor 
prognosis (expected survival less than one year for an illness other than COPD): in 
the internal validation cohort, for example, this comprised only 27 patients (3.4%), 
principally due to metastatic malignancy. Definitions were aligned with usual clinical 
practice, and were pragmatic to reduce missing data and the consequent risk of bias. 
This approach is regarded as a key strength in prognostic research.204, 251 Primary 
outcome data was available in all patients, missing data rates were low, and multiple 
imputation and complete case analyses showed that results were robust. Further 
study strengths can be seen in the appendix (Appendix B: Charms checklist for 
PEARL study)204 which provides a framework to critique prognostic studies. 
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There are several limitations within the study. Most patients in the internal validation 
cohort were identified retrospectively which may have compromised performance. 
However, the risk of any consequent bias is probably low as the relevant indices 
were recorded during the patients’ admission prior to the outcome. When extracting 
data, researchers were blind to outcome. Furthermore, the external validation cohort 
was prospective and individually powered.  
Varied rates of cor pulmonale and left ventricular failure may reflect inconsistency in 
clinical assessment, or could represent true population differences, supporting 
external validity. Despite variation in rates, both were associated with readmission/ 
death without readmission in all three cohorts. Dichotomising continuous indices, 
such as age, allows a score to be calculated at the bedside without the full regression 
equation and a computer. When this approach is adopted, concern about consequent 
loss of prognostic strength may be raised. However, the impact of dichotomising (or 
categorising) continuous variables on performance may be minimal if the relation 
between the index and risk of outcome is non-linear, and the prognostic threshold(s) 
appropriately selected.251 The impact of dichotomising age on the performance of the 
PEARL score was negligible. We did not differentiate between different causes of 
readmission such as respiratory or non-respiratory. This would require the derivation 
and validation of separate scores, and based on data from our validation cohorts 
most admissions are respiratory (more than three in four). Furthermore, 
differentiating between cardiac and respiratory causes of readmission can be 
challenging. Whilst PEARL performed well in all cohorts, and participating units were 
chosen to ensure variation in population and structure of care, confirmation of 
performance in healthcare settings outside of the United Kingdom is desirable. A final 
limitation, which is common to all prognostic research, is that the strength of the 
association of the predictor with the outcome may vary between patients.276 
Other prognostic research shows that accurate prediction of readmission is 
challenging.223 The discrimination of PEARL (external validation AUROC = 0.70) is 
superior to all other tools that predict readmission or death in AECOPD, and 
substantially stronger than clinical judgement (AUROC = 0.56 to 0.59).215 An 
extensive literature search was performed to ensure the inclusion of all potential 
predictor variables that could be easily collected at the bedside. All of the indices in 
the PEARL score have been previously shown to predict our outcome, except for 
eMRCD score. This is important as eMRCD (along with previous admissions) was 
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the strongest predictor. In our study, associated pneumonia, non-invasive ventilation 
and institutional care (nursing or residential home) did not appear in the final model. 
This does not mean that they are not predictors, but rather that they did not add 
prognostic power to the PEARL indices which were stronger predictors. Furthermore, 
eMRCD includes a measure of frailty which may, at least in part, capture the risk 
associated with such indices. The strongest predictors of readmission/ death without 
readmission tended to be measures of underlying disease severity, frailty and co-
morbidity rather than measures related to the acute event. For instance, DECAF 
contains eosinopenia (a marker of acute inflammation/ sepsis), consolidation and 
acidaemia; it is an excellent predictor of acute mortality, but not medium and long-
term outcomes in those who survive to discharge.  
The lack of novel predictors, such as cardiac biomarkers, neural respiratory drive,277 
four meter gait speed,278 and quadriceps size by ultrasound 279 may be seen as a 
limitation. The inclusion of too many indices in model development risks overfitting 
and loss of performance in the validation cohorts.251 Furthermore, the inclusion of 
indices that are not routinely collected may introduce bias as missing data is large,280, 
281 and any association may be due to case selection only. For example, in our study 
only 17% of patients had troponin tests performed, and levels were not related to 
outcome on univariate analysis. We were unable to capture psychological wellbeing, 
social support networks and treatment concordance. These variables are complex to 
measure and may reduce a tool’s usability.  
Previous studies have shown a relationship between anxiety and depression and 
readmission,260, 261 although this was not seen in our derivation cohort (based on a 
preadmission clinical diagnosis). It is possible that an alternative approach to 
assessing anxiety, such as measurement of the Hospital Anxiety and Depression 
score at the point of discharge, may add predictive information. 
FEV1 is associated with exacerbations and hospital admissions in patients with 
stable COPD and guides treatment,5, 122, 123 but in our derivation cohort it was not an 
independent predictor of the primary outcome. The better performance of FEV1 in 
the derivation cohorts of tools such as ADO, BODEX, CODEX and DOSE probably 
reflects differences in population and measured outcome. 
PEARL was superior to ADO, updated ADO, BODEX, CODEX, DOSE and LACE. 
The CODEX study was developed in a large number of hospitals, the population is 
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clearly described and model performance is appropriately assessed. In its derivation 
study it was superior to ADO and BODEX for 90-day readmission or death, though 
this comparison favours CODEX.216 In our study, it was the second best performing 
tool. LACE was developed in unselected patients, rather than those with AECOPD,223 
for 30-day (and not 90-day) outcome. Of importance, PEARL was superior at both 
time-points. The LACE score was selected for comparison as it was derived in a well-
conducted study, demonstrated better discrimination than other generic tools and is 
used in some hospitals. The requirement to score the full Charlson index limits the 
bedside application of both CODEX and LACE. 
A number of studies have shown positive outcomes from interventions aimed to 
reduce readmission.282-284 There is room for further research to improve outcome, 
particularly in COPD.285, 286 The lowest risk group (PEARL 0 to 1) comprise almost a 
third of the population. Such risk stratification can inform research by excluding low 
risk groups (of importance, the risk of death alone was only 2.5% in the low risk, 
PEARL 0-1 group), or by using randomisation techniques that include stratification or 
minimisation by risk group.  
In current practice, clinician judgement is used to identify and target resources 
towards patients with a high readmission risk, although this judgement is known to be 
poor.215 The PEARL score offers robust and consistent prediction of 90-day 
readmission or death, and is superior to alternative tools. PEARL may aid clinical 
decision-making and resource allocation, although quantification of the impact of 
PEARL in terms of cost and patient outcomes requires further research. 
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 Conclusions 
 Many established treatments for AECOPD are not supported by robust 
evidence, and further research is required to: a) better quantify the risks and 
benefits of corticosteroids beyond single courses and identify which subgroups 
benefit from this treatment; and c) identify who will benefit from antibiotic 
therapy to improve antibiotic stewardship. 
 In a meta-analysis, ESD/HAH was associated with a lower rate of 
readmission, though this depended on whether return to hospital was 
considered a readmission. Although few trials reported costs, Early Supported 
Discharge and Hospital at Home for AECOPD were associated with lower 
healthcare costs. 
 The DECAF score is a robust predictor of inpatient death using indices that 
are routinely available at admission, and is superior to other prognostic 
scores. 
 In pneumonic AECOPD, CURB-65 0 and 1 scores are not low risk, and should 
therefore not guide treatment in this patient group. 
 In an RCT and implementation study, the DECAF score can be used to select 
low risk patients for Hospital at Home. Compared to usual care, this approach 
is safe, cost-effective and preferred by 90% of patients. 
 Five independent variables to predict readmission/ death without readmission, 
formed the PEARL score: Previous admissions, eMRCD score, Age, Right 
sided heart failure, and Left sided heart failure. Overall, PEARL was superior 
to other such scores and was also associated with time to readmission. 
 On February 1st 2017 the UK national COPD audit moved to continuous data 
collection and included the DECAF indices for all patients admitted to hospital 
with AECOPD. This will likely lead to wide uptake of the DECAF score in the 
UK. The awaited RCT publication will guide clinicians on how to use the 
DECAF score to direct care. 
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 Appendices 
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Appendix A: Charms checklist for DECAF validation study 
Source of Data 
1) Source of data (e.g. cohort, case-control, randomised trial participants, or registry data) 
 The external validation cohort was prospective, and individually adequately powered. The internal 
validation cohort was partially prospective, with retrospective extension. 
Participants 
1) Participant eligibility and recruitment method (consecutive participants, location, number of 
centres, setting, inclusion and exclusion criteria) 
Eligible patients analysis 
 All eligible patients were included in the validation cohorts, except those that did not have complete 
data for all DECAF indices. This was approximately 1% of the population, and mainly comprised of 
patients with SpO2 92% or less in whom arterial blood gas analysis was not performed 
Eligible patients excluded 
 Exclusion criteria were few. For the internal validation study, patients were excluded for the following 
reasons: survival <1 year n=27 (12 lung cancer, 3 end stage dementia, 3 metastatic cancer, 2 
metastatic bladder cancer, 2 idiopathic pulmonary fibrosis, 1 metastatic renal cancer, 1 metastatic 
bower cancer, 1 metastatic rectal cancer, 1 oesophageal cancer, and 1 mesenteric cancer), less than 
ten pack year smoking history n=24, spirometry not obstructive= 42. Ten patients had no ABG results, 
but had supplemental oxygen or oxygen saturations that were too low to assume a DECAF acidaemia 
score of 0. One patient had no eosinophil count. Robust data is not available for the external 
validation cohort.  
Consecutive patients 
 Extensive efforts were made to capture consecutive patients, including a broad coding search. Patients 
were captured by daily screening (Monday to Friday) on admission units and medical wards (external 
validation cohort) by a dedicated team.  
 In the internal validation cohort, patients were mainly identified retrospectively using a broad coding 
search, with cross referencing to patients identified by clinical staff who routinely review patients 
admitted with AECOPD. This methodology was compared to prospective screening over three months, 
showing superior capture overall, and only one eligible patient was identified by prospective screen 
alone. 
Location, centres, setting, and inclusion and exclusion criteria 
 Six UK centres were involved: the two sites included in the derivation study took part in the internal 
validation cohort, and four geographically distinct hospitals took part in the external validation. All 
patients in the study were recruited from secondary care. Inclusion and exclusion criteria are 
described. 
2) Participant description 
 Detailed description of participants by different sites in table 2 
3) Details of treatments received, if relevant 
 Medical treatment for acute exacerbations of COPD included antibiotics, steroids, nebulised 
bronchodilators, and non-invasive ventilation. In creating a score that is intended for use to guide 
management, it is not appropriate to include acute treatments as predictors. The research team did 
not influence clinical treatment.  
4) Study dates 
 Given for each site in table 2 
Outcome to be predicted 
1) Definition and method for measurement of outcome  
 Outcome clearly defined- Inpatient death 
2) Was the same outcome definition (and method for measurement) in all patients? 
 Yes 
3) Type of outcome single or combined endpoints? 
 159 
  
 Single endpoint 
4) Was the outcome assessed without knowledge of the candidate predictors (I.e., blinded)? 
 The DECAF indices were apparent to the team reporting in-hospital death, however in-hospital death 
is inherently objective, therefore the risk of bias is minimal/absent. 
5) Were candidate predictors part of the outcome (e.g., in panel or consensus diagnosis)?  
 No 
6) Time of outcome occurrence or summary of follow-up 
 Inpatient death. Presence or absence of outcome captured in all patients. 
Candidate predictors 
1) Number and type of predictors (eg. Demographics, patient history, physical examination, 
additional testing, disease characteristics)  
 Candidate predictors refers to indices for derivation study, not the validation study, so the number of 
predictors is not relevant here. The analysis of inpatient mortality was only performed with the five 
DECAF indices. 
2) Definition and methods for measurement of candidate predictors  
 Candidate predictors described in derivation study. In validation study, definitions and methods of 
measurement provided. Each research site was provided with a data collection guide which included 
definitions of terms and diseases. eMRCD score as per table 1, eosinophil count cut-off provided, 
presence of chest radiograph based on assessment from consultant post-take ward round, acidaemia 
based on arterial blood gas analysis, and atrial fibrillation based on electrocardiogram and/ or history 
of (paroxysmal) atrial fibrillation. 
3) Timing of predictor measurement of candidate predictors (e.g. at patients presentation, at 
diagnosis, at treatment initiation) 
 DECAF indices were assessed on admission (see table 1). 
4) Were predictors assessed blinded for outcome, and for each other (if relevant)?  
 Predictors were assessed blinded from the outcome. The external validation cohort was identified 
prospectively, so variables were collected prior to the outcome. The internal validation study was 
performed retrospectively. Three DECAF variables, eosinopenia, acidaemia and atrial fibrillation, are 
objective. Potentially, there may be a degree of inter-observer variation in the reporting of chest 
radiograph consolidation and the eMRCD score, however the research team relied on the observations 
of the attending clinicians. For patients identified retrospectively, the researcher obtaining the 
information from the notes was blinded to the outcome. Collection of individual predictors was not 
blinded from other DECAF indices, although the consequent risk of bias is low. 
5) Handling of predictors in the modelling (e.g. Continuous, linear, non-linear transformations or 
categorised) 
 The DECAF variables were applied as per the derivation study. eMRCD score is categorised, eosinophil 
score and pH are dichotomised, and AF and chest x-ray consolidation are binary. Dichotomising 
variables can cause a loss of discrimination, depending on their relationship with the outcome. This 
was not an issue as the continuous varibles related to DECAF show a non-linear relationship to 
mortality, and the pre-define threshold was optimal. Discrimination of DECAF was very good, and 
similar to that of the derivation study, in both validation cohorts. 
Sample size 
1) Number of participants and number of outcomes/events 
 The internal and external cohorts were individually adequately powered. Internal cohort: 880 
participants, 78 events; external cohort 845 participants, 54 events. 
2) Number of outcomes/events in relation to the number of candidate predictors (events per 
variable) 
 This approach to sample size calculation is only relevant to the derivation study.  
Missing data 
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1) Number of participants with any missing value (include predictors and outcomes) 
2) Number of participants with missing data for each predictor  
 1+2) Number of missing values and number of participants with missing data provided 
3) Handling of missing data (e.g. complete-case analysis, imputation, or other methods)  
 3) Low rates of missing data. Multiple imputation used; complete-case analysis also performed. 
Model development 
1) Modeling method (eg logistic. survival, neural networks, or machine learning techniques) 
2) Modeling assumptions satisfied 
3) Methods for selection of predictors for inclusion in multivariable modelling (e.g. all candidate 
predictors, pre-selection based on unadjusted association with the outcome)  
4) Method for selection of predictors during multivariable modeling (e.g. full model approach, 
backward or forward selection) and criteria used (e.g. p-value, Akaike Information Criterion)  
 1-4) The DECAF model was developed in the DECAF derivation study; these aspects do not apply to the 
validation study. 
5) Shrinkage of predictor weights or regression coefficients (e.g. no shrinkage, uniform Shrinkage, 
penalized estimation) 
 5) Shrinkage refers to adjusting coefficients to protect against overfitting and loss of discrimination in 
validation studies. In developing the DECAF score, the prognostic indices were weighted based on 
their coefficients. The same weighting was used for both validation cohorts, and discrimination 
remained good in both validation cohorts. 
Model performance 
1) Calibration (calibration plot, calibration slope, Hosmer-Lemeshow test) and Discrimination (C-
statistic, D-statistic, log rank) measures with confidence intervals 
 Hosmer-Lemeshow test is provided, and observed risk from derivation and validation cohorts 
described and compared. The validation study showed good calibration. Although the absolute risk 
differed between the derivationa and validation study for high risk patients, this reflects differences in 
overall mortality rates and a large and stepwise increase in mortality is seen between different risk 
groups. 
2) Classification measures (e.g sensitivity, specificity, predictive values, net reclassification 
improvement) and whether a priori cut points were used  
 2) Sensitivity and specificity are provided. Reclassification measures, such as net reclassification 
improvement, look at the value in adding a single predictor to a prediction model. Due to the very 
strong performance of the DECAF score, no reclassification measures were performed or required. 
Model evaluation 
1) Methods used for testing model performance: development dataset only (random split of data, 
resampling methods, e.g. bootstrap or cross-validation, none) separate external validation (e.g. 
temporal, geographical, different setting, different investigators) 
 Internal validation: involved the same hospitals as the derivation study, but at a different time period 
(a form of temporal validation) and additional investigators.  
 External validation was performed in hospitals that are geographically distinct. Hospitals were chosen 
to ensure variation in population characteristics (rurality and socioeconomic factors) and structures of 
care to maximise generalisability. The research staff within external sites were not involved in the 
derivation study.2) In case of poor validation, whether model was adjusted or updated (e.g., 
intercept recalibrated, predictor effects adjusted, or new predictors added) 
 Not applicable 
Results 
1) Final and other multivariable models (e.g. basic, extended, simplified) presented, including 
predictor weights or regression coefficients, intercept, baseline survival, model performance 
measures (with standard or confidence Intervals)  
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2) Any alternative presentation of the prediction models. e.g., sum score, nomogram, score chart, 
predictions for specific risk subgroups with performance 
3) Comparison of the distribution of predictors (including missing data) for development and 
validation datasets  
 1+2+3) These points apply to prognostic research in which data is extracted for systematic reviews, so 
is not applicable. Predictor weights and regression coefficients are given for the DECAF score. 
 
Interpretation and discussion 
1) Interpretation of presented models (confirmatory, if model useful for practice versus exploratory, 
is more research needed) 
 The performance of DECAF is excellent in two separate, and individually adequately powered, 
validation cohorts. This confirms that DECAF can risk stratify patients effectively. The value of using 
DECAF to inform clinical practice, such as to identify patients for Hospital at Home, requires further 
research. 
2) Comparison with other studies, discussion of generalisability strengths and limitations. 
 DECAF is compared to other prognostic scores, with discussion of the strengths and limitations. 
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Appendix B: Charms checklist for PEARL study 
Source of Data 
1) Source of data (e.g. cohort, case-control, randomised trial participants, or registry data) 
 The derivation and external validation cohorts was prospective. The internal validation cohort was 
retrospective, with prospective collection data. 
Participants 
1) Participant eligibility and recruitment method (consecutive participants, location, number of 
centres, setting, inclusion and exclusion criteria) 
Eligible patients analysis 
 Patients who did not survive to discharge were appropriately excluded as the main outcome was 
readmission or death at 90 days from discharge. Otherwise, all patients were included in the 
derivation cohort. The primary outcome for the three cohorts was for inpatient mortality, which led to 
the development of the DECAF score. The readmission analysis was a pre-specified study. In the 
validation cohort, those that did not have complete data for all DECAF indices were not included in the 
analysis, although this was only 1% of the population, and mainly comprised of patients that had 
oxygen saturations sufficiently low to warrant arterial blood gas analysis but that declined this 
investigation.  
Eligible patients excluded 
 Exclusion criteria were few. For the internal validation cohort, patients were not eligible as follows: 
survival <1 year n=27 (twelve lung cancer, three end stage dementia, three metastatic cancer, two 
metastatic bladder cancer, two idiopathic pulmonary fibrosis, one metastatic renal cancer, one 
metastatic bower cancer, one metastatic rectal cancer, one oesophageal cancer, and one mesenteric 
cancer patient), less than ten pack year smoking history n=24, spirometry not obstructive= 42. Ten 
patients had no ABG results, but had supplemental oxygen or oxygen saturations that were too low to 
assume a DECAF acidaemia score of zero. One patient had no eosinophil count. Robust data for the 
derivation and external validation cohort is unavailable. 
Consecutive patients 
 Extensive efforts were made to capture consecutive patients, including a broad coding search. Patients 
were captured by daily screening (Monday to Friday) on admission units and medical wards 
(derivation and external validation cohorts) by a dedicated team. In the internal validation cohort, 
patients were mainly identified retrospectively using a broad coding search, with cross referencing to 
clinical staff whose role it is to review patients with exacerbation of COPD. In the internal validation 
cohort, a dedicated team screened the admission units and medical wards for three months and 
compared patient capture to the coding records search and clinical team capture. Only one patient 
was identified by daily screening that was missed by coding or the clinical team. 
Location, centres, setting, and inclusion and exclusion criteria 
 Six UK centres were involved: the same two sites that were included in the derivation cohort took part 
in the internal validation cohort, and four geographical distinct hospitals took part in the external 
validation cohort. All patients in the study were recruited from secondary care. Inclusion and exclusion 
criteria are described. 
2) Participant description 
 Detailed description of participants by different sites in DECAF validation study.(publication awaited) A 
detailed description of patients in each cohort is shown in table 1. 
3) Details of treatments received, if relevant 
 Treatments to reduce hospital readmission include smoking cessation, inhaled corticosteroids, long-
acting beta agonists, and long-acting muscarinic agonists, and pulmonary rehabilitation. The score is 
intended to be used to inform management, so including treatments as predictors is not appropriate. 
Also, other indices are more strongly associated with readmission or death at 90 days. The research 
team did not influence clinical treatment. 
4) Study dates 
 Dates for recruitment period of each hospital discussed in previous publications.2(awaiting 
publication) 
Outcome to be predicted 
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1) Definition and method for measurement of outcome  
 Readmission or death without readmission 90 days from discharge in patients surviving to discharge. 
Readmission was clearly defined- a patient had to be admitted to hospital and reviewed by a member 
of the clinical team. 
2) Was the same outcome definition (and method for measurement) in all patients? 
 Yes. 
3) Type of outcome single or combined endpoints? 
 Combined outcome. We did not wish to create a score that identified those at risk of readmission, but 
missed those at risk of death without readmission, as some of these deaths may be preventable. 
Predictors of readmission and death are similar. 
4) Was the outcome assessed without knowledge of the candidate predictors (i.e., blinded)? 
 The indices were apparent to the research team for death. Readmission data was collected blind to 
the candidate predictors. Readmission and death are regarded as objective outcome and the 
associated risk of bias is low. 
5) Were candidate predictors part of the outcome (e.g. in panel or consensus diagnosis)?  
 No 
6) Time of outcome occurrence or summary of follow-up 
 All patients were followed up. The outcome was 90 days after discharge. 
Candidate predictors 
1) Number and type of predictors (e.g. demographics, patient history, physical examination, 
additional testing, disease characteristics)  
 The type of predictors is described. There were 20 candidate predictors. 
2) Definition and methods for measurement of candidate predictors  
 The methods for measuring each index is provided, as well as the definitions of those in the PEARL 
score. A data collection guide was provided to each hospital which included definitions and guidance 
on data collection. 
3) Timing of predictor measurement of candidate predictors (e.g. at patients presentation, at 
diagnosis, at treatment initiation) 
 Predictors were collected at the time of admission up to the point of the post-take ward round. 
4) Were predictors assessed blinded for outcome, and for each other (if relevant)?  
 The derivation cohort and external validation cohort were prospective. The internal validation cohort 
was performed retrospectively, but predictors were assessed blinded to the outcome. Collection of 
predictors were not blinded from each other, though the consequent risk of bias is low. 
5) Handling of predictors in the modelling (e.g. Continuous, linear, non-linear transformations or 
categorised) 
 Some predictors were categorised which is described. 
Sample size 
1) Number of participants and number of outcomes/events 
2) Number of outcomes/events in relation to the number of candidate predictors (events per 
variable) 
 1+2) In the derivation cohort, internal validation and external validation cohorts there were 824, 802 
and 791 patients. There were 20 candidate predictors in the derivation cohort, and 309 events, or 15.5 
events per index. The power calculation for the derivation cohort and each individual validation cohort 
is described. 
Missing data 
1) Number of participants with any missing value (include predictors and outcomes) 
2) Number of participants with missing data for each predictor  
3) Handling of missing data (e.g. complete-case analysis, imputation, or other methods)  
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 1+2+3) Missing data by participant and by index provided. Missing data rates were low. Multiple 
imputation was used, and the approach and number of datasets used described. Five datasets were 
used which is regarded as sufficient given the amount of missing data; complete-case analysis was 
performed. 
Model development 
1) Modeling method (e.g. logistic, survival, neural networks, or machine learning techniques) 
 Logistic regression used; methods described. 
2) Modeling assumptions satisfied 
 Yes 
3) Methods for selection of predictors for inclusion in multivariable modelling (e.g. all candidate 
predictors, pre-selection based on unadjusted association with the outcome)  
 Predictors for inclusion selected based on literature search and clinical experience. 
4) Method for selection of predictors during multivariable modeling (e.g. full model approach, 
backward or forward selection) and criteria used (e.g. p-value, Akaike Information Criterion)  
 Backwards logistic regression used, criteria (p-values) described. The PEARL (full model) and PEARL 
(age continuous) were compared with -2 log likelihood. The Akaike Information Criterion is calculated 
based on the -2 log likelihood and the number of indices in the model. Here, the number of indices is 
the same (five) so this part of the score is constant. There was no difference in the -2 log likelihood. 
5) Shrinkage of predictor weights or regression coefficients (e.g. no shrinkage, uniform Shrinkage, 
penalized estimation) 
 5) Shrinkage refers to adjusting coefficients to protect against overfitting and loss of discrimination in 
validation studies. Weightings were assigned to the PEARL score. 
Model performance 
1) Calibration (calibration plot, calibration slope, Hosmer-Lemeshow test) and Discrimination (C-
statistic, D-statistic, log rank) measures with confidence intervals 
 Hosmer-Lemeshow test provided. Actual and observed risks are shown in a calibration plot, and 
observed risk across all cohorts shown in table 4. Discrimination was calculated with AUROC curves 
(and confidence intervals provided). 
2) Classification measures (e.g. sensitivity, specificity, predictive values, net reclassification 
improvement) and whether a priori cut points were used  
 Sensitivity and specificity are provided, with PEARL scores used as cut-offs. Reclassification measures, 
such as net reclassification improvement, look at the value in adding a single predictor to a prediction 
model. No reclassification measures were performed. 
Model evaluation 
1) Methods used for testing model performance: development dataset only (random split of data, 
resampling methods, e.g. bootstrap or cross-validation, none) separate external validation (e.g. 
temporal, geographical, different setting, different investigators) 
 Internal validation involved the same hospitals as the derivation cohort, but at a different time period 
(a form of temporal validation). Geographical validation (external validation) was performed with four 
hospitals. Hospitals were chosen for their differences, as described in the paper, to maximise 
generalisability. The research staff within external sites were not involved in the derivation or internal 
validation cohorts. 
2) In case of poor validation, whether model was adjusted or updated (e.g. intercept recalibrated, 
predictor effects adjusted, or new predictors added) 
 Not applicable 
Results 
1) Final and other multivariable models (e.g. basic, extended, simplified) presented, including 
predictor weights or regression coefficients, intercept, baseline survival, model performance 
measures (with standard or confidence Intervals)  
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2) Any alternative presentation of the prediction models. e.g. sum score, nomogram, score chart, 
predictions for specific risk subgroups with performance 
3) Comparison of the distribution of predictors (including missing data) for development and 
validation datasets  
 1+2+3) Predictor weights and regression coefficients are given for the PEARL score. All models have 
AUROC calculated with confidence intervals. No subgroup analysis performed. Missing data rates for 
both all three cohorts was low.  
 
Interpretation and discussion 
1) Interpretation of presented models (confirmatory, if model useful for practice versus exploratory, 
is more research needed) 
 The performance of PEARL is shown in three cohorts, with consistent risk stratification. Quantifying 
the impact of using PEARL requires further research. 
2) Comparison with other studies, discussion of generalisability, strengths and limitations. 
 Described in discussion 
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Appendix C: Tables, including breakdown of costs for RCT 
 
R
isk
 
Sc
or
e 
Ex
pe
ct
ed
 p
ro
ba
bi
lit
y 
de
riv
at
io
n 
co
ho
rt 
O
bs
er
ve
d 
pr
ob
ab
ili
ty
 d
er
iv
at
io
n 
co
ho
rt 
O
bs
er
ve
d 
pr
ob
ab
ili
ty
 in
te
rn
al
 
va
lid
at
io
n 
co
ho
rt 
O
bs
er
ve
d 
pr
ob
ab
ili
ty
 e
xt
er
na
l 
va
lid
at
io
n 
co
ho
rt 
P 
va
lu
e 
R
ea
dm
is
sio
n 
or
 d
ea
th
 w
ith
in
 9
0 
da
ys
 
D
ea
th
 a
lo
ne
 w
ith
in
 9
0 
da
ys
 
R
ea
dm
is
sio
n 
al
on
e 
w
ith
in
 9
0 
da
ys
 
R
ea
dm
is
sio
n 
or
 d
ea
th
 w
ith
in
 3
0 
da
ys
 
To
ta
l (
al
l p
at
ie
nt
s)
 
Lo
w
 0 
n  25 / 166 17 / 97 12 / 80 0.84 54 7 50 32 343 
% 15.0 15.1 17.5 15.0  15.7 2.0 14.6 9.3  
1 
n  49 / 208 47 / 193 34 / 146 0.98 130 15 125 69 547 
% 25.1 23.6 24.4 23.3  23.8 2.7 22.9 12.6  
In
te
rm
ed
ia
te
 
2 
n  48 / 142 60 / 178 56 / 142 0.51 164 46 149 93 462 
% 34.8 33.8 33.7 39.4  35.5 10.0 32.3 20.1  
3 
n  44 / 86 51 / 126 60 / 140 0.29 155 58 125 100 352 
% 47.5 51.2 40.5 42.9  44.0 16.5 35.5 28.4  
4 
n  55 / 93 35 / 77 45 / 94 0.16 135 33 120 69 264 
% 56.6 59.1 45.5 47.9  51.1 12.5 45.5 26.1  
 
5 
n  43 / 66 40 / 63 55 / 95 0.62 138 24 127 79 224 
H
ig
h 
ris
k 
% 63.4 65.2 63.5 57.9  61.6 10.7 56.7 35.3  
6 
n  27 / 40 28 / 40 35 / 51 1.00 90 28 83 51 131 
% 74.8 67.5 70.0 68.6  68.7 21.4 63.4 38.9  
7 
n  13 / 18 16 / 24 24 / 33 0.90 53 14 49 31 75 
% 83.7 72.2 66.7 72.7  70.7 18.7 65.3 41.3  
8 
n  4 / 4 1 / 2 6 / 7 0.37 11 6 10 6 13 
% 90.2 100 50 85.7  84.6 46.2 76.9 46.2  
9 
n  1 / 1 2 / 2 3 / 3 N/A 6 3 6 5 6 
% 93.9 100 100 100  100 50 100 83.3  
Total  309 / 824 297 / 802 330 / 791 0.11 936 234 844 535 2417 
% 37.5 37.5 37.0 41.7  38.7 9.7 34.9 22.1  
P value compares the three observed proportions by Fishers test (the comparison of expected to observed probabilities is shown separately 
by the Hosmer-Lemeshow statistic and the calibration curve). 
Table 10.1: Online supplemental table showing observed probabilities for all cohorts, and outcome at 
30 and 90 days 
“Expected probability” refers to the predicted risk of 90-day readmission or death calculated from the 
full regression model, and the “observed probability” is the measured outcome rate for each PEARL 
score in the each cohort. 
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Table 10.2: 30 day readmission or death, AUROC curves, for updated ADO score, eMRCD and 
DECAF 
 HAH, £ UC, £ 
Bed stay 385.3 1040.1 
Inpatient healthcare review 186.8 266.1 
Diagnostic tests 69.4 101.3 
Laboratory tests 67.4 70.0 
NIV costs 9.87 73.2 
Table 10.3: Costs associated with the index admission 
 HAH n=60 UC n=58 
Length of hospital stay at 90 days, n (IQR) 1 (1-7) 5 (2-12) 
Length of hospital stay (index admission), n (IQR) 1 (1-1) 3 (2- 4.25) 
Length of stay within HAH, n (IQR) 4 (IQR 2-5) N/A 
Patients with one or more hospital readmission, n 22 23 
Patients readmitted requiring ITU, n 0 0 
Patients readmitted requiring NIV, n 2 6 
Patients with one or more A+E attendances post discharge, n  29 26 
Patients with one or more GP attendance post discharge, n 26 30 
Patients with one or more secondary care appointment, n 48 41 
Patients with a social care package post discharge, n 7 5 
Table 10.4: Length of stay, readmission, appointment and social care data. 
 
 Prognostic score Derivation 
Internal 
validation 
External 
validation 
 
30
 d
ay
 re
ad
m
is
sio
n 
or
 
de
at
h 
PEARL score 0.70 (0.66-0.74) 
0.64 
(0.60-0.69) 
0.64 
(0.60-0.69) 
 
ADO 
(updated) 
0.62 
(0.57-0.67) 
0.60 
(0.55-0.64) 
0.56 
(0.51-0.60) 
 
eMRCD score 0.64 (0.59-0.68) 
0.60 
(0.55-0.64) 
0.57 
(0.53-0.62) 
 
DECAF score 0.57 
(0.53-0.62) 
0.59 
(0.54-0.64) 
0.54 
(0.49-0.59) 
 
90
 d
ay
 re
ad
m
is
sio
n 
or
 
de
at
h 
PEARL score 
0.73 
(0.70-0.77) 
0.68 
(0.64-0.72) 
0.70 
(0.66-0.73) 
 
ADO (updated) 0.65 (0.61-0.69) 
0.63 
(0.59-0.66) 
0.58 
(0.54-0.62) 
 
eMRCD score 0.68 (0.65-0.72) 
0.61 
(0.57-0.65) 
0.61 
(0.57-0.65) 
 
DECAF score 0.59 (0.55-0.63) 
0.57 
(0.53-0.61) 
0.57 
(0.53-0.61) 
 
PEARL AUROC (95% CI) are superior to all the above scores (p<0.05) by method of 
DeLong. 
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7.2 Costs used in the study 
This section continues from section 7.2 in chapter 7. 
7.2.1 Medication 
The British National Formulary was the source used to calculate the unit cost for 
individual medication doses (Table 10.5). This was multiplied by the number of 
administrations of each medication over the 90 day period. For inpatient care and 
Hospital at Home care, all individual doses were recorded on a hospital kardex. It 
was assumed that all patients received 14 days of their usual medication at 
discharge from UC or HAH. Long-term medication were cross-referenced with the 
GP. Out-of-hospital medication were costed on the assumption that the patient took 
their medication without missing doses (if a patient receives a medication but does 
not take it, the cost remains). There were 358 unique formulations of medication 
taken by patients in the study. 
Type of medication 
Cost 
(£) Type of medication 
Cost 
(£) Type of medication 
Cost 
(£) 
Acamprosate Ca E.C. 333mg 0.171 Epilim Chrono MR 500mg 0.291 Olanzapine 2.5mg 0.031 
Accrete D3 0.049 Eprosartan 600mg 0.499 Omeprazole 10mg 0.277 
Acetylctsteine nebulisers 2.126 Ertapenem 1g iv 31.65 Omeprazole 20mg 0.232 
Aciclovir 200mg 0.065 Erythromycin 250mg 0.182 Omeprazole 40mg iv 1.294 
Aciclovir 800mg 0.108 Escitalopram 20mg 0.057 Oromorph/oral morphine 10mg/5ml 0.018 
Aclidinium bromide 0.477 Esomeprazole 20mg 0.121 Oxybutynin 5mg 0.038 
Acitretin 10mg 0.397 Esomeprazole 40mg 0.141 Pantoprazole 40mg 0.048 
Adcal D3 400/1.5g 0.026 Etanercept injection 50mg/ml 89.38 
Paracetamol dispersible 
500mg 0.076 
Alendronic acid 70mg 0.230 Felodipine MR 10mg 0.202 Paracetamol iv 1gm 1.133 
Alfentanil 500mcg/ml 0.634 Ferrous fumarate 210mg 0.033 Paracetamol oral 0.026 
Allopurinol 100mg 0.031 Ferrous sulphate 200mg 0.063 Paracetamol suspension 250mg/5ml 0.010 
Amiloride 5mg 0.240 Fexofenadine 120mg 0.105 Paroxetine 20mg 0.066 
Aminophylline iv 
250mg/10ml 0.650 Finasteride 5mg 0.049 Paroxetine 30mg 0.060 
Aminophylline MR 225mg 0.043 Fluconazole 150mg 0.890 Peptac 0.004 
Amitriptyline 10mg 0.030 Fluconazole 50mg 0.126 Perindopril 2 mg 0.038 
Amitriptyline 25mg 0.031 Fluoxetine 20mg 0.033 Perindopril 4mg 0.046 
Amitriptyline 50mg 0.037 Fluoxetine 60mg 0.479 Phenoxymethylpenicillin 250mg 0.039 
Amlodipine 10mg 0.031 Folic Acid 0.032 Phosphate enema(standard) 0.031 
Amlodipine 5mg 0.029 Fondaparinux 5mg/ml 6.279 Phyllocontin 225mg 0.043 
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Amoxicillin 1g iv 1.096 Fortisip 1.400 Piroxicam 20mg 0.129 
Amoxicillin 250mg 0.057 Fortisip compact drink 2.020 Pramipexole 180mcg 0.041 
Amoxicillin 500mg 0.068 Furosemide iv 50mg 0.660 Pravastatin 40mg 0.057 
Amoxicillin 500mg iv 0.548 Furosemide 20mg 0.029 Prednisolone 5mg 0.035 
Amoxicillin suspension 
250mg/5ml 0.012 Furosemide 40mg 0.028 Prednisolone 5mg soluble 1.783 
Anusol ointment 0.083 Furosemide iv 20mg/2mls 0.350 Prednisolone Gastro-res 5mg 0.051 
Aqueous cream 0.010 Gabapentin 100mg 0.025 Pregabalin 100mg 1.150 
Arachis oil enema 37.50 Gabapentin 300mg 0.034 Pregabalin 200mg 1.150 
Aspirin 300mg 0.105 Gaviscon susp 0.014 Pregabalin 300mg 1.150 
Aspirin 75mg 0.035 Gentamicin iv 80mg/2ml 1.000 Pregabalin 75mg 1.150 
Aspirin dispersible 75mg 0.027 Gliclazide 40mg 0.120 Pro-cal shots 30ml 0.024 
Aspirin EC 75mg 0.030 Gliclazide 80mg 0.035 Procyclidine 0.127 
Atenolol 25mg 0.028 Glycopyrronium inhaler 44mcg 0.917 Prostap 3 DCS 225.7 
Atenolol 50mg 0.028 Goserelin implant 10.8mg 235.0 Pulmicort turbohaler 400 0.277 
Atorvastatin 10mg 0.037 GTN 5mg iv 14.76 Quetiapine 150mg 0.043 
Atorvastatin 20mg 0.043 GTN spray 400mcg 0.017 Quinine Sulphate 200mg 0.067 
Atorvastatin 40mg 0.050 Hydrocortisone 100mg iv 0.917 Quinine Sulphate 300mg 0.075 
Atorvastatin 80mg 0.086 Hydromol cream 0.044 Ramipril 1.25mg 0.038 
Aveeno cream 1% 0.040 Hydromol ointment 0.023 Ramipril 10mg 0.043 
Azithromycin 250mg 0.385 Hydroxocobalamin 1mg/ml 2.182 Ramipril 2.5mg 0.037 
Beclometasone nasal spray 
50mcg 0.011 
Hydroxychloroquine 
200mg 0.081 Ramipril 5mg 0.036 
Bendroflumethiazide 2.5mg 0.026 Hyoscine hydrobromide s/c 400mcg 3.775 Ranitidine 150mg 0.022 
Betnovate cream 0.1% 0.132 Hypotonic saline neb 3 or 6% 0.649 Risedronate 35mg 0.248 
Biotene oral gel 0.089 Hypromellose eye drops 0.3% 0.109 Rivaroxaban 15mg 1.800 
Bisacodyl 5mg 0.035 Ibuprofen 400mg 0.043 Rivaroxaban 20mg 1.800 
Bisoprolol 1.25mg 0.037 Ibuprofen Gel 10% 0.049 Ropinirole 500mcg 0.074 
Bisoprolol 10mg 0.031 Ibuprofen gel 5% 0.046 Salbutamol evohaler 100mcg 0.008 
Bisoprolol 2.5mg 0.034 Imipramine 25mg 0.041 Salbutamol nebules 2.5mg 0.096 
Bisoprolol 5mg 0.030 Indapamide 2.5mg 0.051 Salbutamol nebules 5mg 0.191 
Budesonide formoterol 
inhaler 0.275 Instillagel 10ml 0.234 Saline nebs 2.5ml 0.675 
Bumetanide 1mg 0.043 Ipratropium nebs 500 mcg 0.144 Sando K 0.077 
Calcichew D3 0.077 Isosorbide mononitrate 10mg 0.038 Sando phosphate 0.164 
Calcichew/calcium carbonate 0.093 Isosorbide mononitrate 20mg 0.032 Senna 7.5mg 0.058 
CalcichewD3 Forte 0.071 Isosorbide mononitrate 40mg 0.043 Seretide evohaler 125 0.292 
Calcipotriol Ointment 0.193 Isosorbide mononitrate MR 60mg 0.375 Seretide accuhaler 100 0.300 
Calcium and ergocalciferol 0.545 Ivabradine 7.5mg 0.717 Seretide accuhaler 250 0.583 
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Calogen 0.021 K CEE L syrup 0.015 Seretide accuhaler 500 0.682 
Candesartan 16mg 0.051 Lacri-lube ointment 0.840 Seretide evohaler 250 0.496 
Candesartan 2mg 0.163 Lactulose solution 0.005 Sertraline 50mg 0.056 
Carbamazepine M.R.200mg 0.093 Lansoprazole 15mg 0.037 Simple linctus 0.004 
Carbocisteine 375mg 0.108 Lansoprazole 30mg 0.046 Simvastatin 20mg 0.030 
Carbocisteine liquid 250/5ml 0.028 Latanoprost eye drops 50mcg/ml 0.700 Simvastatin 40mg 0.034 
Celluvisc 1% eye drops 0.100 Laxido 0.142 Slow K 600mg 0.043 
Cetirizine 10mg 0.032 Lercanidipine 10mg 0.053 Sodium chloride flush 5 mls 0.211 
Chlorhexidine Gluconate 
0.2% mouthwash 0.012 Lercanidipine 20mg 0.058 Sodium valproate MR 500mg 0.202 
Chlorpheniramine 4 mg 0.030 Levofloxacin 500mg 1.832 Solifenacin 5mg 0.921 
Ciprofibrate 100mg 3.954 Levothyroxine 100mcg 0.066 Spironalactone 100mg 0.081 
Ciprofloxacin 500mg 0.099 Levothyroxine 25mcg 0.096 Sulphasalazine suspension 250mg/5ml 0.085 
Ciprofloxacin 750mg 0.800 Levothyroxine 50mcg 0.066 Symbicort 200/6 0.317 
Citalopram 10mg 0.030 Lidocaine 5% patch 2.413 Symbicort 400/12 0.633 
Citalopram 20mg 0.033 Lisinopril 2.5mg 0.029 Tamiflu 75mg 1.541 
Citalopram 40mg 0.037 Lisinopril 20mg 0.034 Tamsulosin MR 400mcg 0.349 
Clarithromycin 500mg 0.194 Lisinopril 5mg 0.030 Tazocin iv 4.5g 12.90 
Clarithromycin 500mg iv 9.450 Loperamide oral solution 1mg/5ml 0.012 Teicoplanin 200 iv 0.140 
Clarithromycin suspension 
250mg/5ml 0.068 Loratidine 10mg 0.032 Temazepam 10mg 0.209 
Clenil Modulite 100mcg 0.037 Lorazepam 1mg 0.084 Temazepam Elixir 10mg/5ml 0.354 
Clopidogrel 300mg 0.233 Losartan 100mg 0.042 Terbinafine 250mg 0.102 
Clopidogrel 75mg 0.058 Losartan 25mg 0.034 Terbutaline turbohaler 0.069 
Clotrimazole 1% cream 0.058 Losartan 50mg 0.035 Theophylline M/R 300mg 0.085 
Co-amoxiclav suspen sugar 
free 250mg/5ml 0.750 
Magnesium Aspartate 
sachets 243mg 0.895 Theophylline M/R 400mg 0.101 
Co-amoxiclav 625mg 0.136 Magnesium Sulphate 2 mmol/ml 5.834 Theophylline M/R 200mg 0.053 
Co-amoxiclav iv 1.2g 1.060 Meropenem 1g iv 15.35 Thiamine 100mg 0.116 
Co-amilofruse 2.5/20mg 0.107 Mesalazine SR 1g 0.615 Ticagrelor 90mg 0.975 
Co-amilofruse 5/40mg 0.105 Metformin 1g MR 0.152 Tigecycline iv 50mg 32.31 
Co-careldopa 25mg/100mg 0.157 Metformin 500mg 0.045 Tinzaparin 23,000u (40,000u vial) 34.20 
Co-codamol 8mg/500mg 0.034 Metoclopromide 10mg 0.030 Tinzaparin 10,000u 5.950 
Codeine 15mg 0.037 Metoclopromide iv 10mg 0.323 Tinzaparin 11,000u (12000u syringe) 7.140 
Codeine 30 0.043 Metoprolol 50mg 0.063 Tinzaparin 12,000u 7.140 
Codeine linctus 15mg/5ml 0.009 Metronidazole 400mg 0.065 Tinzaparin 18,000u 10.71 
Co-dydramol 30mg/500mg 0.122 Metronidazole 500mg iv 3.100 Tinzaparin 2,500u 1.980 
Colecalciferol 20,000u 0.967 Miconazole oral gel 0.055 Tinzaparin 3,500u 2.771 
Colecalciferol 800 u (Fultium) 0.120 Micralax enema 0.406 Tinzaparin 4,500u 3.563 
Colomycin neb 5.600 Midazolam s/c 5mg/5mls 0.600 Tinzaparin 8,000u 4.760 
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Colpermin capsules 0.122 Mirtazapine 15mg 0.050 Tiotropium (respimat) 2.5mcg 0.542 
Combivent nebs 0.397 Mirtazapine 30mg 0.049 Tiotropium 18mcg 1.117 
Co-trimoxazole 960mg 0.235 Mirtazapine 45mg 0.062 Tirofiban 250 mcg/ml iv 146.1 
Creon 10,000 0.129 Mometasone nasal spray 0.017 Tizanidine 4mg 0.233 
Creon 40,000 0.418 Monomil XL 60mg 0.375 Tolterodine 2mg 0.045 
Cyclizine iv 1.730 Montelukast 10mg 0.063 Tramadol 50mg 0.033 
Cyclizine oral 0.093 Morphine iv 10mg 0.936 Trimethoprim 100mg 0.033 
Dexamethasone 2mg 0.982 Morphine Sulphate 30mg 0.208 Trimethoprim 200mg 0.215 
Diazepam 2mg 0.031 Morphine sulphate M.R. 10mg 0.087 Trospium 20mg 0.317 
Diclofenac Gel 1.16% 0.056 Morphine sulphate M.R. 60mg 0.405 Ultibro Breezhaler 1.083 
Difflam mouthwash 0.022 Moxonidine 200mcg 0.061 Uniphyllin MR 200mg 0.053 
Dihydrocodeine 30mg 0.048 Mupirocin ointment 1.297 Uniphyllin MR 400mg 0.101 
Diltiazem M/R 180mg 0.237 Naseptin nasal cream 0.149 Varenciline 1mg 0.975 
Diltiazem M/R 240mg 0.411 Nefopam 0.406 Venlafaxin 75mg 0.047 
Diltiazem MR 120mg 0.185 Nicorandil 10mg 0.048 Verapamil 40mg 0.024 
Diltiazem MR 90mg 0.130 Nicorandil 20mg 0.097 Viscotears 0.260 
Docusate sodium 100 mg 0.070 Nicotine inhalater 15mg 0.756 Vitamin B Co 0.062 
Dosulepin 75mg 0.056 Nicotine Gum 4mg 0.107 Warfarin 1mg 0.030 
Doxycycline 100mg 0.121 Nicotine patch 14mg 1.343 Warfarin 3mg 0.032 
Duoresp 160/4.5 0.250 Nicotine patch 21mg 1.424 Warfarin 5mg 0.033 
Duoresp 320/9 0.500 Nicotine patch 7mg 1.303 Water for injections 2ml 0.275 
Enalapril 20mg 0.056 Nicotine patch 25mg 1.481 Zomorph 10mg 0.058 
Enalapril 10mg 0.039 Nifedipine MR 40mg 0.480 Zomorph 30mg 0.138 
Ensure 0.009 Nifedipine SR 30mg 0.245 Zomorph 60 mg 0.270 
Ensure compact 2.988 Nitrofurantoin 50mg 0.334 Zopiclone 3.75mg 0.050 
Ensure plus juice 0.009 Nystatin suspension 100,000 units/ml 0.079 Zopiclone 7.5mg 0.048 
Ensure plus milk 0.006 Octenison wash 0.005   
Epilim Chrono MR 300mg 0.175 Olanzapine 10mg 0.094   
Table 10.5: Unit costs of medication per dose 
7.2.2 Accident and Emergency attendances 
These were costed from the NHS Reference Costs (2015) (Department of Health 
2015), as shown in Table 10.6.1 An alert was sent to the research team when a 
patient attended accident and emergency. To ensure no episodes were missed, 
patients were asked to keep a record of their attendances (in case they attended 
accident and emergency in a different healthcare trust) and all electronic records 
were reviewed after the follow up period. 
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Type of attendance Cost (£)* Source 
A+E attendance VB01Z 377.9 NHS reference cost 2015. EM type 1.  Service code VB01Z. 
A+E attendance VB02Z 347.5 NHS reference cost 2015. EM type 1.  Service code VB02Z. 
A+E attendance VB03Z 252.3 NHS reference cost 2015. EM type 1.  Service code VB03Z. 
A+E attendance VB04Z 227.0 NHS reference cost 2015. EM type 1.  Service code VB04Z. 
A+E attendance VB05Z 189.5 NHS reference cost 2015. EM type 1.  Service code VB05Z. 
A+E attendance VB06Z 133.7 NHS reference cost 2015. EM type 1.  Service code VB06Z. 
A+E attendance VB07Z 164.1 NHS reference cost 2015. EM type 1.  Service code VB07Z. 
A+E attendance VB08Z 153.0 NHS reference cost 2015. EM type 1.  Service code VB08Z. 
A+E attendance VB09Z 108.4 NHS reference cost 2015. EM type 1.  Service code VB09Z. 
A+E attendance VB10Z 112.5 NHS reference cost 2015. EM type 1.  Service code VB10Z. 
A+E attendance VB11Z 90.2 NHS reference cost 2015. EM type 1.  Service code VB11Z. 
*Costs inflated for 2015-16 prices 
Table 10.6: Accident and emergency attendances 
7.2.3 Primary and secondary care outpatient attendances 
Type of attendance Cost (£)* Source 
Anaesthetic clinic, consultant 109.4 NHS reference cost 2015. Service code 190 consultant. 
Anaesthetic clinic, nurse 87.9 NHS reference cost 2015. Service code 190 non consultant. 
Cardiology clinic, consultant 142.4 NHS reference cost 2015. Service code 320 consultant. 
Clinical psychology 195.4 NHS reference cost 2015. Service code 656 non consultant. 
Dietetics clinic 71.2 NHS reference cost 2015. Service code 654 non consultant. 
Endocrine clinic, consultant 158.2 NHS reference cost 2015. Service code 302 consultant. 
ENT clinic, nurse 72.7 NHS reference cost 2015. Service code 120 non consultant. 
Gastroenterology clinic, consultant 141.7 NHS reference cost 2015. Service code 301 consultant. 
General surgery clinic, consultant 140.5 NHS reference cost 2015. Service code 100 consultant. 
GP attendance 44.6 Curtis 2015, 11.7m patient contact. 
GP attendance, bloods by nurse 11.2 Curtis 2015, 15.5m patient contact. 
GP attendance, practice nurse review 11.2 Curtis 2015, 15.5m patient contact. 
Haematology clinic, consultant 164.2 NHS reference cost 2015. Service code 303 consultant. 
Haematology ward attendance 347.5 NHS reference cost 2015. Service code DCRDN, band 2. 
Maxillo-Facial surgery clinic, consultant 115.4 NHS reference cost 2015. Service code 144 consultant. 
Neurosurgery clinic, consultant 215.4 NHS reference cost 2015. Service code 150 consultant. 
Oncology clinic, consultant 173.1 NHS reference cost 2015. Service code 370 consultant. 
Ophthalmology clinic, technician 64.8 NHS reference cost 2015. Service code 130 non consultant. 
Ophthalmology clinic, consultant 97.4 NHS reference cost 2015. Service code 130 consultant. 
Orthopaedic clinic, consultant 116.3 NHS reference cost 2015. Service code 110 consultant. 
Orthopaedic clinic, nurse 93.7 NHS reference cost 2015. Service code 110 non consultant. 
Physiotherapy rehabilitation session 39.2 NHS reference cost 2015. Service code 342 non consultant. 
Plastic surgery clinic, consultant 95.6 NHS reference cost 2015. Service code 160 consultant. 
Podiatry clinic, podiatrist 39.7 NHS reference cost 2015. Service code 653 non consultant. 
Respiratory clinic, consultant 165.9 NHS reference cost 2015. Service code 340 consultant. 
Respiratory clinic, nurse 120.4 NHS reference cost 2015. Service code 340 non consultant. 
Respiratory clinic, nurse 120.4 NHS reference cost 2015. Service code 340 non consultant. 
Respiratory clinic, oxygen nurse 120.4 NHS reference cost 2015. Service code 340 non consultant. 
Urology clinic, consultant 103.5 NHS reference cost 2015. Service code 101 consultant. 
Urology clinic, nurse 78.0 NHS reference cost 2015. Service code 101 non consultant. 
*Costs inflated for 2015-16 prices 
Table 10.7: Cost of attendances 
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These were mostly costed from the NHS Reference Costs (2015) (Department of 
Health 2015) and are shown in Table 10.7. 
Patients kept a record of outpatient attendances (including attendances at external 
healthcare trusts), and this was cross-referenced with electronic medical records. If a 
patient cancelled a clinic attendance, no cost was allocated. If a patient did not attend 
their appointment without informing clinic, the cost was allocated. 
7.2.4 Diagnostic tests 
These were mostly costed from the NHS Reference Costs (2015) (Department of 
Health 2015) and are shown in Table 10.8. Tests were recorded from medical 
electronic records (covering primary and secondary care), and cross referenced with 
records maintained by patients. 
Type of test Cost (£)* Source 
24 hour tape 155.0 NHS reference cost 2015.  Currency code EY51Z 
CT one area, post 
contrast 173.3 NHS reference cost 2015.  Currency code RD21A 
CT scan pelvis 114.5 NHS reference cost 2015.  Currency code RD23Z 2 areas without contrast 
CT two areas, with 
contrast 156.0 NHS reference cost 2015.  Currency code RD24Z 2 areas with contrast 
DEXA bone scan 59.8 NHS reference cost 2015.  Currency code RD50Z 
Diagnostic endoscopic 
upper GI tract 510.7 NHS reference cost 2015.  Currency code FZ60Z 
ECG 18.4 
Galasko GI, Barnes SC, Collinson P, et al. What is the most cost-effective strategy to 
screen for left ventricular systolic dysfunction: natriuretic peptides, the 
electrocardiogram, hand-held echocardiography, traditional echocardiography, or 
their combination? European heart journal. 2006 Jan;27(2):193-200. 
Echocardiogram 65.9 NHS reference cost 2015.  Currency code RD51A 
Lower endoscopy 373.9 NHS reference cost 2015.  Currency code FZ51Z 
MRCP liver 138.8 NHS reference cost 2015.  Currency code RD01A outpatient 
MRI one area, no 
contrast 127.7 NHS reference cost 2015.  Currency code RD01A MRI one area no contrast 
MRI one area, post 
contrast only 431.6 NHS reference cost 2015.  Currency code RD02A MRI one area post contrast 
Plain film x-ray 30.4 NHS reference cost 2015.  Currency code DAPF. 
Sleep study 212.8 NHS reference cost 2015.  Currency code DZ50Z 
Spirometry 54.7 52 for 2012 secondary care from "HTA report 2015" (for multiplier look in PRSSU). Adjusted 2014/15 
Tilt room test 142.9 
Krahn AD, Klein GJ, Yee R, et al. Cost implications of testing strategy in patients with 
syncope: randomized assessment of syncope trial. J Am Coll Cardiol. 2003 Aug 
6;42(3):495-501. PubMed PMID: 12906979. 
Ultrasound 64.8 NHS reference cost 2015.  Currency code RD40Z less than 20 minutes 
*Costs inflated for 2015-16 prices 
Table 10.8: Cost of diagnostic tests 
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7.2.5 Laboratory tests 
Individual laboratory tests, including add-on costs, were provided by Northumbria 
Healthcare NHS trust and are shown in Table 10.9. 
Laboratory test name Cost Laboratory test name Cost Laboratory test name Cost 
ABG (arterial blood gas) 6.56 GGT 0.53 PTH 7.86 
Albumin 0.47 HbA1c 1.49 Random urine protein 1.33 
Alpha-1-Antitrysin 8.79 HEP B surface 9.12 Retics 3.9 
Amylase 0.85 HIB Antibody 16.39 Rheumatoid factor 1.86 
Antigens (urine) 42.7 Immunoglobulins 4.65 Routine faeces 19.99 
Blood bank 7.23 INR 4.53 Serum immunofixation 31.12 
Blood cultures 14.7 Intrinsic factor 10.41 Sputum culture 7.59 
Blood film 3.39 Lactate 1.13 T3 2.44 
Blood glucose 0.51 LFTs 2.44 T4 2.11 
blood ketones 6.31 Lipids 0.41 TB culture 27.74 
Bone profile 1.48 Magnesium 0.54 Theophylline 23.28 
Calcium 0.52 Mixing studies APTT 4.59 Total CK 1.01 
Cholesterol 0.51 MRSA rejected sample 5.93 TRF saturation 1.23 
Coagulation screening 7.46 MRSA screen 7.66 Troponin T (HS) 4.73 
CRP 0.73 Mycoplasma 10.62 TSH 1.95 
D-Dimer 19.06 NT pro BNP 19.33 Unsuitable sample 6 
EGFR 0.47 Osmolality 3.84 Urate 0.8 
ESR 3.86 Paraprotein screen 3.44 Urea and electrolytes 2.58 
FBC 3.9 Phosphate 0.51 Urine immunofixation 31.12 
Ferritin 4.51 Point of care FBC 21.46 Urine Microscopy and culture 6.58 
Flu assay (PCR) 57.92 Procalcitonin 17.62 Vitamin B12 4.82 
Folate 4.55 Prolactin 3.49 Vitamin D 9.86 
Gastric parietal cell antibody 9.75 Prostate specific antigen 2.82   
Table 10.9: Cost of laboratory tests 
7.2.6 Health care staff 
The Personal Social Services Research Unit’s Unit Costs of Health and Social Care 
2015 cost compendium was used to allocated most costs, and are shown in Table 
10.10. All contacts included add on costs and qualifications. 
We had recorded start and end times for 105 medical clerkings, which averaged 0.75 
hours for a non-consultant and 0.33 for a consultant. These averages were used in 
instances in which no end time was stated. Inpatient reviews were assumed to be 15 
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minutes in duration, unless otherwise documented, again based on average review 
times. The duration of reviews during the Hospital at Home period was recorded for 
all visits, which included travel time and time spent with the patient. 
Type of healthcare worker Cost (£)* Source 
Community psychiatric nurse 20.1 PSSRU Unit costs of health and social care 2015 
Dietician band 5 39.2 PSSRU Unit costs of health and social care 2015 
Dietician band 6 44.5 PSSRU Unit costs of health and social care 2015 
Dietician home visit 11.0 PSSRU Unit costs of health and social care 2015, 15m 
District nurse home visit 12.5 PSSRU Unit costs of health and social care 2015, 15m 
Doctor consultant 153.0 PSSRU Unit costs of health and social care 2015 
Doctor F1 42.5 PSSRU Unit costs of health and social care 2015 
Doctor F2 50.1 PSSRU Unit costs of health and social care 2015 
Doctor ST1 64.7 PSSRU Unit costs of health and social care 2015 
Doctor ST2 67.0 PSSRU Unit costs of health and social care 2015 
Doctor registrar ST3 68.4 PSSRU Unit costs of health and social care 2015 
Doctor registrar ST4 70.0 PSSRU Unit costs of health and social care 2015 
Doctor registrar ST5 71.7 PSSRU Unit costs of health and social care 2015 
Doctor registrar ST6 73.3 PSSRU Unit costs of health and social care 2015 
Doctor registrar ST7 75.0 PSSRU Unit costs of health and social care 2015 
GP doctor home visit 43.4 PSSRU Unit costs of health and social care 2015 
GP doctor phone call 27.1 PSSRU Unit costs of health and social care 2015 
GP nurse home visit 11.1 PSSRU Unit costs of health and social care 2015 
NHS 111 8.0 Department of health, NHS 111 
Occupational therapist 39.2 PSSRU Unit costs of health and social care 2015 
Occupational therapist home visit 22.1 PSSRU Unit costs of health and social care 2015, 30m 
Pharmacist, band 6 50.2 PSSRU Unit costs of health and social care 2015 
Physio home visit, band 6 11.1 PSSRU Unit costs of health and social care 2015 
Physiotherapist band 5 39.2 PSSRU Unit costs of health and social care 2015 
Physiotherapist band 6 44.5 PSSRU Unit costs of health and social care 2015 
Physiotherapist band 7 49.5 PSSRU Unit costs of health and social care 2015 
Psychology 52.2 PSSRU Unit costs of health and social care 2015 
Rapid response team 51.2 PSSRU Unit costs of health and social care 2015 
Respiratory Specialist Nurse Band 6 46.2 PSSRU Unit costs of health and social care 2015 
Respiratory Specialist Nurse Band 7 60.2 PSSRU Unit costs of health and social care 2015 
Respiratory Specialist Nurse Band 8a 68.6 PSSRU Unit costs of health and social care 2015 
Respiratory Specialist Nurse home visit 46.2 PSSRU Unit costs of health and social care 2015 
Social worker 57.2 PSSRU Unit costs of health and social care 2015 
Speech and language therapist, band 5 38.1 PSSRU Unit costs of health and social care 2015 
Support worker, band 2 24.1 PSSRU Unit costs of health and social care 2015 
Table 10.10: Cost of contact with healthcare staff 
The PSSRU unit of costs does not provide the hourly rate for registrars of different 
grade, but provides information on calculating costs. The actual salaries for doctors 
of all grades was calculated by obtaining basic salaries, adding a 50% banding 
supplement and adjusting for a 48 hour week. The salary on-costs were changed 
accordingly based on the actual salary.  
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For the Respiratory Specialist Nurses the average cost of the band 6, 7 and 8a 
nurses was calculated (several new appointments were made over the time course of 
the study, so most band 6 nurses were at the low end of the band 6 pay scale, whilst 
band 7 and 8a nurses were at the top end). The salary on-costs were changed 
accordingly based on the actual salary. 
7.2.7 Inpatient ward stay costs 
The cost of a day in hospital was micro-costed by the trust, and are shown in Table 
10.11. This included direct, indirect and overhead costs. Certain costs were removed 
to ensure they were not double counted, such as drug costs and pharmacy input. For 
the cost of a day on the medical admissions unit, an average day was obtained from 
costs over a two year period (2013-2015) and adjusted for current prices. In the 
instance that a patient spent less than a day on the unit, an hourly rate was applied. 
The cost of a rehab bed day was calculated in the same way. The cost of a day on a 
respiratory ward was calculated from two difference respiratory wards over a two 
year period (2013-2015) to give an average bed day cost. 
Ward stay type of cost per bed day Cost (£) Source 
Medical admissions unit 294.9 Micro-costed by healthcare trust 
Medical ward 246.2 Micro-costed by healthcare trust 
Rehabilitation ward 168.8 Micro-costed by healthcare trust 
Table 10.11: Ward costs 
7.2.8 Other inpatient stays/ procedures 
Some patients had inhospital stays at other healthcare trusts. The cost of the episode 
was obtained from the provider and/ or a tariff cost was used, as shown in Table 
10.12. 
Reason for admission Cost (£) Source 
Intermediate hip procedure for trauma 7452.3 NHS reference cost 2015.  Currency code HT14A. 
Osteonecrosis  2383.0 Cost of admission provided by external healthcare trust 
Myocardial infarction with percutaneous 
intervention 4613.0 Cost of admission provided by external healthcare trust 
Myocardial infarction with percutaneous 
intervention, short stay 2554.0 Cost of admission provided by external healthcare trust 
Urinary retention 1881.0 Cost of admission provided by external healthcare trust 
Crohn's disease 2763.5 NHS reference cost 2015.  Currency code FZ37K X1.0132 
Minor hip procedure for trauma 2517.5 NHS reference cost 2015. HT15Z. X1.0132 
Surgical tooth removal 462.0 Cost of admission provided by external healthcare trust 
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Table 10.12: Cost of other inpatient stays/ procedures 
7.2.9 Oxygen therapy  
Patients who received oxygen therapy either already had long term oxygen therapy 
in place or were given a hospital oxygen concentrator to avoid delays in returning 
home. The cost of LTOT therapy is £2.29 per day, adjusted to current prices.273 The 
cost of the hospital oxygen concentrator is £0.57 per day (Airsep Visionaire = £900, 
plus five-year warranty and maintenance = £140). The Respiratory Specialist Nurse 
delivered and set up the oxygen and provided education, which was captured 
separately within the patient visit time. We had concerns that using the cost £0.57 
was too conservative, therefore we used a daily cost of oxygen at £2.29 per day for 
everyone. The additional cost of running a home oxygen assessment and review 
services were captured elsewhere. 
7.2.10 Non-invasive ventilation 
The cost of non-invasive ventilation was calculated based on the cost of a machine 
over a five year period, and the costs of other equipment. NIV is provided on a 
respiratory support unit with higher staffing costs, and 1.5 hours of nursing time was 
included. Other care/ treatment over and above the average patient with AECOPD in 
terms of physiotherapy, doctors, diagnostic tests, laboratory tests (including arterial 
blood gas analysis) and medication was captured separately. 
Type of cost Unit cost (£) Cost per day (£) 
V60 Ventilator (machine, servicing, etc.) 12000 6.6 
Circuit (tubing and mask changed weekly) 50.8 7.3 
Filter (changed x2 per week) 2.7 0.8 
Nebuliser T piece 1.3 0.2 
Face shield (used one in three episodes) 77.7 3.7 
cleaning of machine- band 6, 10 mins, once per episode 8.5 2.4 
Nurse time (1.5 hours extra per patient per day) band 6 51 76.5 
Overall (includes adjustment to 2015/16)  98.7 
Table 10.13: Cost of non-invasive ventilation 
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Appendix D: Hospital at Home manual 
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Hospital at Home selected by low risk DECAF score  
  
Chronic Obstructive Pulmonary Disease (COPD) is a common lung disease 
characterised by progressive breathlessness, cough and phlegm. Acute 
exacerbations (AECOPD) are episodes, often triggered by infection, during which 
symptoms deteriorate and are the second commonest reason for hospital admission.  
Hospital at home (HAH) manages patients in their own home for a condition that 
otherwise would require inpatient care. The National Institute for Health and Care 
Excellence endorse HAH for AECOPD and highlight that selection should be based 
on prognosis, but acknowledge the (previous) lack of a suitable tool. To address this 
shortfall, we developed the DECAF score (Steer, Thorax 2012 and Echevarria, 
Thorax 2016), which accurately predicts survival in patients hospitalised with 
AECOPD. Of importance, approximately 50% of patients currently admitted to 
hospital have a low risk of death (1 - 1.4%), thus are potentially suitable for HAH. 
This is more than twice the proportion of patients included in earlier trials. Our model 
of HAH includes 24/7 clinical and social support, tailored to the individual patient’s 
needs. The range of healthcare disciplines and level of support available are greater 
than typically seen in previous trials of HAH or Early Supported Discharge, reflecting 
the broad selection criteria. 
We conducted a Randomised Controlled Trial (RCT) at Northumbria Hospitals to 
compare HAH to usual inpatient care in patients with AECOPD and low risk DECAF 
score (supported by a Research for Patient Benefit grant). This model of HAH proved 
to be safe (no acute deaths), clinically effective (no increase in readmissions), cost-
effective and was preferred by 90% of patients. To explore factors influencing wider 
implementation of this model of care, patients, carers, clinicians and hospital 
managers were interviewed. Patients valued the availability of home comforts, 
greater independence and continuity of care provided by the HAH specialist team. 
Positive influences on perceived rate of recovery, sleep quality, mood, convenience 
for friends and family (particularly grandchildren visiting) and carer burden were also 
reported. A few patients were concerned about being alone, particularly at night (a 
9pm phone call was valued), or professionals visiting their home. In the early phase 
of the trial, clinician concerns occasionally delayed return home. Nurses cited greater 
workload and responsibility, but providing HAH was viewed positively. Operational 
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concerns included keeping medical records in a patient’s home and inability to 
capture activity within current payment systems.  
Useful numbers: 
 Respiratory Specialist Nurse for Hospital at Home: XXXX  
 Respiratory Consultant (NSECH): XXXX  
 HOOF: XXXX  
 Adult Social Care, Northumbria patients (Wansbeck General Hospital): XXXX  
 Adult Social Care, North Tyneside General Hospital: XXXX  
 Escalation plan number NE Ambulance Service: XXXX  
 Consultant clinical psychologist: XXXX  
What support is offered within Hospital at Home? 
Prior to return home under HAH, patients will be reviewed by a respiratory consultant 
and respiratory specialist nurse (RSN) to confirm the diagnosis, eligibility and both 
acute and chronic disease management. The HAH package of care is tailored to the 
individual patient’s needs. The patient will be reviewed by a physiotherapist regarding 
breathing control, sputum clearance, home exercise programme and subsequent 
early pulmonary rehabilitation. Access to a pharmacist, occupational therapist and 
same day short term social support is available. Both a nebuliser and temporary 
controlled oxygen therapy will be supplied, with instruction on use at home, if 
required. The specialist nurse will accompany the patient during return home and 
oversee clinical management at home.  
Patients receiving HAH are seen at least once daily by a RSN and undergo 
monitoring of their respiratory rate, oxygen saturation, heart rate, blood pressure, 
temperature and, if they have significant dependent oedema, daily weight. They have 
access to most of the medical treatments available in hospital, including intravenous 
therapy, but excluding acute non-invasive ventilation. The RSNs provide 24-hour 
telephone support throughout the duration of HAH, with consultant support.  
During HAH, the specialist respiratory team retain clinical responsibility for the 
patient. At the end of Hospital at Home the patient will be “discharged” as if they had 
been in hospital.  
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Return to Hospital  
“Return to Hospital” is the term used to describe a patient returning to hospital during 
a period of HAH and is regarded as an increase in the level of care, not a 
readmission. The patient remains under the care of the specialist team throughout 
the HAH period, and will contact the RSN directly if they are concerned. The RSN 
may provide reassurance or arrange a home visit and/or return to hospital, in liaison 
with the on-call respiratory consultant. “Readmission” describes the patient returning 
to hospital after they have been discharged from HAH. 
Identifying eligible patients 
Patients with an exacerbation of COPD triaged for hospital admission who are low 
risk (DECAF 0 or 1) should be considered for Hospital at Home treatment. Patients 
will be primarily identified by the RSNs screening and assessing new respiratory 
admissions.  
Selection criteria  
 Primary diagnosis of AECOPD  
 DECAF score 0 or 1  
 No other acute condition which necessitates hospital admission  
 Absence of acute confusion precluding discharge  
  
DECAF score  
Dyspnoea: please remember to ask the patient about breathlessness on a good day 
within the last three months, not on admission.  
Acidaemia: if an arterial blood gas has not been performed, provided the patient’s 
SpO2 is 92% or greater breathing room air, it is highly unlikely that the patient’s pH < 
7.30 (threshold required to score). If a venous blood gas pH is not acidaema, the 
arterial pH cannot be acidaemia (arterial pH = venous pH + 0.03).  
Management pathway  
Patients with a low risk DECAF score managed in hospital are unlikely to require an 
escalation in care. When this does occur, the patient is usually hypercapnic on 
admission and their condition typically deteriorates within the first 24 hours. Patients 
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who are acidaemic on admission but otherwise low risk by DECAF remain at low risk 
(Echevarria Thorax 2016).  
The timing of return home under hospital at home is determined by the admission 
arterial blood gas.  
 Normal PaCO2 or SpO2 >92% breathing room air & ABG considered 
clinically unnecessary = return home as soon as possible (most patients).  
 Hypercapnia, normal pH = return home if not deteriorating at 24hrs.  
 Hypercapnia and pH < 7.35 = return home within 24 hrs of resolution of 
acidaemia, and discontinuation of acute NIV if provided.  
In hospital planning for Hospital at Home 
RSN review  
The RSNs screen and assess new admissions to the acute respiratory admissions 
unit. Some eligible patients may have already been identified by medical staff, and 
will be highlighted to the RSN. 
When a suitable patient is identified for HAH, the RSN will ensure all required clinical 
assessments have been performed and that adequate support is in place. This may 
involve delegating tasks to ward staff. The RSN will facilitate return home. For HAH 
to work effectively, flexibility and clear communication is required. 
AECOPD proforma  
The AECOPD proforma includes an initial assessment sheet, which should be 
completed by the RSN on the day the patient returns home, and daily review 
sheets to be completed on subsequent days during HAH. 
Assessment of needs  
Following review by the RSN and respiratory consultant, a management plan will be 
put in place including: 1) acute management of this exacerbation; 2) review and 
optimisation of long-term COPD management; and 3) assessment of home 
circumstances. This may involve reviewing patients on a non-respiratory ward. On 
occasion, if the consultant is not available, the medical review may be performed by 
a specialist respiratory registrar. The RSN and ward staff will identify the patient’s 
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social support needs. Adult social support should be contacted immediately if same 
day support is required. 
Hospital at Home COPD return home checklist  
This will be completed prior to the patient returning home, and is a simple checklist to 
ensure all the practical aspects of discharge have been met.  
Patients’ medical notes and admission file  
The AECOPD proforma should be filed in red admission file with the admission 
clerking, nursing notes, drug kardex and observation chart. The red admission file will 
follow the patient home and remain with them throughout the HAH period of care. 
Prior to return home, a photocopy of the current admission documentation in the red 
file should be made and filed in volume 1 of the medical notes (retained on the 
respiratory ward for the duration of HAH to ensure ease of access if required). There 
is a consent form related to retention of the red file in the patient’s home during HAH. 
The RSN will ensure this is signed by the patient. 
If the patient returns to hospital during HAH the red file must accompany the patient. 
Whilst such patients require a thorough review, they will not need a new clerking or 
new drug Kardex. On discharge from HAH, the red file should be returned to the 
respiratory ward and the original complete admission documents filed in volume 1 of 
the patients notes, replacing the earlier photocopy.  
Medication prior to return home  
Not all RSNs have completed the prescribing course. All medication, including 
anticipated medication, should be prescribed before the patient leaves hospital. See 
below “Procedure for Completion of Drug Chart for Patients receiving HAH” below for 
further information.  
Antibiotic protocol for Hospital at Home  
No allergies / History of intolerance 
1. Not previously treated, or treated with Amoxicillin: First line- Doxycycline; 
Second line- Co-amoxiclav.  
2. Previously treated with Doxycycline: First line- Co-amoxiclav; second line- 
Levofloxacin 500mg bd.  
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Intolerant of Doxycycline  
First line- Co-amoxiclav; second line- Levofloxacin 500 mg bd.  
Intolerant of Penicillin  
First line- Doxycycline; second line- Levofloxacin 500 mg bd. 
If a patient is colonised with Haemophilus Influenza (recurrent positive cultures), an 
extended course of co-amoxiclav of 10-14 days is appropriate.  
If pseudomonas is cultured, consider oral ciprofloxacin or intravenous antibiotics 
depending on sensitivities. Discuss dose and duration with a consultant.  
Proton Pump Inhibitors  
Proton pump inhibitors are (PPI) commonly stopped in patients when starting 
antibiotics due to the risk of Clostridia Difficile (C diff). It is important to balance the 
risks.  
GI bleed within 12 months score 2; GI bleed > 12 months score 1; Female score 1; 
Co-prescription antiplatelet therapy, NSAIDS or SSRIs score 1; Co-prescription oral 
anticoagulant score 1; Chronic renal disease GFR < 60 score 1; BMI < 19 score 1.  
Total risk score:  
 2+ continue PPI  
 1 switch to H2 antagonist for the duration of antibiotic therapy plus 7 
days 
 0 withhold PPI for the duration of antibiotic therapy plus 7 days 
 No existing indication for PPI on review – discontinue.  
Procedure for Completion of Drug Chart for Patients receiving HAH  
Patients suitable for HAH treatment will already have had their inpatient drug chart 
completed with the necessary medicines to treat the acute exacerbation. Prior to 
the patient being sent home the RSN should ensure that the following medication is 
prescribed:  
Regular medication:  
1. Tinzaparin prophylaxis if deemed necessary on VTE assessment – 
discontinue once the patient achieves their normal level of mobility.  
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2. Salbutamol 2.5mg nebules four times a day – with a note to be reviewed 48 
hours post admission.  
3. Ipratropium Bromide 500 microgram nebules four times a day – with a note to 
be reviewed 48 hours post admission.  
4. Prednisolone 30mg once daily for 5 days  
5. First line antibiotic including stop/ review date – according to antibiotic 
protocol.  
6. Patient’s regular inhalers – if patient on a LAMA place a cross in the 
administration box for the first 48 hours and a note to withhold whilst on 
regular ipratropium nebules.  
7. Patient’s regular medication – this should be reconciled by the pharmacy team 
prior to return home. If the patient hasn’t been seen by a member of the 
pharmacy team (due to time of admission etc.), please ensure this is reviewed 
by a doctor. All appropriate medication must be prescribed. 
8. Oxygen – if the patient needs oxygen, this must be prescribed on the drug 
chart.  
9. Nicotine patches and short acting nicotine replacement (inhalator, gum or 
lozenge) if patient a current smoker and willing to have NRT – if patient 
smokes >20/day start 21mg patch.  
As required medication:  
1. Salbutamol 2.5mg Nebules for shortness of breath.  
2. Ipratropium bromide 500 microgram nebules for shortness of breath.  
3. Salbutamol Inhaler (or Terbutaline) – whichever short acting beta2 agonist the 
patient was using prior to admission.  
4. Paracetamol as required.  
5. Carbocisteine – 375-750mg up to three times a day if problems clearing 
sputum (if not already on regular carbocisteine).  
6. Sando K tablets – 2 tablets up to three times a day for hypokalaemia. To be 
commenced only if blood results indicate hypokalaemia.  
7. Furosemide – 40-80mg once daily prn if the patient develops worsening 
dependent oedema. Only to be commenced on discussion with consultant. 
Occasionally higher dose or intravenous diuretic may be required.  
8. OR if not on an ACE-inhibitor, angiotensin receptor blocker or potassium 
sparing diuretic: Co-amilofruse 5/40 1-2 tablets once daily prn if patient 
develops worsening dependent oedema. Only to be commenced on 
discussion with consultant. 
 
Supply of medication:  
The RSN should obtain all medication the patient will require during HAH prior to 
return home. Any medication that the patient takes home with them must either be 
over-labelled or dispensed from pharmacy: i.e. patients must not go home with 
unlabelled medication. This includes the patients’ regular medication as patients 
should not have to contact their GP for a prescription during HAH. If required, the 
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RSN will also supply a nebuliser, temporary oxygen concentrator and venturi mask 
(to achieve target SpO2 = 88-92%).  
  
Restricted antibiotics (ciprofloxacin and levofloxacin) will be available via the 
Omnicell cabinets to ensure strict controls are in place.  
Discharge from Hospital at Home:  
When the patient is discharged from HAH the patient should receive a copy of their 
discharge letter and the nursing staff must ensure that the patient has sufficient 
supplies of medication. If a rescue pack is considered appropriate, this must also 
be included in the discharge letter and supplied to the patient with written and 
verbal information.  
Overlabelled Medication Available Hospital at Home: 
1. Anoro (1 inhaler)  
2. Amoxicillin 500mg capsules (box of 21)  
3. Carbocisteine 375 mg capsules (box of 120)  
4. Co-amilofruse 5/40 tablets (box of 28)  
5. Co-amoxiclav 625mg tablets (box of 21)  
6. Ciprofloxacin 250mg tablets  
7. DuoResp 320/9 (1 inhaler)  
8. Doxycycline 100mg capsules (box of 8)  
9. Furosemide 40mg tablets (box of 28)  
10. Ipratropium 500microgram Nebules (box of 20)  
11. Levofloxacin 500mg tablets 
12. Nicotine 21mg patches (box of 7 patches)  
13. Prednisolone 5mg tablets – (box of 28 for acute course and 42 for rescue 
pack)  
14. Salbutamol 100 microgram/puff inhaler (1 inhaler)  
15. Salbutamol 2.5mg Nebules (box of 20)  
16. Sando K tablets (tube of 20)  
17. Seebri (1 inhaler)  
18. Tiotropium 18 microgram Inhaler (1 inhaler)  
19. Ultibro (1 inhaler)  
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Procedure for Completion of Drug Chart written by: XXX, Senior Clinical 
Pharmacist. 
  
Organising transport for return home  
Patients who do not require controlled oxygen therapy or other assistance during 
transfer home may use private transport. Plans for transfer home will be reviewed by 
the RSN. If an ambulance is required the RSN should contact Ambulance Control 
and request an urgent ambulance (1-2 hour response). The RSN will review return 
home to help establish the patient in their own home.  
A patient should be flagged up to the NEAS (North East Ambulance Service) by 
sending a referral form (see appendix) to the following email address: XXX The 
patient can be removed once they are discharged, or will automatically come off the 
system after 2 weeks.  
Maintaining the Patient at Home 
RSN review 
The patient will have been reviewed by a RSN prior to returning home. Where 
possible, the RSN for HAH will accompany the patient home or, if not feasible, visit 
them shortly after return home. A detailed handover of HAH patients must occur 
when one RSN takes over from another on the rota. The RSN will have a standard 
set of equipment that they take to see the patient (see Hospital at Home equipment 
checklist). 
The patient will be reviewed daily during HAH, seven days per week. As well as 
nurse visits, patients will be routinely contacted by telephone in the evening. In 
particular, patients living alone often value an evening phone call. 
AECOPD proforma  
A new daily review sheet should be completed each day. This includes prompts to: 
review the patient’s symptoms and social support needs; perform an examination 
(recording physiological observations); review treatments (including pulmonary 
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rehabilitation) and the need for bloods/ ABGs; and deliver education to the patient 
and carer.  
Kardex  
This will be reviewed and updated by the RSN daily. With consent, it is useful to 
review the patients’ medication store to get an impression of the patient’s 
understanding of, and concordance with, their usual medication. This will inform 
patient education strategies and medication choice.  
Smoking Cessation  
Smoking cessation is the most effective treatment for COPD. Highlight that smoking 
not only causes progression of COPD, but also increases the risk of flare ups / 
exacerbations. Patients who smoke should have nicotine patches and short term 
NRT prescribed prior to discharge. Patients are more likely to smoke in their own 
home compared to hospital; be vigilant. If a patient is smoking during HAH this 
should be documented, and smoking cessation advice and support should be offered 
in the patient’s home. 
MRSA eradication  
The results of any MRSA swabs will not be available before the patient returns home. 
If the patient is MRSA positive, MRSA eradication therapy should be started.  
Oxygen  
If a patient requires temporary controlled oxygen therapy, the RSN will facilitate the 
transfer of an oxygen concentrator to the patient’s home. The oxygen concentrator 
may require two people for transfer and set-up, however such patients are more 
likely to need other support, such as HCAs, OT, or physiotherapy. Oxygen should be 
prescribed and to maintain saturations between 88-92%, with point of care arterial 
blood gas monitoring if required.  
Blood monitoring  
Patients will have venous bloods checked at home by the RSN as and when 
required, for analysis in hospital. Arterial blood gases (ABG) should be analysed in 
the patient’s home using the point of care analyser. If this is unavailable, the ABG 
sample should be taking just before leaving the patient’s home and transferred to the 
 189 
  
hospital for immediate analysis on ice: the longer the time to analysis, the greater 
chance of error. 
Occupational therapy  
Patients’ OT needs will have been identified in the hospital, though new needs may 
be identified when the RSN returns home with the patient. A key safe will help with 
access to the house for those patients that are unable to answer the door 
independently. Key safes will be stored with both the RSNs and with OT. There is an 
array of available equipment to help patients at home to sit upright in bed, and OTs 
will choose the best option based on their assessment of the patient.  
Physiotherapy  
The patients will be assessed by a physiotherapist prior to return home or within the 
first few days of return home. This will include assessment and education on 
breathing control, sputum clearance and an individual exercise plan, working towards 
pulmonary rehabilitation. Where possible, a joint assessment with the RSN will be 
performed.  
Outside of this formal assessment, patients who need assistance with chest 
clearance will be identified by the RSN, who will contact the physiotherapist to 
provide additional support. All patients will be offered pulmonary rehabilitation, to 
commence within 4 weeks of discharge. Pulmonary rehabilitation is one of the most 
successful treatments for COPD, and patients may be more receptive to this 
intervention when education is provided to them and their family in the patient’s 
home.  
Psychological Therapy  
XXXXXX should be contacted if it is felt that patients could benefit from psychological 
therapy. Please see appendix “Working with and managing psychological distress in 
the Hospital at Home project” for further information.  
Adult Social Care  
Patients who have care needs will be seen by HealthCare Assistants with basic 
training in COPD. RSN should coincide their visits with HCA visits where possible as 
this will be helpful, and also an opportunity to deliver additional training and support.  
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Out of hours calls  
Patients will be able to phone the RSN on call for HAH at any time of the day. Based 
on our experience, the call volume is expected to be low. A routine evening phone 
call can address any issues, and help prioritise morning visits if there is more than 
one patient in Hospital at Home, which may minimise overnight calls.  
Return to Hospital 
Identifying patients who need to return to hospital  
The decision to have a patient return to hospital will be made by the RSN. Where 
possible, the RSN should discuss the patient with a respiratory consultant, and have 
the results of upto-date bloods and arterial blood gases available to inform the 
decision. In some instances, it may be unclear if the patient needs to return to stay in 
hospital: such a patient can be brought back to hospital for a chest x-ray and medical 
review, and could return home if sufficiently well. Ideally, this should be carefully co-
ordinated to allow a timely review once the chest x-ray, bloods and ABG have been 
performed.  
Ambulance transfer from Hospital at Home to hospital  
A minority of patients receiving Hospital at Home may need to return to hospital. 
NEAS will be informed of, and maintain a record of, all patients receiving Hospital at 
Home.  
All patients will have medical notes (red file) and a drug Kardex at home, which 
must return to hospital with the patient. If oxygen is required it should be delivered 
by Venturi mask (target saturations 88-92%).  
Patients returning to hospital via this route will bypass Accident and Emergency and 
go directly to the acute respiratory ward NSECH.  
Organising the ambulance for return to hospital  
1. The patient contacts Respiratory Special Nurse (RSN); outside of office hours, 
the nurse will either:  
a. Offer phone advice and visit the patient in the morning  
b. Organise return to hospital  
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2. If return to hospital is required, the RSN will contact the bed manager to 
arrange a bed on the acute respiratory ward. Patients will bypass Accident 
and Emergency.  
3. The RSN will phone for an ambulance, indicating the level of urgency and the 
patient’s destination.  
MRSA and C. Diff.  
If a patient has watery stools (stool type 7 on the Bristol Stool Scale) or is found to be 
MRSA positive, then the patient will need to be isolated when they return to hospital. 
The bed manager should be informed as early as possible.  
Discharge from Hospital at Home  
The COPD care bundle should be completed for all patients who are discharged from 
Hospital at Home, as occurs in hospital. A copy will be sent by the RSN to hospital 
pharmacist. The RSN will liaise with pharmacy to let them know the patient has been 
discharged so they can perform a one week follow-up phone call (including review of 
education regarding rescue medication). 
The decision to discharge a patient from Hospital at Home will be made by the RSN 
in liaison with the respiratory consultant. It is expected that the average duration of 
HAH will be similar to the length of hospital stay for an acute exacerbation of COPD 
managed as an inpatient (4-5 days).  
The criteria below can be used to help guide when a patient is ready for discharge. 
All patients will vary, and the patient’s baseline status must also be considered.  
  
 Symptoms improving (breathlessness, sputum)  
 Oxygen saturations >88% on room air, or if on LTOT usual oxygen 
requirements  
 Pulse less than 110  
 Respiratory rate less than 25  
 Systolic blood pressure greater than 90mmHg  
 Apyrexial for greater than 24 hours  
 Off nebulisers for greater than 24 hours  
 Mobility adequate  
 Social support adequate and in place  
  
The discharge from HAH date must be clearly documented in the notes and a 
discharge letter will be dictated on G2 by the RSN (with copies for the patient, their 
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GP and the medical notes). If the patient needs a 2-week supply of medication and 
an emergency pack this will need to be prescribed.  
  
The red file will be returned to the hospital by the RSN. It should be given to the ward 
clerk on the ward from which the patient returned home. Patients in HAH remain 
eligible for all treatments and services that are available for those being discharged 
from hospital, such as Supported Pulmonary Discharge (NTGH) and community 
matron review (WGH). Patients should have 6 week follow-up in respiratory clinic, 
either with a respiratory nurse or doctor. The patient should be seen by a doctor of 
they have consolidation on their chest x-ray.  
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Hospital at Home Appendix 
Hospital at Home Return Home Checklist  
  
  Required   Done  
Patient reviewed by consultant (resp or gen med)      
Patient reviewed by respiratory consultant or registrar      
All jobs addressed from consultant ward rounds      
Discharge medications organised      
Family/carer informed patient is returning home      
RSN phone number given to patient and family/ carer      
Letter faxed to GP + filed in notes      
Admission details photocopied; copy left in hospital notes      
Consent from for admission notes to return home signed      
Inform North East Ambulance service      
Inform Northern Doctors      
      
Dementia CQUIN target completed      
VTE (DVT) CQUIN target completed      
      
Oxygen concentrator organised, forms signed                 Yes / No    
OT organised                                                          Yes / No    
Physio organised *                                         Yes / No    
Adult social care organised                                           Yes / No    
Ambulance organised                             Yes / No    
- Patient flagged on NE ambulance service system      
      
Equipment prepared for home visit      
*All patients should receive early pulmonary rehabilitation  
    
Equipment check for Home visits  
Required?  YES  NO  
Medication pack      
   Salbutamol nebules      
   Ipratropium bromide nebules      
   Amoxillin (low dose and high dose)      
   Co-amoxiclav      
   Doxycycline      
   Ciprofloxacin      
   Prednisolone      
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   Furosemide      
   Co-amilofruse      
   Tinzaparin- 3,500 and 2,500 units      
      
Nebuliser machine      
Cleaning equipment      
Masks      
Tubing      
      
Oxygen      
   Tubing      
   Venturi masks        24    28   35      
      
Investigations- routine bloods      
   Urea and electrolytes blood vials      
   Full blood count vials      
   Clotting test blood vials      
   Needles      
   Syringes      
   Sharps box      
   Sterile skin prep      
   Gloves      
   Handwash      
   Tourniquet      
   Cotton wool/ gauze and tape      
   Sputum pots      
         
Arterial Blood Gases      
   Arterial Blood Gas syringes      
   ABG point of care machine      
   ABG machine cartridges      
   Ice bag (if ABG machine unavailable)      
      
Observations      
   Oxygen saturations    (check working)      
   Blood pressure- automatic       
   Blood pressure- manual      
   Stethoscope      
   Temperature      
   Scales      
   Timer (resp rate)      
   BMs      
      
Telehealth equipment      
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Medication Administration Record-  Medication support provided by social services.                                             
OUTCOME OF RISK ASSESSMENT (i. e. Prompt OR Administer):   
Name:   D.o.B.   SWIFT / NHS No:  
GP Details:   Chemist Details:   
Allergies:   Start Dates:   
Medication Details  (including 
name, strength, dose, route 
and directions)  
 Signature    
Date    
  
                            
  Morning                               
Lunch                               
Teatime                               
Evening                               
  Morning                               
Lunch                               
Teatime                               
Evening                               
  Morning                               
Lunch                               
Teatime                               
Evening                               
NOTE:  
All doses must be signed for, if not given for any reason mark with ‘O’ and  ensure documented in the care 
plan and reported to Team Supervisor  
    
MAR Chart Completed by...........................................……Date.................................  
19  
         Checked by.................................................... Date..................................  
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North East Ambulance Service  
This sheet can be found at    XXX  
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Consent form for admission notes to return home with the patient  
This sheet can be found at    X:\Respiratory\Hospital at Home  
  
  
 
 
 
 
 
 
 
I ……………………………………………………  consent to my medical 
notes staying in my home for the duration of my treatment in Hospital at 
Home. I understand that it is my responsibility to control access to my 
notes by people not from the hospital, including by family members and 
friends. I accept that there is a risk that someone may look in my notes 
without my permission.  
  
I understand that my medical notes are the legal record of the medical 
assessment and treatment I receive. The attending clinical team will have 
full access to my records and will return the notes to the hospital at the 
end of this period of care. Should I become unwell, and need to return to 
hospital, it is important that these notes are brought back to hospital with 
me. The notes remain the property of Northumbria Healthcare NHS 
Foundation Trust.  
  
  
  
    
DD  MM  YYYY  
Patient (PRINT)  Signature  Date    
 
  
DD  MM  YYYY  
Witness (PRINT)  Signature  Date    
  
    
PARTICIPANT NAME 
NHS NUMBER 
DATE OF BIRTH 
ADDRESS 
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COPD re-admission avoidance checklist  
Intervention  Done  
Smoking cessation – advice, NRT, referral  □  
Arrange Long Term Oxygen Therapy assessment if required  
(pO2 <7.3 kPa; or <8kPa + cor pulmonale* or polycythaemia**)  □  
Pulmonary rehab assessment and referral. Copy discharge letter to physio.  □  
Education to patient and carer including self-management  □  
  - Rescue pack issued (check sensitivities from previous sputum)  □  
  - Inhaler technique and concordance   □  
Annual ‘flu vaccination  □  
Pneumonia vaccination  □  
Azithromycin in recurrent exacerbators (benefit primarily in nonsmokers)  □  
Consider supported discharge  □  
Liaise with other members of MDT (e.g. community matron)  □  
Contact number – respiratory outreach service  □  
Follow up appointment  □  
Consider nebuliser assessment for select patients (full trial by protocol)  □  
Discuss patient with supervising consultant pre-discharge, focusing on re-admission avoidance  □  
  
*Echocardiogram showing right ventricular dysfunction  
*Clinical signs of right sided heart failure such as ankle oedema  
**Raised haemoglobin and/ or haematocrit  
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Working with and Managing Psychological Distress in the Hospital at Home 
project  
Background  
Patient’s experiencing an acute exacerbation of COPD will commonly and 
understandably experience relatively high level of anxiety, low mood (loss of 
pleasure/ poor sleep etc) and panicky feelings intertwined with increased levels of 
breathlessness. (Maurer et al 2008). However in most cases this could be expected 
to reduce over time (both towards the end of a ‘hospital’ episode and during the first 
several weeks of discharge and rehabilitation) with the resolution of the exacerbation 
and gradual return to usual day to day functioning. Taking a bio-psycho-social 
approach to understanding distress is key is helping people.  
Levels of help  
Emotional support by front line staff in the hospital at home project (CNS’s, physio’s 
etc) is a core requirement in the care of individual patients and their families. Good 
listening, communication and relationship building skills help patients to feel 
supported, valued, and understood. Also appropriate psycho-education and 
information giving will help patients to understand and normalise their distress in the 
context of their exacerbation.   
Front line staff can provide advice and support their patients in basic skills to manage 
distress e.g. breathing control to manage panic/anxiety, use of distraction, use of 
relaxation.  
Good care management plans that actively involve patients (and family/ carers in the 
home) and are tailored to their specific needs can go a long way to helping patients 
feel calmer, more in control and hopeful about improvement through an exacerbation:  
 small, gradually increasing mobility goals and help with practice and achieving 
these as part of rehabilitation plan through the hospital at home period   
 gradually increasing independence in self-care throughout the exacerbation/ 
hospital at home period  
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 referral onto supported pulmonary discharge and community matron support 
post hospital at home period 
 referral onto rehabilitation at home or in hospital after hospital at home.  
Be alert to social triggers to a patients’ distress:  
 social isolation, need for external carers etc.  
o involvement of social services  
 other family members; anxiety, lack of knowledge/ understanding of COPD or 
lack of confidence in supporting the person with breathlessness  
o Talking with and involving partners/ family carers   
Where distress in relation to COPD and its symptoms remains high and persistent, 
despite these areas being addressed, or the person is struggling to engage in these 
areas of help, then referral to respiratory clinical psychology can be considered. if felt 
to be appropriate, this can be considered during the exacerbation (after initial 3-4 
days) or at a 6 week post exacerbation review.  
Respiratory Clinical Psychology – potential options of help   
Respiratory clinical psychology can provide:  
1. Staff case consultation, discussion and advice  
2. Staff training, support and supervision in their own delivery of basic 
psychological help and support to distressed patients  
3. Patient assessment and advice to contribute to multidisciplinary 
understanding, planning and management of the patient.  
4. If appropriate and the patient is willing to engage in and use a psychological 
approach to the management of their distress, providing a contracted piece of 
therapeutic work (typically 6-8 sessions, but tailored to individual need).  
5. Ongoing liaison with MDT members involved in the care of the patient.  
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